Document:

Exhibit
10.5

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

EXECUTION
VERSION

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ONCOLOGY
VENTURE ApS

 

 

 

and

 

 

 

R-PHARM
US OPERATING, LLC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

DEVELOPMENT,
OPTION AND LICENSE AGREEMENT

 

 

 

 

 

 

     

     

    

 

THIS
DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of the 1st
day of March, 2019 (the “Effective Date”)

 

BY
AND BETWEEN:

 

		(1)	Oncology
                                            Venture ApS, a company organized and existing under the laws of Denmark, whose principal
                                            place of business is located at Venlighedsvej 1, 2970 H0rsholm, Denmark (“OV”);
                                            and

 

		(2)	R-PHARM
                                            US Operating, LLC, a limited liability corporation organized and existing under the laws
                                            of Delaware, with offices at 3120 Princeton Pike, Suite 201, Lawrence, N.J. 08648 U.S.A.
                                            (“R-Pharm”). OV and R-Pharm are sometimes referred to herein individually
                                            as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS,
R-Pharm owns or controls certain intellectual property and other rights with respect to the Compound (as defined below) and markets and
sells the Product (as defined below) in certain countries, including the United States;

 

WHEREAS,
R-Pharm does not currently develop and/or commercialize, by itself or through its Affiliates (as defined below) and/or Third Parties
(as defined below), the Product in the Field (as defined below) in the Territory (as defined below);

 

WHEREAS,
the Compound has previously been tested in phase II and III clinical trials in the Territory for treatment of metastatic breast cancer,
but has not received Regulatory Approval (as defined below) from the European Medicines Agency (EMA) in the Territory;

 

WHEREAS,
OV has previously developed and validated the DRP Biomarker (as defined below) specific for the Compound, which is useful for selecting
highly likely responder patients for the Compound;

 

WHEREAS,
OV desires to conduct a clinical trial using the Product and the DRP Biomarker for the treatment of patients with metastatic breast cancer,
as more particularly described in the Clinical Development Plan (as defined below);

 

WHEREAS,
R-Pharm and OV desire to collaborate with respect to the conduct of such clinical trial as set forth herein; and

 

WHEREAS,
OV wishes to obtain, and R-Pharm wishes to grant to OV, a license to develop the Product in new clinical trials in the Territory and
an Exclusive Option (as defined below) to an exclusive license with respect to the Product under R-Pharm’s intellectual property
and other rights therein for the purposes of exploiting the Product and the DRP Biomarker as a companion diagnostic in the Field in the
Territory in accordance with the terms and conditions set forth below, as more particularly described herein.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein contained, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1.
DEFINITIONS

 

The
capitalized terms used in this Agreement shall have the meanings as defined below:

 

1.1
“Adverse Ruling” has the meaning set forth in Section 11.4.

 

    1

     

    

 

1.2 “Affiliate”
means, with respect to a Party, any Person that directly or indirectly controls, is controlled by, or is under common control with
that Party. For the purpose of this definition, “control” shall mean: (a) direct or indirect, ownership of fifty percent
(50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation; (b) fifty percent
(50%) or more of the equity interest in the case of any other type of legal entity or status as a general partner in any partnership;
(c) any other arrangement whereby the entity or Person controls
or has the right to control the board of directors or equivalent governing body of a corporation or other entity; (d) if a Party is exposed,
or has rights, to variable returns from its involvement with an entity or Person and has the ability to affect its returns through its
power over such entity or Person; or (e) the ability to cause the direction of the management or policies of a corporation or other entity.
In the case of entities organized under the Applicable Laws of certain countries, the maximum percentage ownership permitted by Applicable
Law for a foreign investor may be less than fifty percent (50%), and in such case such lower percentage shall be substituted in the preceding
sentence, provided that such foreign investor has the power to direct the management and policies of such entity. The Parties understand
and agree that, with respect to OV, “Affiliates” expressly includes Medical Prognosis Institute, ApS (“MPI”)
and 2X Oncology, Inc. (“2X”).

 

1.3
“Agreement” has the meaning set forth in the preamble hereto.

 

1.4 “Agreement
IP” means all Know-How, Patents and other intellectual property under the Control of a Party that was conceived, discovered,
developed or otherwise made by or on behalf of a Party under or in connection with this Agreement, or by use of or reference to the other
Party’s Background IP.

 

1.5
“Amount” has the meaning set forth in Section 7.8.

 

1.6 “Applicable
Law” means all applicable federal, state, local, national and supra-national laws, statutes, rules, and regulations, including
any rules, regulations, regulatory guidelines, or other requirements of the Regulatory Authorities, that may be in effect from time to
time during the Term and applicable to a particular activity or country or other jurisdiction hereunder, including all data protection
requirements such as those specified in the EU Data Protection Directive and the regulations issued under the United States Health Insurance
Portability and Accountability Act of 1996 (“HIPAA”).

 

1.7 “Background
IP” means Know-How, Patents and other intellectual property under the Control of a Party that was conceived, discovered, developed
or otherwise made or acquired (other than from the other Party) by the Party prior to the Effective Date or independently and outside
the activities contemplated by this Agreement without reference to or use of the other Party’s Confidential Information or Background
IP. Background IP ofOV expressly includes DRP Biomarker.

 

1.8
“Breaching Party” has the meaning set forth in Section 11.4.

 

1.9 “Business
Day” means a day (other than a Saturday, Sunday or a public holiday) on which the banks are open for business in Princeton,
New Jersey, or Basel, Switzerland or Copenhagen, Denmark.

 

1.10 “Calendar
Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1,
except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first
to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last
day of the Term.

 

1.11 “Calendar
Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except
that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective
Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last
day of the Term.

 

    2

     

    

 

1.12 “cGCP”
means the current Good Clinical Practices as such term is defined from time to time by the EMA or FDA pursuant to its regulations,
guidelines or otherwise, as well as, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use (ICH), that may be in effect from time to time and are applicable to the conduct of the mBC Clinical Trial hereunder.

 

1.13 “cGMP”
means the current Good Manufacturing Practices officially published and interpreted by EMA, FDA, or other applicable Regulatory Authorities
that may be in effect from time to time and are applicable to the manufacture of the Product or DRP Biomarker.

 

1.14 “Change
of Control” means, with respect to a Party, that: (a) any Third Party acquires directly or indirectly the beneficial ownership
of any voting security of such Party, or if the percentage ownership of such Third Party in the voting securities of such Party is increased
through stock redemption, cancellation, or other recapitalization, and immediately after such acquisition or increase such Third Party
is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting
power of all of the then outstanding voting securities of such Party; (b) a merger, consolidation, recapitalization or reorganization
of such Party is consummated, other than any such transaction, which would result in shareholders or equity holders of such Party immediately
prior to such transaction, owning at least fifty percent (50%) of the outstanding voting securities of the surviving entity (or its parent
entity) immediately following such transaction; or (c) the sale or transfer to a Third Party of all or substantially all of such Party’s
consolidated assets taken as a whole. The announced and imminent merger between OV and its Affilate MPI shall not be deemed a Change
of Control event hereunder.

 

1.15 “Clinical
Development Plan” means OV’s plan for the Development of Product in the Field in the Territory, including the conduct
of the mBC Clinical Trial, using the DRP Biomarker to select and enroll highly likely responder patients, as may be amended from time
to time at the discretion of the Joint Development Committee. The initial Clinical Development Plan will be agreed to by the Parties
and attached hereto as Exhibit A within ninety (90) days after the Effective Date.

 

1.16
“Commercialization Data” has the meaning set forth in Section 5.7.

 

1.17
“Commercialization Plan” has the meaning set forth in Section 5.3a).

 

1.18 “Commercialize”
means any and all activities directed to the preparation for sale of, offering for sale of, or sale of the Product, including activities
related to marketing, promoting, distributing, importing and exporting such Product, and interacting with Regulatory Authorities regarding
any of the foregoing. “Commercializing” and “Commercialization” shall have correlative meanings.

 

1.19 “Commercially
Reasonable Efforts” means those diligent efforts and resources consistent with customary practices of comparable companies
in the specialty pharmaceutical industry that such a company typically devotes to a product or compound owned by it or to which it has
rights of the type it has hereunder, or similar market potential at a similar stage in the development or product life thereof, in light
of the intellectual property and competitive landscape relevant to such product, the safety and efficacy profile of a product, pricing
and launching strategy for the respective product, the development and regulatory approval (including any reimbursement approval) risks
associated with such product, the Patent or other proprietary position of the Product (including the ability to obtain or enforce, or
have obtained or enforced, such Patent or other proprietary positions), the regulatory requirements involved and the potential profitability,
cost, market share, price or reimbursement to the performing Party of the Product marketed or to be marketed.

 

    3

     

    

 

1.20 “Competing
Product” means any product containing Ixabepilone, an epothiline or epothilone derivative, other than the Product.

 

1.21 “Compound”
means the compound Ixabepilone (Ixempra®) (CAS No. 219989-84-1) as further described in Exhibit B.

 

1.22
“Compound Agreement IP” has the meaning set forth in Section 8.lb)(i).

 

1.23 “Confidential
Information” means any and all proprietary Know-How, information and data, including scientific, pre-clinical, clinical, regulatory,
manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method,
which is provided by or on behalf of one Party or its Affiliate to the other Party or its Affiliate in connection with this Agreement.
All information disclosed under that certain Mutual Non-Disclosure and Confidentiality Agreement by and betweenR-Pharm US LLC and OV
dated October 11, 2017 shall be deemed Confidential Information under this Agreement.

 

1.24 “Control”
or “Controlled” means with respect to any item of Know-How, Patent or other proprietary right, the possession
of the right, whether directly or indirectly (other than through the rights granted under this Agreement), to grant a license, sublicense
or other right to any such Know-How, Patent or other proprietary right without violating the terms of any agreement or other arrangement
with any Third Party. Notwithstanding the foregoing, for the purpose of defining whether intellectual property, Patents, Know-How, Confidential
Information or other proprietary right is Controlled by a Party, if such intellectual property, Patents, Know-How, Confidential Information
or other proprietary right is first acquired, licensed or otherwise made available to such Party after the Effective Date and if the
use, practice or exploitation thereof by or on behalf of the other Party, its Affiliates or sublicensees would require the first Party
to pay any additional amounts to the Third Party from which the first Party acquired, licensed or otherwise obtained such intellectual
property, Patents, Know-How, Confidential Information or other proprietary right (“Additional Amounts”), following the Effective
Date, such intellectual property, Patents, Know-How, Confidential Information or other proprietary right shall be deemed to be Controlled
by the first Party only if the other Party agrees to pay (if necessary) and does in fact pay all Additional Amounts with respect to such
other Party’s use of or license to such intellectual property, Patents, Know-How, Confidential Information or other proprietary
right to the extent specified in this Agreement.

 

1.25 “Cover,”
“Covering” or “Covered” means that, with respect to a product or technology and a Patent, but for ownership
of or a license under such Patent, the Development, Commercialization or other use of such product or practice of such technology by
a Person would infringe a claim of such Patent or, with respect to a claim included in any patent application, would infringe such claim
if such patent application were to issue as a patent.

 

1.26
“Default Notice” has the meaning set forth in Section 11.4.

 

1.27
“Delivery” has the meaning set forth in Section 6.2a).

 

1.28 “Develop”
means all activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing,
toxicology, formulation, process development, clinical trials, statistical analysis and report writing, the preparation and submission
of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful
or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval.
“Developing” and “Development” shall have correlative meanings.

 

    4

     

    

 

1.29
“Disclosing Party” has the meaning set forth in Section 10.1.

 

1.30
“Dollars” or”$” means United States Dollars.

 

1.31 “DRP
Biomarker” means the proprietary, gene-expression-based, predictive biomarker for the Product, developed and validated by OV
at any time, which DRP Biomarker is useful for selecting patients likely to respond to the Product.

 

1.32
“DRP Biomarker Agreement IP” has the meaning set forth in Section 8.lb)(ii).

 

1.33 “Drug
Approval Application” means an application for Regulatory Approval to market and sell the Product in a country or region, including
a Marketing Authorization Application (a “MAA”) filed with the EMA or with the applicable Regulatory Authority of
a country in the European Union with respect to the mutual recognition or any other national approval procedure, and all supplements,
amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing.

 

1.34
“Effective Date” has the meaning set forth in the preamble hereto.

 

1.35 “EMA”
means the European Medicines Agency and any successor agency(ies) or authority having substantially the same function.

 

1.36 “EU
Data Protection Directive” means Directive 95/46/EC of the European Union and any successor law, including the General Data
Protection Regulation (GDPR) (Regulation (EU) 2016/679).

 

1.37
“Exclusions List” has the meaning set forth in the definition of Violation.

 

1.38
“Exclusive Option” has the meaning set forth in Section 2.1.

 

1.39
“Exclusive Option Exercise Payment” has the meaning set forth in Section 7.2.

 

1.40 “Existing
Regulatory Documentation” means, to the extent in R-Pharm’s possession or available to R-Pharm, all data,
documentation, and clinical materials (including any and all CTA (Clinical Trial Authorization) and IMPD (Investigational Medical
Product Dossier) and related EMA regulatory submissions and correspondence) and IND (Investigational New Drug) applications and
related FDA regulatory submissions and correspondence, including such Existing Regulatory Documentation from R- Pharm’s
licensee in Switzerland and from prior Compound owner, Bristol Myers Squibb Inc., solely relating to the Compound and reasonably
necessary for the conduct of the Compound development program in the Territory.

 

1.41 “FDA”
means the United States Food and Drug Administration and any successor agency(ies) or authority having substantially the same function.

 

1.42 “Field”
means, (i) during the Option Period, any and all therapeutic and/or diagnostic uses related to mBC, or (ii) following the Option
Exercise Date, any and all therapeutic and/or diagnostic uses in humans.

 

1.43 “First
Commercial Sale” means, with respect to the Product in a given country in the Territory, the first commercial sale of Product
by OV, its Affiliate, or permitted sublicensee to a non- sublicensee Third Party on arm’s length terms for end use or consumption
of Product in the Field in such country following Regulatory Approval of Product in such country or, ifno such Regulatory Approval (or
similar approval) is required to market Product in such country, the date on which Product is first commercially launched in the Field
in such country by OV, its Affiliate or permitted sublicensee. For clarity, First Commercial Sale shall be determined on a Product-by-Product
and country-by-country basis.

 

    5

     

    

 

1.44
“Force Majeure” has the meaning set forth in Section 14.21.

 

1.45 “Generic
Product” means, with respect to a Product in a country, any product that (i) is sold in such country by a Third Party that
is not a permitted sublicensee of OV and did not purchase such product in a chain of distribution that included any of OV or its Affiliates
or permitted sublicensees under a Regulatory Approval granted by a Regulatory Authority to a Third Party; (ii) contains the Compound
as the sole active ingredient; and (iii) is approved for sale by the applicable Regulatory Authority in such country in the Field for
the same Indication.

 

1.46 “Governmental
Authority” means any court, agency, department, authority or other instrumentality of any national, supra-national, state,
county, city or other political subdivision.

 

1.47
“HIPAA” has the meaning set forth in the definition of Applicable Law.

 

1.48
“Indemnification Claim Notice” has the meaning set forth in Section 13.3b).

 

1.49
“Indemnified Party” has the meaning set forth in Section 13.3b).

 

1.50
“Indemnifying Party” has the meaning set forth in Section 13.3b).

 

1.51 “Indication”
means a separate and distinct disease or medical condition in humans for which the Product has received Regulatory Approval with
an approved label claim to treat such disease or condition, as applicable; it being understood that references to Indications with regard
to the Product shall be based upon entirely different diseases or condition (including but not limited to cancers arising from different
tissues) in particular target patient populations (and, for the avoidance of doubt, different line therapies for the same disease or
condition, such as (for example) first line treatment for a disease or condition as compared to second line treatment for such same disease
or condition, shall not be deemed to be a different Indication).

 

1.52
“Indirect Taxes” has the meaning set forth in Section 7.9.

 

1.53
“Insolvency Event” has the meaning set forth in Section 11.5.

 

1.54
“Joint Agreement IP” has the meaning set forth in Section 8.lb)(iv).

 

1.55
“Joint Development Committee” or “JDC” has the meaning set forth in Section 3.1a).

 

1.56 “Know-How” means
any and all technical, scientific and other know-how and information (whether patentable or not), including (a) ideas, discoveries,
inventions, improvements, technology or trade secrets, (b) pharmaceutical, chemical and biological materials, products, components
or compositions, (c) methods, procedures, formulas, processes, tests, assays, techniques, regulatory requirements and strategies,
(d) biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety,
manufacturing and quality control data and information related thereto, (e) technical and non- technical data and other information
related to the foregoing, (f) drawings, plans, designs, diagrams, sketches, specifications or other documents containing or relating
to such information or materials and (g) all applications, registrations, licenses, authorizations, approvals and correspondence
submitted to Regulatory Authorities.

 

    6

     

    

 

1.57 “Litigation
Conditions” means, with respect to a Third Party Claim, (a) such Third Party Claim does not seek injunctive relief or non-monetary
damages from the Indemnified Party and (b) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party
and Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge such Third Party Claim in full and is
able to reasonably demonstrate that it has sufficient financial resources to meet such indemnification obligations.

 

1.58
“Losses” has the meaning set forth in Section 13.1.

 

1.59
“MAA” has the meaning set forth in the definition of Drug Approval Application.

 

1.60
“mBC” means metastatic breast cancer.

 

1.61
“mBC Clinical Trial” has the meaning set forth in Section 4.1.

 

1.62
“mBC Clinical Trial Completion” has the meaning set forth in Section 4.4d).

 

1.63 “mBC
Clinical Trial Data” means all data (including raw data) and results generated by or on behalf of a Party in the performance
of the mBC Clinical Trial.

 

1.64
“mBC Clinical Trial Report” has the meaning set forth in Section 4.4d).

 

1.65
“Milestone Events” has the meaning set forth in Section 7.3.

 

1.66
“Milestone Payments” has the meaning set forth in Section 7.3.

 

1.67 “Net
Sales” means, with respect to a given period, the gross amount billed or invoiced for sale of Product (or if not billed or
invoiced, the amount received) during such period by OV, its Affiliates, or permitted sublicensees (each, a “Selling Party”)to
Third Parties less the following deductions :

 

		a)	discounts
                                            (including trade, quantity and cash discounts), cash and non-cash coupons, retroactive price
                                            reductions, and charge-back payments and rebates granted to any Third Party (including to
                                            Governmental Authorities, purchasers, reimbursers, customers, distributors, wholesalers,
                                            and group purchasing and managed care organizations or entities (and other similar entities
                                            and institutions));

 

		b)	credits
                                            or allowances, if any, on account of price adjustments, recalls, claims, damaged goods, rejections
                                            or returns of items previously sold (including Products returned in connection with recalls
                                            or withdrawals);

 

		c)	rebates
                                            (or their equivalent), administrative fees, chargebacks and retroactive price adjustments
                                            and any other similar allowances granted by a Selling Party (including to Governmental Authorities,
                                            purchasers, reimbursers, customers, distributors, wholesalers, and group purchasing and managed
                                            care organizations and entities (and other equivalent entities and institutions)) which effectively
                                            reduce the selling price or gross sales of the Product, normal and customary inventory management
                                            fees and other bona fide service fees paid to distributors and wholesalers;

 

    7

     

    

 

		d)	insurance,
                                            customs charges, freight, postage, shipping, handling, and other transportation costs to
                                            the extent added to the sale price and set forth separately as such in the total amount invoiced;
                                            and

 

		e)	import
                                            taxes, export taxes, excise taxes, sales tax, value-added taxes, consumption taxes, duties
                                            or other taxes levied on, absorbed, determined or imposed with respect to such sales (excluding
                                            income or net profit taxes or franchise taxes of any kind).

 

There
should be no double counting in determining the foregoing deductions from gross amounts invoiced to calculate “Net Sales”
hereunder.

 

1.68
“Non-Breaching Party” has the meaning set forth in Section 11.4.

 

1.69
“Option Exercise Date” has the meaning set forth in Section 2.2.

 

1.70
“Option Request Notice” has the meaning set forth in Section 2.2.

 

1.71
“Option Fee” has the meaning set forth in Section 7.1.

 

1.72
“Option Period” shall have the meaning set forth in Section 2.la).

 

1.73
“OV” has the meaning set forth in the preamble hereto.

 

1.74
“OV Confidential Information” has the meaning set forth in Section 10.1.

 

1.75
“OV Indemnitees” has the meaning set forth in Section 13.1.

 

1.76
“Party” and “Parties” have the meaning set forth in the preamble hereto.

 

1.77 “Patents”
means all national, regional and international patents and patent applications, including any continuations, continuations-in-part,
divisionals, provisionals, or any substitute applications, any patent issued with respect to any such patent applications, any reissue,
reexamination, renewal, or extension (including any supplemental protection certificate) of any such patent, and any confirmation patent
or registration patent or patent of addition based on any such patent.

 

1.78
“Payment” has the meaning set forth in Section 9.3.

 

1.79 “Person”
means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization
or other entity.

 

1.80 “Product”
means any pharmaceutical product containing the Compound, in all forms, presentations, formulations, methods of administration, and
dosage forms.

 

1.81
“Receiving Party” has the meaning set forth in Section 10.1.

 

1.82 “Regulatory
Approval” means, with respect to a country or other jurisdiction in the Territory, any and all approvals (including Drug Approval
Applications), licenses, registrations, or authorizations of any Regulatory Authority necessary to Commercialize the Product in such
country or other jurisdiction.

 

1.83 “Regulatory
Authority” means any applicable Government Authority involved in granting approvals for the manufacturing, marketing, reimbursement
or pricing of a Product in the Territory.

 

    8

     

    

 

1.84 “Regulatory
Documentation” means all (a) applications (including all Drug Approval Applications), registrations, licenses,
authorizations, and approvals (including Regulatory Approvals), and (b) correspondence and reports submitted to or received from
Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory
Authority), in each case ((a) and (b)) relating to the Product.

 

1.85 “Regulatory
Exclusivity” means, with respect to any country in the Territory, an additional market protection, other than Patent protection,
granted by a Regulatory Authority in such country which confers an exclusive Commercialization period during which OV or its Affiliates
or permitted sublicensees have the exclusive right to market and sell the Product in such country through a regulatory exclusivity right
(e.g., new chemical entity exclusivity, orphan drug exclusivity or pediatric exclusivity).

 

1.86
“Regulatory Submissions” has the meaning set forth in Section 4.6b).

 

1.87 “Royalty
Term” means, with respect to the Product and a given country of sale in the Territory, the period beginning on the date of
the First Commercial Sale of such Product in such country of sale, and ending on the latest to occur of(a) the first date on which there
is no Valid Claim that Covers such Product or such Product in combination with the DRP Biomarker in such country of sale, and (b) the
seventh (7th) anniversary of the First Commercial Sale of such Product in such country of sale.

 

1.88
“R-Pharm” has the meaning set forth in the preamble hereto.

 

1.89
“R-Pharm Confidential Information” has the meaning set forth in Section 10.1.

 

1.90
“R-Pharm Indemnitees” has the meaning set forth in Section 13.2.

 

1.91 “R-Pharm
Know-How” means all Know-How that is (a) Controlled by R-Pharm or any of its Affiliates as of the Effective Date or at any
time during the Term and (b) necessary or reasonably useful for the Development or Commercialization of the Product. The use of “Affiliate”
in this definition shall exclude any Third Party that becomes an Affiliate due to such Third Party’s or such Third Party’s
Affiliate’s acquisition of R-Pharm as a result of a Change of Control.

 

1.92 “R-Pharm
Patents” means the Patents that are (a) Controlled by R-Pharm or any of its Affiliates as of the Effective Date or at any time
during the Term and (b) claim or cover (i) the Product, or the Development or Commercialization thereof, or (ii) any R-Pharm Know-How,
in each case, that are necessary or reasonably useful for the Development or Commercialization of the Product. The use of “Affiliate”
in this definition shall exclude any Third Party that becomes an Affiliate due to such Third Party’s or such Third Party’s
Affiliate’s acquisition of R-Pharm as a result of a Change of Control.

 

1.93 “Sublicense
Income” means all consideration, including, upfront payments, license fees, and milestone payments, actually received by OV
or its Affiliates for the grant by OV or its Affiliates of a sublicense or grant of rights with respect to a Product or the R-Pharm Know-How
or R-Pharm Patents to a Third Party; provided, however, that Sublicense Income shall not include (1) royalties on Net Sales for which
R-Pharm will receive a royalty payment pursuant to Section 7.4, (2) any proceeds from the sale of securities payments made at fair market
value in arms length transactions, or (3) any proceeds involving funding or reimbursement of Development costs, at fair market value
in arms length transactions, for the performance of development activities only to the extent that such payments are specifically allocated
to develop Product at rates standard and customary in the industry.

 

1.94
“Term” has the meaning set forth in Section 11.1.

 

1.95
“Terminated Product Technology” has the meaning set forth in Section 11.6c)1.1.1(a)(ii).

 

1.96 “Territory”
means all current and future countries of the European Union (EU), including Great Britain but excluding Switzerland and Lichtenstein.

 

1.97
“Third Party” shall mean any Person other than a Party or an Affiliate of a Party.

 

1.98
“Third Party Claims” has the meaning set forth in Section 13.1.

 

    9

     

    

 

1.99 “Valid
Claim” means a claim of: (a) an issued and unexpired patent, which claim has not lapsed or been dedicated to the public,
withdrawn, cancelled, abandoned, disclaimed, revoked or held unpatentable, unenforceable or invalid by an unappealable decision of a
court or other governmental agency of competent jurisdiction, or has not been appealed within the time allowed for appeal, and which
claim has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue, re- examination or
disclaimer or otherwise, or (b) a patent application that has been pending less than six (6) years from the date of filing of the
earliest patent application from which such patent application claims priority, which claim has not been cancelled, withdrawn or
abandoned or finally rejected by an administrative agency action from which no appeal can be taken.

 

1.100 “Violation” means
that a Party or any of its officers or directors or any other personnel (or other permitted agents of a Party performing activities
hereunder) has been: (1) convicted of any of the felonies identified among the exclusion authorities listed on the U.S. Department
of Health and Human Services, Office of Inspector General (OIG) website, including 42 U.S.C. 1320a-7(a)
(http://oig.hhs.gov/exclusions/authorities.asp); (2) identified in the OIG List of Excluded Individuals/Entities (LEIB) database
(http://exclusions.oig.hhs.gov/) or listed as having an active exclusion in the System for Award Management (http://www.sam.gov); or
(3) listed by any US Federal agency as being suspended, debarred, excluded or otherwise ineligible to participate in Federal
procurement or non- procurement programs, including under 21 U.S.C. 335a (http://www.fda.gov/ora/compliance_ref/debar/) (each of
(1), (2) and (3) collectively the “Exclusions Lists”).

 

1.101
“Withholding Party” has the meaning set forth in Section 7.8.

 

2.
GRANT OF RIGHTS; OVERVIEW

 

2.1 Grant
of Exclusive Option & Rights to OV. Subject to OV’s compliance with its payment obligations of the Option Fee according
to Section 7.1, R-Pharm hereby grants OV:

 

a) an
exclusive option, exercisable by OV any time on or prior to November 15, 2020 (the “Option Period”), to obtain the
licenses set forth in Section 2.3 (the “Exclusive Option”).

 

b) a
non-sublicenseable, non-transferrable exclusive, royalty-free license during the Option Period under the R-Pharm Patents and the R-Pharm
Know-How to Develop the Product in the Field in the Territory solely for the purposes of performing its obligations as set forth in,
and subject to, the Clinical Development Plan, including for the purposes of conducting the mBC Clinical Trial.

 

2.2 Exercise
of the Exclusive Option. OV may exercise the Exclusive Option by providing written notice to R-Pharm on any Business Day during
the Option Period, but no later than thirty (30) days in advance of the end of the Option Period (the “Option Request
Notice”); provided, however, that OV shall not be deemed to have entered into the licenses set forth in Section 2.3 unless
OV first offers in writing to R-Pharm the right to enter into an agreement pursuant to which OV would grant to R-Pharm an exclusive
license to Develop and otherwise exploit the Product together with the DRP Biomarker as a companion diagnostic in the Territory (a “Re-Acquisition
Agreement”). Within three (3) months following R- Pharm’s receipt of the Option Request Notice (the “R-Pharm
Option Term”), if R-Pharm desires to enter into a Re-Acquisition Agreement, R-Pharm shall send a written reply to such
effect (the “Re-Acquisition Reply”). Upon OV’s receipt of the Re-Acquisition Reply, R-Pharm and OV shall
negotiate the terms of a Re-Acquisition Agreement in good faith for a period not to exceed the R-Pharm Option Term, which period may
be mutually extended in writing by the Parties. The terms of any Re-Acquisition Agreement shall include fair market value terms and
conditions that are customary in agreements of a nature similar to the Re-Acquisition Agreement. If R-Pharm fails to send a
Re-Acquisition Reply or, after providing a Re- Acquisition Reply, the Parties fail, despite good faith negotiations, to execute a
Re-Acquisition Agreement, then OV shall be deemed to have entered into the licenses set forth in Section 2.3 as of the expiration of
the R-Pharm Option Term (the “Option Exercise Date”). If OV fails to provide the Option Request Notice before the
expiration of the Option Period, then the Exclusive Option shall expire and this Agreement will terminate pursuant to Section
11.3.

 

    10

     

    

 

2.3 Grant
of Exclusive License. Upon the Option Exercise Date and subject to OV’s compliance with its payment obligations according to
Section 7.l(b) and Section 7.2, R-Pharm hereby grants to OV:

 

a) an
exclusive (including with regard to R-Pharm and its Affiliates) license, with the right to grant sublicenses solely in accordance with
Section 2.4, under the R-Pharm Patents, the R-Pharm Know-How, R-Pharm’s interests in the Joint Agreement IP and R-Pharm’s
rights in the mBC Clinical Trial Data, to Develop and Commercialize the Product in the Field in the Territory.

 

b) an
exclusive (including with regard to R-Pharm and its Affiliates) license and right of reference, with the right to grant sublicenses and
further rights of reference solely in accordance with Section 2.5, under the Regulatory Approvals and any other Regulatory Documentation
that R-Pharm or its Affiliates may Control with respect to the Product as necessary for purposes of Developing and Commercializing the
Product in the Field in the Territory.

 

c) The
grants set forth in this Section 2.3 will automatically come into full force and effect on the Option Exercise Date without any further
action required by either Party under this Agreement.

 

2.4 License
Grants to R-Pharm. Upon the Effective Date, OV grants to R-Pharm a non- exclusive, royalty-free license, without the right to grant
sublicenses, under the DRP Biomarker Agreement IP, and OV’s interests in the Joint Agreement IP and any other Agreement IP, to
Develop and manufacture the Product solely for purposes of performing its obligations as set forth in the Clinical Development Plan and
solely as necessary for such purposes.

 

2.5 Sublicenses.
OV shall have the right to sublicense any or all of the rights granted to OV pursuant to Section 2.3 to its Affiliates or to Third
Parties without the consent of R-Pharm. OV shall ensure that each of its Third Party sublicensees is bound by a written agreement that
is consistent with, and subject to the applicable terms and conditions of, this Agreement. In addition, OV shall be responsible for the
performance of any of its sublicensees that are exercising rights under a sublicense of the rights granted by R-Pharm to OV under this
Agreement and the grant of any such sublicense shall not relieve OV of its obligations under this Agreement. Promptly following the execution
of each Third Party sublicense agreement, OV shall provide R-Pharm with a copy of each such sublicense agreement, which copy may be redacted
to remove provisions that are not necessary to monitor compliance with this Section 2.5. To the extent, OV sublicenses its rights to
commercialize Product, any such sublicensee will be required to purchase the Product from R-Pharm, according to the terms and conditions
herein.

 

    11

     

    

 

2.6 Subcontracting.
OV may not engage a Third Party subcontractor to perform its activities hereunder, including the mBC Clinical Trial (or any portion
thereof), unless approved by R-Pharm in writing, such approval not to be unreasonably withheld, conditioned or delayed. OV shall remain
solely and fully liable for the performance of its activities by such subcontractors, and shall ensure that each of its subcontractors
performs its obligations in accordance with the terms of this Agreement. In all cases, any such subcontracting shall be consistent with
the applicable terms and conditions of this Agreement, including confidentiality provisions no less stringent than those contained in
this Agreement and intellectual property provisions that assign to OV the rights in all Inventions as set forth herein.

 

2.7 Retention
of Rights. All rights and licenses not expressly granted to OV pursuant to this Agreement are reserved by R-Pharm.

 

2.8 Exclusivity.
During the Term, OV shall not, and shall cause its Affiliates not to, (i) directly or indirectly, research, develop, commercialize
or manufacture any Competing Product, or (ii) license, authorize, appoint, or otherwise enable any Third Party to research, develop,
commercialize, or manufacture any Competing Product.

 

2.9 Obligations
of OV. Following the Effective Date and as more fully set forth in Article 4, OV will, either itself or through its Affiliates, use
Commercially Reasonable Efforts to:

 

a)
supply and utilize the DRP Biomarker for the Product during the Option Term;

 

b) establish
the Clinical Development Plan, which shall include a detailed development plan of the Product in combination with the DRP Biomarker as
a companion diagnostic to select patients. The Clinical Development Plan shall include a design and implementation plan for at least
one targeted-enrollment Phase 2 trial of Product in metastatic breast cancer, utilizing the DRP Biomarker to select high likely responder
patients. The Clinical Development Plan is expected to include the screening of approximately 250 patients to then enroll (on a rolling
basis) pre-selected patients identified as high likely responders to Product. OV will continue the screening and selection process to
identify and enroll fifteen (15) patients (the “15 Required Patients”). OV may, in its sole discretion, decide to continue
to identify and enroll additional patients beyond the 15 Required Patients including patients for randomized trial(s). OV will utilize
its existing breast cancer patient screen in Denmark to facilitate the project. OV anticipates that such trial will be completed within
twelve (12) to eighteen (18) months of the Effective Date.

 

c) fund
and conduct all DRP Biomarker screening to identify likely responder patients for the mBC Clinical Trial.

 

d)
fund and conduct the mBC Clinical Trial as outlined in the Clinical Development Plan.

 

e) if
OV has exercised its Exclusive Option and the Parties have not executed a Re- Acquisition Agreement, Develop and Commercialize Product
in the Field in the Territory.

 

2.10 Obligations
of R-Pharm. Following the Effective Date and as more fully set forth herein, R-Pharm will, either itself or through its Affiliates,
use Commercially Reasonable Efforts to:

 

a)
provide OV with copies of any Existing Regulatory Documentation within thirty (30) days following the Effective Date.

 

b) provide
OV with existing, unexpired, clinical grade stock of Product sufficient for the 15 Required Patients but no more than 20 patients to
enable OV’s conduct of the mBC Clinical Trial. Such Product shall be provided to OV at no cost. Additional Product will be provided
at an additional cost in accordance with Section 2.lO(c)

 

c) provide
OV with additional clinical grade stock of Product sufficient for any subsequently approved (by R-Pharm) Phase 2/3 pivotal trial conducted
by OV, which supply shall be provided to OV at a cost of twenty percent (20%) above R-Pharm’s documented manufacturing cost.

 

d) cooperate
and reasonably assist OV, as may be requested by OV, in the conduct of the mBC Clinical Trial and OV’s activities set forth
herein, as well as any regulatory filings and regulatory meetings pertaining to the conduct of the mBC Clinical Trial. OV shall
solely bear the costs of conducting any targeted-enrollment trial(s), including the mBC Clinical Trial, and shall pay to R-Pharm an
agreed- upon, fair compensation for provided cooperation and assistance.

 

2.11 Future
Product Supply & Manufacturing. As more fully set forth in Section 6.lb), if OV has exercised its Exclusive Option and the Parties
have not executed a Re-Acquisition Agreement, then one year prior to the anticipated receipt of Regulatory Approval for the Product the
Parties shall negotiate a separate supply agreement for the manufacturing and supply of Product for the post-approval marketing and commercial
sale in Territory in the Field. Such post-approval supply shall be provided to OV at a cost of thirty percent (30%) above R-Pharm’s
documented manufacturing cost.

 

    12

     

    

 

2.12 New
Regulatory Filings & Approvals. As more fully set forth in Article 4, OV shall seek Regulatory Exclusivity of the Product in
the Territory, whereby OV will seek additional market protection from the relevant Regulatory Authority which confers an exclusive
commercialization period in the applicable country through a regulatory exclusivity right, such as data protection, data
exclusivity, market exclusivity, new chemical entity exclusivity, new use or Indication exclusivity, new formulation exclusivity, or
orphan drug exclusivity. OV shall obtain all approvals of the Product (including Regulatory Exclusivities) in the name of R-Pharm;
provided that to the extent applicable law in a country in the Territory requires any such approval to be held in the name of OV, OV
shall hold such approval on behalf of and for the benefit of R-Pharm. To the extent in OV’s name, upon termination or
expiration of this Agreement, OV will transfer and assign all approvals for the Product (and all data and documentation included in,
referenced in, or filed therein support thereof) to R-Pharm or its designee. In the event that OV elects to exercise its Exclusive
Option and the Parties do not execute a Re-Acquisition Agreement, R- Pharm shall transfer and assign all approvals and regulatory
filings for the Product in Territory to OV, in the name ofOV.

 

2.13 Third
Party Acquirer. OV shall have the right to identify and secure a Third Party to acquire (via sale, license, merger or otherwise)
and assume the rights to the DRP Biomarker. Any agreement with such a Third Party to the DRP Biomarker shall be at the sole discretion
ofOV, with advance written notice to R-Pharm.

 

3.
GOVERNANCE

 

3.1
Joint Development Committee.

 

a) Formation.
Within 60 days of the Effective Date, the Parties shall establish a joint development committee (the “Joint Development
Committee” or “JDC”). The JDC shall consist of four (4) representatives, with two (2) representatives from each
of the Parties, as follows:

 

		●	Peter
                                            Buhl-Jensen, M.D., CEO of OV, as Chairman of the JDC.

 

		●	Steen
                                            Knudsen, Ph.D., CSO and Founder of Medical Prognosis Institute, ApS.

 

		●	Bheshad
                                            Sheldon, CMO of R-Pharm.

 

		●	Jignesh
                                            Shah, COO of R-Pharm.

 

From
time to time, each Party may substitute one (1) or more of its representatives to the JDC on written notice to the other Party. In the
event that OV grants a sublicenses in accordance with Section 2.5, OV shall substitute one (I) of its representatives to the JDC with
a representative of such sublicensee. Each Party shall have the right to designate one (1) additional member, who may attend as anon-voting
observer. The JDC will implement and oversee the Clinical Development Plan for the Product in combination with DRP Biomarker in the Territory.
In addition, in the event that OV has exercised its Exclusive Option and the Parties have not executed a Re-Acquisition Agreement, the
JDC will implement and oversee the Commercialization Plan for the Product in the Field in the Territory.

 

b) Meetings
and Minutes. The JDC shall meet (by video-conference, conference call or otherwise in person as determined by the JDC members) on
at least a quarterly basis to discuss the progress under the Clinical Development Plan. Either Party may call JDC meetings on no less
than fifteen (15) Business Days’ notice (but no more often than once per quarter, unless agreed to by the Parties); provided, that
under exigent circumstances requiring input by the JDC, either Party may call a meeting on shorter notice. The chairperson shall provide
the agenda for each meeting (provided that the chairperson shall reasonably consider inclusion of any item on the agenda proposed by
a member of the JDC). The chairperson of the JDC shall prepare and circulate for review and approval of the minutes of each meeting within
thirty (30) days after the meeting. The Parties shall agree on the minutes of each meeting promptly, but in no event later than the conclusion
of the next meeting of the JDC. Such minutes shall be deemed approved unless one or more JDC representatives object to the accuracy of
such minutes prior to the conclusion of the next meeting of the JDC. Reasonably in advance of each regularly scheduled meeting of the
JDC, OV shall provide an update in writing to R-Pharm with respect to the mBC Clinical Trial, which update shall contain information
about overall mBC Clinical Trial progress, recruitment status, interim analysis (if results available) and final analysis of the mBC
Clinical Trial.

 

c) Procedural
Rules. All decisions on the JDC will be taken by unanimous consent with each Party having a single vote. Except where any decision
is granted to one Party herein, in the event that the JDC does not reach a unanimous consent on an issue within thirty (30) days after
the issue is first presented to the JDC, then (A) OV shall have the final decision-making authority with respect to matters involving
the DRP Biomarker, patient selection in the mBC Clinical Trial and the Commercialization Plan, and (B) R-Pharm shall have the final decision
making authority with respect to all matters involving the Compound or Product and not described in clause (A). Any decision to amend
the Clinical Development Plan shall require the unanimous consent of the JDC.

 

d) Limitations
on Authority. Each Party shall retain the rights, powers, and discretion granted to it under this Agreement and no such rights, powers,
or discretion shall be delegated to or vested in the JDC unless such delegation or vesting of rights is expressly provided for in this
Agreement or the Parties expressly so agree in writing. The JDC shall not have the power to amend, modify, or waive compliance with this
Agreement, which may only be amended or modified as provided in Section 14.4 or compliance with which may only be waived as provided
in Section 14.10.

 

e) Expenses.
Each Party shall be responsible for all travel and related costs and expenses for its members and other representatives to attend
meetings of, and otherwise participate on, the JDC.

 

    13

     

    

 

4.
DEVELOPMENT AND REGULATORY

 

4.1 mBC
Clinical Trial. The Parties shall’ collaborate with regard to a clinical trial to be conducted by OV using the Product and
the DRP Biomarker for the treatment of patients with mBC, as more particularly described in the Clinical Development Plan (the “mBC
Clinical Trial”).

 

4.2 Amendments
to the Clinical Development Plan. Either Party, directly or through its representatives on the JDC, may propose amendments to the
then-current Clinical Development Plan from time to time as appropriate, including to add additional clinical studies to the Clinical
Development Plan (as more fully set forth in Section 4.10) or in light of changed circumstances. If approved by the JDC, the amended
Clinical Development Plan shall become effective for the applicable period on the date approved by the JDC (or such other date as the
JDC shall specify). Any JDC-approved amended Clinical Development Plan shall supersede the previous Clinical Development Plan for the
applicable period. Notwithstanding the foregoing, in the event that the JDC does not approve a given amendment to the Clinical Development
Plan, then the then-current Clinical Development Plan shall continue in effect without modification (i.e., no changes shall be
made to the Clinical Development Plan unless and until agreed to by the JDC) such that only the activities set forth in the then-current
Clinical Development Plan shall continue.

 

4.3 Development
Costs. OV shall be solely responsible for one hundred percent (100%) of all costs of the mBC Clinical Trial and for all costs incurred
by it and its Affiliates in connection with its Development of Product hereunder (and other activities related thereto as set forth in
the Clinical Development Plan, including regulatory activities); provided that, to the extent required to be supplied in accordance with
the Clinical Development Plan, R-Pharm shall supply, in accordance with this Agreement, the Product for the conduct of the mBC Clinical
Trial at its cost. OV shall supply, in accordance with this Agreement, the DRP Biomarker for use in the mBC Clinical Trial at its own
cost. In addition, R-Pharm may assist and cooperate with OV as OV may reasonably request from time to time in connection with the conduct
of the mBC Clinical Trial (including in connection with any regulatory activities), and OV shall reimburse R-Pharm for its direct costs
and for all its reasonable out-of-pocket expenses in connection therewith.

 

4.4
Conduct of the mBC Clinical Trial and the Clinical Development Plan.

 

a) Conduct.
Subject to the terms and conditions of this Agreement and Clinical Development Plan, OV shall be responsible for operational execution
and management of the mBC Clinical Trial. OV shall conduct the mBC Clinical Trial in accordance with this Agreement and the Clinical
Development Plan.

 

b) Sponsor.
OV shall act as the sponsor of the mBC Clinical Trial. OV shall be responsible for obtaining all necessary approvals and clearances,
including IRB approvals and other Regulatory Approvals and customs clearances necessary for the conduct of the mBC Clinical Trial, and
OV shall ensure that all such approvals and clearances are obtained prior to initiating performance of the mBC Clinical Trial. OV shall
ensure that (i) the mBC Clinical Trial is performed in accordance with this Agreement, the Clinical Development Plan, and all Applicable
Laws, including cGCP, (ii) Product administered under the mBC Clinical Trial is done so in accordance with the Clinical Development Plan,
and (iii) all directions from any Regulatory Authority or ethics committee with jurisdiction over the mBC Clinical Trial are followed.

 

c) Consent
Forms. OV shall prepare the patient informed consent form for the mBC Clinical Trial in consultation with R-Pharm. Any changes to
such model form that relate to the Product shall be subject to R-Pharm’s written consent, not to be unreasonably withheld, conditioned,
or delayed. R-Pharm will provide such consent, or a written explanation for why such consent is being withheld, within fifteen (15) Business
Days after receiving OV’s request therefor. OV shall obtain all patient authorizations and consents for the mBC Clinical Trial,
and OV shall ensure that all patient authorizations and consents in connection with the mBC Clinical Trial permit, in accordance with
HIPAA, the EU Data Protection Directive or any other similar Applicable Law, sharing of mBC Clinical Trial Data with R-Pharm in accordance
with this Agreement.

 

    14

     

    

 

d) Report.
OV shall provide R-Pharm with (a) an electronic draft of the final clinical study report and the tables and listings (“mBC
Clinical Trial Report”) for R-Pharm to provide comments to OV (which comments shall be provided within forty-five (45) days
of receipt of the draft of the mBC Clinical Trial Report) and (b) a final version of the mBC Clinical Trial Report, in each case as soon
as reasonably practicable following mBC Clinical Trial Completion. OV shall consider in good faith any comments provided by R-Pharm on
the mBC Clinical Trial Report and shall not include any statements relating to the Product which have not been approved by R-Pharm. For
purposes of the mBC Clinical Trial, “mBC Clinical Trial Completion” shall occur upon database lock of the mBC Clinical
Trial.

 

e) Suspension.
OV shall not suspend or cease the conduct of the mBC Clinical Trial (or any arm thereof) without the consent of the JDC.

 

f) Reports
and Information. OV shall maintain reports and all related documentation in good scientific manner and in compliance with Applicable
Law in connection with the mBC Clinical Trial. OV shall provide to R-Pharm all mBC Clinical Trial information and documentation reasonably
requested by R-Pharm to (i) enable R-Pharm to comply with any of its legal or regulatory obligations, or any request by any Regulatory
Authority, related to the Product, and (ii) determine whether the mBC Clinical Trial has been performed in accordance with this Agreement.

 

4.5
mBC Clinical Trial Data.

 

a) Ownership. mBC
Clinical Trial Data will be owned by R-Pharm. In the event that OV exercises the Exclusive Option and the Parties have not executed
a Re-Acquisition Agreement, all of R-Pharm’s right, title and interest in and to such mBC Clinical Trial Data shall be
included in the exclusive license to OV. OV (on behalf of itself and its Affiliates) shall assign, and hereby assigns, to R- Pharm,
its interest in and to such mBC Clinical Trial Data. At the request of R-Pharm, OV will execute such documents (including any
necessary assignments) to effect such ownership of such mBC Clinical Trial Data.

 

b) Copies.
OV shall provide to R-Pharm copies of all mBC Clinical Trial Data generated by or on behalf of OV in the conduct of the mBC Clinical
Trial, in electronic form or other mutually agreeable alternate form on mutually agreeable timelines; provided, however, that a complete
copy of the mBC Clinical Trial Data shall be provided to R-Pharm no later than forty-five (45) days following the completion of the mBC
Clinical Trial. Such complete copy may be provided via providing access to the R-Pharm to its electronic database holding all such mBC
Clinical Trial Data.

 

c) Restrictions
on Use. OV shall not, without the prior written consent of R-Pharm, use the mBC Clinical Trial Data for any purpose other than: (i)
to perform its obligations under this Agreement; (ii) to file and prosecute patent applications for DRP Biomarker Agreement IP, and enforce
and defend any resulting patents in accordance with Article 8; (iii) as required by a Regulatory Authority or as may otherwise by required
by Applicable Law; (iv) as may be necessary to comply with such Party’s internal policies and procedures with respect to pharmacovigilance
and adverse event reporting; and (v) such other uses as consented by R-Pharm in writing.

 

    15

     

    

 

4.6
Regulatory Responsibility with respect to the mBC Clinical Trial.

 

a) Interactions.
OV shall be responsible for taking the lead with all interactions with Regulatory Authorities (meetings, telephone, etc.) in a given
country in the Territory and for other regulatory matters related to the mBC Clinical Trial in such country in the Territory as permitted
by Applicable Law. R-Pharm shall be entitled to have reasonable representation (but no more than two people unless otherwise mutually
agreed) present at all meetings or other substantive interactions with Regulatory Authorities (and OV shall provide notice to R-Pharm
sufficiently in advance of any such meeting or interaction unless such advance notice is not possible due to the urgency of the situation,
in which case OV shall inform R-Pharm of the content of such a meeting as soon as reasonably possible after the meeting has taken place).

 

b) Regulatory
Submissions. OV shall be responsible for preparing all submissions, documents or other correspondence submitted to applicable Regulatory
Authorities for the mBC Clinical Trial (collectively, the “Regulatory Submissions”). R-Pharm shall have the right
to review, comment upon and approve (such approval not to be unreasonably withheld, conditioned, or delayed) all substantive Regulatory
Submissions, which Regulatory Submissions shall be provided by OV to R-Pharm reasonably prior to submission thereof. OV shall consider
R-Pharm’s comments to such Regulatory Submissions in good faith. OV shall obtain and maintain (including all routine maintenance)
all investigational study applications for the mBC Clinical Trial, and all such applications, shall be in the name of R-Pharm (or its
Affiliate).

 

c) mBC
Clinical Trial Correspondence. With respect to the mBC Clinical Trial, OV shall (i) promptly provide to R-Pharm a copy of all
substantive correspondence from any Regulatory Authority with respect to the mBC Clinical Trial related to the Product and (ii)
promptly provide to R- Pharm a copy of final Regulatory Submissions related to the Product after submission thereof. In addition, OV
shall keep R-Pharm informed regarding all regulatory matters related to the Product with respect to the mBC Clinical
Trial.

 

d) Adverse
Event Reporting. OV will be solely responsible for compliance with all Applicable Laws pertaining to safety reporting for the mBC
Clinical Trial, and for holding and maintaining the safety database with respect to information on adverse events concerning the Product
in the EU. As soon as reasonably practical after the Effective Date (but in all cases prior to the first dosing of the first patient
in the mBC Clinical Trial) the Parties will enter into a Pharmacovigilance Agreement (in substantially the form attached hereto as Exhibit
C}. to ensure the exchange of relevant safety data within appropriate timeframes and in appropriate format to enable the Parties
to fulfill local and international regulatory reporting obligations. The Pharmacovigilance Agreement will include safety data exchange
procedures governing the coordination of collection, reporting, and exchange of information concerning any adverse experiences, pregnancy
reports, and any other safety information arising from or related to the use of the Product and the DRP Biomarker in the mBC Clinical
Trial, consistent with Applicable Law. Such guidelines and procedures shall be in accordance with, and enable the Parties and their Affiliates
to fulfill local and international regulatory reporting obligations to Governmental Authorities.

 

4.7 Regulatory
Documentation. All Regulatory Documentation (including all Regulatory Approvals) relating to the Product shall be owned by, and shall
be the sole property and held in the name of, R-Pharm or its Affiliate or other designee. In furtherance of the foregoing, OV shall obtain
all Regulatory Approvals of the Product (including Regulatory Exclusivities) in the name of R-Pharm; provided that to the extent Applicable
Law in a country in the Territory requires any such Regulatory Approval to be held in the name of OV, OV shall hold such Regulatory Approval
on behalf of and for the benefit of R-Pharm. To the extent in OV’s name, upon termination or expiration of this Agreement, OV will
transfer and assign all Regulatory Documentation for the Product (and all data and documentation included in, referenced in, or filed
therein support thereof) to R-Pharm or its designee.

 

    16

     

    

 

4.8 Exchange
of Information following Exercise of the Exclusive Option. If OV has exercised its Exclusive Option and the Parties have not executed
a Re-Acquisition Agreement, the terms and conditions of this Section 4.8 shall apply as of the Option Exercise Date:

 

a) Transfer.
As soon as reasonably practicable following the Option Exercise Date and payment of the Option Exercise Payment, R-Pharm shall disclose
and provide to OV all Regulatory Documentation in the Control of R-Pharm that solely relates to the Product reasonably necessary for
the Development or Commercialization thereof and that R-Pharm has not previously provided to OV pursuant to this Agreement. For the avoidance
of doubt, all such Regulatory Documentation shall remain the sole and exclusive property of R-Pharm.

 

b) Assistance.
At the request of OV, R-Pharm shall provide OV (and its designees) with assistance as reasonably requested by OV to effectuate the
transfer to, and implementation and use by, OV of the information, documentation and materials set forth in Section 4.8a), in each case
in a timely manner. OV shall reimburse R-Pharm for its direct costs and for all its reasonable out-of-pocket expenses in connection with
such assistance.

 

4.9 Regulatory
Matters following Exercise of the Exclusive Option. If OV has exercised its Exclusive Option and the Parties have not executed a
Re-Acquisition Agreement, the terms and conditions of this Section 4.9 shall apply as of the Option Exercise Date:

 

a) Regulatory
Activities. As between the Parties, OV shall have the primary responsibility to (i) prepare, obtain, and maintain Drug Approval Applications,
Regulatory Approvals and other regulatory submissions and applications for the Product in the Field in the Territory, and (ii) conduct
communications with Regulatory Authorities for the Product in the Field in the Territory. OV shall promptly notify R-Pharm of any material
filings made regarding Regulatory Approval of the Product in the Territory and of receipt of Regulatory Approval of Product in any country
in the Territory. OV shall provide R-Pharm final drafts of any such material filings for R-Pharm’s review and comment, and OV shall
consider in good faith any such comments of R-Pharm. All Regulatory Documentation (including all Regulatory Approvals) relating to Product
in the Field in the Territory shall be owned by, and shall be the sole property and held in the name of, OV or its Affiliate.

 

b) Interactions
with Regulatory Authorities. As between the Parties, OV shall have the primary responsibility to communicate and otherwise interact
with Regulatory Authorities with respect to the Product in the Field in the Territory, including with respect to any Drug Approval Applications
and other Regulatory Approvals in connection therewith. OV shall provide R-Pharm with (a) access to or copies of all material written
or electronic correspondence relating to the Development or Commercialization of the Product received by OV from the Regulatory Authorities,
and (b) copies of all meeting minutes and summaries of all meetings, conferences, and discussions held by OV with the Regulatory Authorities,
in each case ((a) and (b)) within fifteen (I 5) Business Days of its receipt or production of the foregoing, as applicable. If such written
or electronic correspondence received from any such Regulatory Authority relates to the withdrawal, suspension, or revocation of a Regulatory
Approval for the Product in the Territory, or the initiation of any investigation, review, or inquiry by such Regulatory Authority concerning
the safety of the Product, then OV shall notify R-Pharm and provide R-Pharm with copies of such written or electronic correspondence
as soon as practicable, but not later than two (2) Business Days after receipt of such correspondence.

 

    17

     

    

 

4.10 Additional
Clinical Trials. Subject to the terms of this Section 4.10, during the Option Period, OV will have the right to propose amendments
to the Clinical Development Plan to include additional clinical trials using the Product and the DRP Biomarker for the treatment of patients
with mBC. If OV desires to conduct any such additional clinical trial, it will notify the JDC in writing, and discuss such additional
clinical trial with R-Pharm at the JDC and provide the JDC any information reasonably requested by the JDC related to such additional
clinical trial. The JDC will consider in good faith any such proposal for an additional clinical trial, and if, and only if, the JDC
approves to amend the Clinical Development Plan to include such additional clinical trial, OV may thereafter conduct such additional
clinical trial (but subject to the terms and conditions imposed by the JDC as part of the JDC’s approval of the additional clinical
trial). In all cases, OV shall keep the JDC updated with respect to all such additional clinical trials (including the results generated
therefrom) at each meeting of the JDC, and shall provide to R-Pharm such other information with respect to any such additional clinical
trial as reasonably requested by R-Pharm.

 

4.11 Global
Safety Database. R-Pharm shall hold and maintain the global safety database for the Product with respect to information on adverse
events concerning the Product, as and to the extent required by Applicable Law.

 

5.
COMMERCIALIZATION

 

5.1 General.
In the event that OV has exercised its Exclusive Option and the Parties have not executed a Re-Acquisition Agreement, OV (and its
Affiliates), either itself or with or through Third Party(ies), shall be solely responsible for Commercializing the Product in each country
in the Territory in accordance with the Commercialization Plan and this Agreement.

 

5.2 Diligence.
In the event that OV has exercised its Exclusive Option and the Parties have not executed a Re-Acquisition Agreement, and following
receipt of all applicable Regulatory Approvals, OV (itself or with or through its Affiliates) shall use Commercially Reasonable Efforts
to Commercialize the Product in the Field in the Territory.

 

5.3
Commercialization Plan and Information.

 

a) Commercialization
Plan. No later than thirty (30) days following the initiation of pivotal clinical trial designed to generate data sufficient to file
a Drug Approval Application for the Product in the Field in the Territory, and on an annual basis thereafter, OV shall develop and submit
to the JDC for its review, comment and approval a reasonable written plan that summarizes the material Commercialization activities to
be undertaken with respect to the Product in the Field in the Territory for the following Calendar Year (each, a “Commercialization
Plan”). Each Commercialization Plan shall contain a three (3)-year rolling annual plan for the Commercialization of the Product.

 

b) Specific
Commercialization Obligations. In connection with the Commercialization of the Product in the Territory, OV shall use Commercially
Reasonable Efforts to launch the Product in each country (or other regulatory jurisdiction) after all applicable Regulatory Approvals
for the Product in such country (or other regulatory jurisdiction) have been obtained.

 

5.4 Reports.
OV shall provide R-Pharm with a summary of any material Commercialization matters resulting from OV’s Commercialization of
the Product (including, subject to confidentiality obligations to a Third Party, a summary of material Commercialization matters in connection
with the Commercialization of the Product) under this Agreement.

 

5.5 Compliance.
OV shall, in Commercializing the Product, comply with all Applicable Laws as well as all applicable Regulatory Approvals for the
Product.

 

    18

     

    

 

5.6 Pricing.
OV shall have the right, in consultation with R-Pharm through the JDC, to establish and modify the terms and conditions with respect
to the sale of the Product in the Territory, including any terms and conditions relating to the price (including discounts and rebates)
at which the Product will be sold in any country in the Territory.

 

5.7 Commercialization
Data. OV shall own all marketing and sales data and information resulting from the Commercialization of the Product in the Field
in the Territory (the “Commercialization Data”). Upon request from R-Pharm, OV shall provide to R-Pharm a copy of
such Commercialization Data. R-Pharm shall have the irrevocable right and license to use all Commercialization Data (and the right to
grant its Affiliates and Third Parties the right to use such Commercialization Data) in connection with the exercise of its rights and
performance of its obligations with respect to the Product under this Agreement.

 

5.8 Commercialization
Progress Updates. OV shall provide R-Pharm with a summary of any material Commercialization matters resulting from OV’s Commercialization
of the Product (including, subject to confidentiality obligations to a Third Party, a summary of material Commercialization matters in
connection with the Commercialization of the Product) under this Agreement.

 

6.
SUPPLY

 

6.1
Supply of Product for the mBC Clinical Trial.

 

a) Supply.
R-Pharm will, either itself or through its Affiliates, use Commercially Reasonable Efforts to provide OV such quantities of existing,
unexpired, clinical grade stock of Product sufficient to enable OV’s conduct of the mBC Clinical Trial in accordance with the Clinical
Development Plan.

 

b)
Cost. The supply of Product by R-Pharm for the mBC Clinical Trial shall be at no cost
to OV.

 

c) Additional
Supply of Product. To the extent OV requires from R-Pharm any stock of Product for any additional clinical trials for the
treatment of patients with mBC, and if the JDC approves to amend the Clinical Development Plan to include such additional clinical
trials, R-Pharm will, either itself or through its Affiliates, use Commercially Reasonable Efforts to provide OV, at a cost of
twenty percent (20%) above manufacturing cost (to the extent a Third Party manufactures Product for R- Pharm, the manufacturing cost
shall be the acquisition cost (including compliance and freight cost required to release and deliver Product)), as adjusted for
foreign currency exchange, such quantities of existing, unexpired, clinical grade stock of Product sufficient to enable OV’s
conduct of such additional clinical trials. If OV elects to exercise its Exclusive Option and the Parties have not executed a
Re-Acquisition Agreement, following receipt of Regulatory Approval in the Territory, to the extent OV requires from R- Pharm any
stock of Product for post-approval marketing and commercial sale in the Field in the Territory, the Parties would need to negotiate
a separate supply agreement pursuant to which R-Pharm would sell, at a cost of thirty percent (30%) above manufacturing cost (to the
extent a Third Party manufactures Product for R-Pharm, the manufacturing cost shall be the acquisition cost (including compliance
and freight cost required to release and deliver Product)), as adjusted for foreign currency exchange, and OV would purchase, such
Product for post-approval marketing and commercial sale in the Field in the Territory.

 

6.2
Provision of Product.

 

a) Delivery;
Storage. R-Pharm will deliver the Product to OV EXW (INCOTERMS 2010) at R-Pharm’s manufacturing facility as specified by OV
in writing (“Delivery”). Risk of loss for the Product shall transfer from R-Pharm to OV at Delivery. All costs associated
with the subsequent transportation, warehousing and distribution of Product shall be borne by OV. OV will: (i) take delivery of the Product
supplied hereunder; (ii) warehouse and promptly ship the supplied Product to the Clinical Trial sites, in compliance with cGMP, cGCP
and other Applicable Law ; and (iii) provide, from time to time at the reasonable request of R-Pharm, the following information to R-Pharm:
any applicable chain of custody forms, in transport temperature recorder(s), records and receipt verification documentation, such other
transport or storage documentation as may be reasonably requested by R-Pharm, and usage and inventory reconciliation documentation related
to such Product.

 

    19

     

    

 

b) DRP
Biomarker. OV shall be solely responsible, at its own cost, for manufacturing and supplying (including acceptance and release testing)
the DRP Biomarker for the mBC Clinical Trial in accordance with the Clinical Development Plan, and the subsequent handling, storage,
transportation, warehousing and distribution of such DRP Biomarker. OV shall ensure that all such activities are conducted in compliance
with cGMP, cGCP and other Applicable Law.

 

6.3 Use,
Handling and Storage. OV shall (i) use the Product supplied hereunder solely for purposes of performing the mBC Clinical Trial; (ii)
not use the Product supplied hereunder in any manner inconsistent with this Agreement; and (iii) use, store, transport, handle and dispose
of all Product supplied hereunder in compliance with Applicable Law and all reasonable instructions of R-Pharm consistently applied.

 

6.4 Records
for the Product. OV will keep complete and accurate records pertaining to its use and disposition of the Product (including its
storage, shipping (cold chain) and chain of custody activities) and, upon request of R-Pharm, will make such records reasonably
available for review by R- Pharm for the purpose of conducting investigations for the determination of Product safety or efficacy
and such OV’s compliance with this Agreement with respect such Product.

 

7.
PAYMENTS

 

7.1
Initial Payments.

 

a) Upfront
Payment. In consideration of the Exclusive Option granted to OV and the rights granted hereunder and the transfer of inventory of
Product by R-Pharm to OV pursuant to Section 6.la), OV shall pay R-Pharm a non-refundable, non-creditable option fee equal to one hundred
thousand dollars ($100,000.00) (the “Option Fee”), which shall be due on or before December 1, 2018.

 

b) Anniversary
Payment. OV shall pay R-Pharm a non-refundable, non-creditable fee equal to two hundred fifty thousand dollars ($250,000.00), which
shall be paid by OV to R-Pharm on or before March 1, 2020.

 

7.2 Option
Exercise Payment. In partial consideration of the rights granted under this Agreement, upon the terms and conditions contained
here, in the event OV elects to exercise the Exclusive Option following the expiration of the R-Pharm Option Term (where R-Pharm has
not entered into a Reacquistion Agreement) in accordance with Section 2.2, OV shall pay R-Pharm a non-refundable, non- creditable
payment of two hundred fifty thousand dollars ($250,000.00), which shall be paid by OV to R- Pharm within thirty (30) days of the
Option Exercise Date.

 

    20

     

    

 

7.3 Milestones
Payments. As additional consideration for the grant of rights under this Agreement, and on the terms and subject to the conditions
set forth herein, in the event that the following milestone events (each a “Milestone Event” and collectively, the
“Milestone Events”) are achieved by OV, its Affiliates, or permitted sublicensees following the expiration of the
R-Pharm Option Term (where R-Pharm has not entered into a Reacquistion Agreement), then OV shall notify R-Pharm thereof in writing within
five (5) Business Days (and R-Pharm shall promptly issue an invoice for the applicable Milestone Payment), and OV shall pay to R-Pharm
the corresponding milestone payment associated with the applicable Milestone Event as set forth below (each a “Milestone Payment”
and collectively the “Milestone Payments”) within thirty (30) days of receipt of an invoice issued by R-Pharm
in respect of such Milestone Payment.

 

a) Upon
receipt of Regulatory Approval for the Product for the treatment of the first Indication in the first country in the Territory, [***];
and

 

b) Upon
receipt of Regulatory Approval for the Product for the treatment of each additional Indication in the first country in the Territory
for each such additional Indication, [***] for each such Indication.

 

7.4 Royalties.
If OV has exercised its Exclusive Option and the Parties have not executed a Re-Acquisition Agreement, the terms and conditions of
this Section 7.4 shall apply as of the Option Exercise Date.

 

a) Royalty
Rates. As further consideration for the rights granted to OV hereunder, commencing upon the First Commercial Sale of the Product
in the Territory, during the Royalty Term on a country-by-country basis, OV shall pay to R-Pharm a royalty on Net Sales of Product in
the Territory in a given Calendar Year at the applicable royalty rates set forth below:

 

	Annual
    Net Sales of the Product in the Territory in a given Calendar Year	 	Applicable Royalty Rate (Percentage of Net Sales)	 
	Portion
    of annual Net Sales of Product in a given Calendar Year up to and including thirty million Dollars ($30,000,000.00)	 	 	[***]	 
	Portion
    of annual Net Sales of Product in a given Calendar Year over thirty million Dollars ($30,000,000.00)	 	 	[***]	 

 

b)
Royalty Reductions.

 

(i) Third
Party Intellectual Property. In the event that OV enters into an agreement with a Third Party after the Effective Date in order to
obtain a license or right under a Patent, Know-How or other intellectual property right owned or controlled by such Third Party that
is necessary to Commercialize Product in a country in the Territory, then OV shall be entitled to deduct from the royalties payable hereunder
[***] of the royalties paid to such Third Party pursuant to any such agreement.

 

(ii) Generic
Products. In the event that in any country or other jurisdiction in the Territory during the Royalty Term for a Product unit volume
of all Generic Products in such country or other jurisdiction in a calendar quarter equal or exceed [***] of the sum of unit volume of
such Product and all Generic Products in such country or other jurisdiction, then, for each such country or other jurisdiction , the
royalties payable to R-Pharm for the Net Sales of such Product in such country or other jurisdiction shall be reduced by [***] of the
applicable royalty rate(s) set forth in Section 7.4a) for such Calendar Quarter. Unless otherwise agreed by the Parties, the unit volumes
of each Generic Product sold during a Calendar Quarter shall be as reported by IMS America Ltd. or any successor or any other independent
sales auditing firm reasonably agreed upon by the Parties.

 

    21

     

    

 

(iii) Cumulative
Reductions Floor. In no event will the royalty payable to R- Pharm pursuant to Section 7.4 be reduced below [***].

 

7.5 Sublicense
Income. OV shall pay to R-Pharm [***] of any Sublicense Income within ninety (90) days of the end of each calendar quarter in which
OV or any of its Affiliates receives any Sublicense Income.

 

7.6 Payments
and Reports. OV shall calculate all amounts payable to R-Pharm pursuant to Section 7.4 and Section 7.5 at the end of each
Calendar Quarter, which amounts shall be converted to Dollars, in accordance with Section 7.7. OV shall pay to R-Pharm the amounts
due with respect to a given Calendar Quarter within ninety (90) days after the end of such Calendar Quarter. Each payment due to R-
Pharm shall be accompanied by, at a minimum, showing on a country-by-country basis, (a) a statement of the amount of gross sales of
each Product in the Territory during the applicable Calendar Quarter (including such amounts expressed in local currency and as
converted to Dollars) and the number of each Product sold, (b) an itemized calculation of Net Sales (deductions provided for in the
definition of “Net Sales”) during such Calendar Quarter, and (c) a calculation of the amount of royalty payment due on
such Net Sales for such Calendar Quarter. Without limiting the generality of the foregoing, OV shall require its Affiliates and
permitted sublicensees to account for its Net Sales in the Territory and Sublicense Income and to provide such reports with respect
thereto as if such sales were made by OV.

 

7.7 Currency
Conversion. All payments to a Party hereunder shall be made in Dollars. For the purpose of calculating any sums due under, or otherwise
reimbursable pursuant to, this Agreement (including the calculation of Net Sales or Sublicense Income expressed in currencies other than
Dollars), a Party shall convert any amount expressed in a foreign currency into Dollar equivalents, calculated using the applicable currency
conversion as published by The Wall Street Journal, Eastern Edition, as of the last business day of the Calendar Quarter in which
such expense or revenue was recorded in accordance with generally accepted accounting principles in the United States by such Party.

 

7.8 Withholding
Taxes. Where any sum due to be paid to either Party hereunder is subject to any withholding or similar tax, the Parties shall use
their commercially reasonable efforts to do all such acts and things and to sign all such documents as will enable them to take advantage
of any applicable double taxation agreement or treaty. In the event there is no applicable double taxation agreement or treaty, or if
an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, the payor shall remit
such withholding or similar tax to the appropriate government authority and deduct the amount paid from the amount due to payee and secure
and send to payee the best available evidence of the payment of such withholding or similar tax. Any such amounts deducted by the payor
in respect of such withholding or similar tax shall be treated as having been paid by the payor for purposes of this Agreement. In the
event that a government authority retroactively determines that a payment made by a Party to the other pursuant to this Agreement should
have been subject to withholding or similar (or to additional withholding or similar) taxes, and such Party (the “Withholding
Party”) remits such withholding or similar taxes to the government authority, including any interest and penalties that may
be imposed thereon (together with the tax paid, the “Amount”), the Withholding Party will have the right (a) to offset
the Amount against future payment obligations of the Withholding Party under this Agreement, (b) to invoice the other Party for the Amount
(which shall be payable by the other Party within sixty (60) days of its receipt of such invoice) or (c) to pursue reimbursement of the
Amount by any other available remedy.

 

    22

     

    

 

7.9 Indirect
Taxes. All payments are exclusive of value added taxes, sales taxes, consumption taxes and other similar taxes (the “Indirect
Taxes”). If any Indirect Taxes are chargeable in respect of any payments, the paying Party shall pay such Indirect Taxes at
the applicable rate in respect of such payments following receipt, where applicable, of an Indirect Taxes invoice in the appropriate
form issued by the receiving Party in respect of those payments. The Parties shall issue invoices for all amounts payable under this
Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. If the
Indirect Taxes originally paid or otherwise borne by the paying Party are in whole or in part subsequently determined not to have been
chargeable, all necessary steps will be taken by the receiving Party to receive a refund of these undue Indirect Taxes from the applicable
governmental authority or other fiscal authority and any amount of undue Indirect Taxes repaid by such authority to the receiving Party
will be transferred to the paying Party within forty-five (45) days of receipt.

 

7.10 Records
and Audits. During the Term and for a period of three years thereafter, OV shall keep (and shall cause its Affiliates and permitted
sublicensees to keep) complete and accurate records pertaining to the purchase, storage, sale, or other disposition of the Product and
sublicensing in sufficient detail to permit R-Pharm to confirm the accuracy of all payments due hereunder. R-Pharm shall have the right
to audit such records to confirm payments. Such audits may be exercised during normal business hours upon reasonable prior written notice
to OV. If such audit identifies a deficiency, OV shall pay R-Pharm the amount of the deficiency plus interest per Section 7.11, within
30 days of the date R-Pharm delivers to OV a written report reflecting the results of such audit. R-Pharm shall bear the full cost of
such audit unless such audit discloses an underpayment by OV, in which case, OV shall bear the full cost of such audit and shall remit
to R-Pharm payment for the costs of such audit within 30 days of invoice receipt.

 

7.11 Late
Payments. If any payment due under this Agreement is not made when due, the payment shall accrue interest from the date due until
payment is received, at the rate of one-month London Inter-Bank Offering Rate plus [***] as set by the British Bankers Association as
of the due date; provided, however, that in no event shall such rate exceed the maximum annual interest rate allowable by applicable
law. The payment of such interest shall not limit either Party from exercising any other rights it may have as a consequence of the lateness
of any payment.

 

8.
INTELLECTUAL PROPERTY

 

8.1
Ownership.

 

a) Background
IP. All Background IP shall be and remain exclusively the property of the Party that made or acquired such Background IP.

 

b)
Agreement IP.

 

(i) Compound
Agreement IP. R-Pharm shall exclusively own all right, title and interest in and to all Agreement IP that is an improvement, modification
or is otherwise related to any R-Pharm Background IP or the Compound or the Product or its manufacture or use but not the DRP Biomarker
Agreement IP (“Compound Agreement IP”). OV shall promptly disclose to R-Pharm all Compound Agreement IP that is conceived,
discovered, developed or otherwise made by OV, its Affiliates, and permitted sublicensees, and its and their agents and subcontractors.
OV hereby assigns, and shall cause its Affiliates, and permitted sublicensees and its and their agent and subcontractors to assign, to
R-Pharm the entire right, title and interest in and to all Compound Agreement IP. R-Pharm shall have the exclusive right to prepare applications
for, prosecute, maintain and defend, at its own costs, the Compound Agreement IP. OV shall reasonably assist and cooperate with R-Pharm
at R-Pharm’s expense in perfecting, maintaining, defending and enforcing the rights granted to R-Pharm in this Section 8b)(i),
including the provision of any requested documentation necessary for prosecution or maintenance of patents claiming such Compound
Agreement IP, and the execution of any required documents therefor. OV shall not file any patent applications claiming, or amend any
patent applications to claim, any Compound Agreement IP.

 

    23

     

    

 

(ii) DRP
Biomarker Agreement IP. OV shall exclusively own all right, title and interest in and to all Agreement IP that is an improvement,
modification or is otherwise specifically related to the DRP Biomarker or its manufacture (“DRP Biomarker Agreement IP”).
R-Pharm shall promptly disclose to OV all DRP Biomarker Agreement IP that is conceived, discovered, developed or otherwise made by
R-Pharm, its Affiliates, and permitted sublicensees, and its and their agents and subcontractors. R-Pharm hereby assigns, and shall cause
its Affiliates, and permitted sublicensees and its and their agent and subcontractors to assign, to OV the entire right, title and interest
in and to all DRP Biomarker Agreement IP. OV shall have the exclusive right to prepare applications for, prosecute, maintain and defend,
at its own costs, the DRP Biomarker Agreement IP. R-Pharm shall reasonably assist and cooperate with OV at OV’s expense in perfecting,
maintaining, defending and enforcing the rights granted to OV in this Section 8b)(ii), including the provision of any requested documentation
necessary for prosecution or maintenance of patents claiming such DRP Biomarker Agreement IP, and the execution of any required documents
therefor. R-Pharm shall not file any patent applications claiming, or amend any patent applications to claim, any DRP Biomarker Agreement
IP.

 

(iii) Sole
Agreement IP. As between the Parties, each Party shall own and retain all right, title and interest in and to any Agreement IP other
than Compound Agreement IP or DRP Biomarker Agreement IP that is conceived, discovered, developed or otherwise made solely by or on behalf
of such Party or its Affiliates or, its permitted sublicensees, and its and their agents and subcontractors.

 

(iv) Joint
Agreement IP. As between the Parties, the Parties shall each own an equal, undivided interest in and to any Agreement IP other than
Compound Agreement IP or DRP Biomarker Agreement IP that is conceived, discovered, developed or otherwise made jointly by or on behalf
of R-Pharm or its Affiliates and its and their agents and subcontractors, on the one hand, and OV or its Affiliates, permitted sublicensees
and its and their agents and subcontractors, on the other hand (“Joint Agreement IP”). Each Party shall promptly disclose
to the other Party any Joint Agreement IP of which it becomes aware. Each Party shall have the right to make, have made, use, sell, offer
for sale, import and otherwise exploit the Joint Agreement IP without the consent of or accounting to the other Party, subject to the
exclusive license grants contemplated in this Agreement.

 

8.2 Prosecution,
Maintenance and Enforcement. R-Pharm shall have the exclusive right to prepare applications for, prosecute, maintain, defend, and
enforce, at its own costs, the R-Pharm Know How, Compound Agreement IP and any other Agreement IP solely owned by R-Pharm. OV shall have
the exclusive right to prepare applications for, prosecute, maintain, defend, and enforce, at its own costs, any Agreement IP solely
owned by OV. The Parties shall work in good faith to coordinate the prosecution, maintenance, defense, and enforcement of any Joint Agreement
IP.

 

9.
COMPLIANCE MATTERS

 

9.1 General.
In conducting its activities hereunder, each Party shall comply in all respects with Applicable Law and accepted pharmaceutical industry
business practices, including, if and to the extent applicable to the respective Party or its activities hereunder, the FFDCA, the Anti-Kickback
Statute (42 U.S.C. § 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. § 1320a-7a), the False Claims Act (31 U.S.C. §
3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA
or other applicable Governmental Authority. Each Party shall promptly notify the other Party in writing if it becomes aware of any material
deviations from Applicable Law with respect to activities under this Agreement.

 

    24

     

    

 

9.2 Debarment
and Other Violations. OV shall not employ or subcontract with any Person that is excluded, debarred, suspended, proposed for suspension
or debarment, in Violation or otherwise ineligible for government programs for the performance of the mBC Clinical Trial or any other
activities under this Agreement. OV hereby certifies that it has not employed or otherwise used in any capacity and will not employ or
otherwise use in any capacity, the services of any Person suspended or debarred under United States law, including 21 USC 335a, or any
foreign equivalent thereof, in performing any portion of the mBC Clinical Trial or other activities under this Agreement and that OV
has, as of the Effective Date, screened itself, and its officers and directors, against the Exclusions Lists and that it has informed
R-Pharm whether it or any of its officers or directors is in Violation. OV shall notify R-Pharm in writing immediately if any such suspension
debarment or Violation occurs or comes to its attention with respect to any Person performing activities under this Agreement, and shall,
with respect to any Person so suspended, debarred or in Violation, promptly remove such Person from performing activities, function or
capacity related to the mBC Clinical Trial or otherwise related to activities under this Agreement.

 

9.3 Anti-Corruption.
In conducting its respective activities hereunder, OV has not taken and will not during the Term, take any action directly or indirectly
to offer, pay, or authorize such offer or payment, of money or anything of value (hereinafter collectively referred as a “Payment”)
to improperly or corruptly seek to influence any Government Official where such Payment would constitute a violation of any Applicable
Law, and has not accepted, and will not accept in the future any such Payments. In addition, regardless of legality, OV shall not make
any Payment either directly or indirectly to Government Officials if such Payment is for the purpose of influencing decisions or actions
or otherwise gaining an improper business advantage with respect to the subject matter of this Agreement. OV shall not contact, or otherwise
knowingly meet with, any Government Official for the purpose of discussing activities arising out of or in connection with this Agreement,
without the prior written approval of the other Party, except where such meeting is consistent with the purpose and terms of this Agreement
and in compliance with Applicable Law.

 

10.
CONFIDENTIALITY

 

10.1 Confidential
Information. During the Term, either Party (the “Disclosing Party”) may from time to time furnish the other
Party (the “Receiving Party”) with Confidential Information. The “R- Pharm Confidential
Information” means any and all Confidential Information for which R-Pharm is the Disclosing Party and OV the
Receiving Party hereunder. The “OV Confidential Information” means any and all Confidential Information for which
OV is the Disclosing Party and R-Pharm the Receiving Party hereunder.

 

10.2 Confidentiality.
Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that
for the Term and for seven (7) years thereafter, the Receiving Party shall keep confidential and shall not publish or otherwise disclose
and shall not use for any purpose any Confidential Information of the Disclosing Party except pursuant to this Agreement.

 

10.3 Exclusions.
Notwithstanding anything herein to the contrary, the obligations of confidentiality and nonuse under this Article 10 applicable to
Confidential Information hereunder shall not apply to information that:

 

a) at
the time of disclosure, is known publicly or thereafter becomes known publicly through no fault of the Receiving Party, its Affiliates
or agents;

 

b) is
disclosed to the Receiving Party on a non-confidential basis by a Third Party that is not legally prohibited from disclosing such information;

 

    25

     

    

 

c) was
developed by the Receiving Party independently of information obtained from the Disclosing Party, as shown by the Receiving Party’s
prior written records;

 

d) was
already known to the Receiving Party before receipt from the Disclosing Party, as shown by the Receiving Party’s prior written
records; provided that the foregoing shall not apply with respect to Confidential Information in possession of the Receiving Party prior
to the Effective Date, but transferred to the Disclosing Party pursuant to this Agreement; or

 

e)
is released with the prior written consent of the Disclosing Party.

 

10.4
Permitted Disclosures.

 

a) General.
Notwithstanding the provisions of Section 10.2 and subject to Section 10.4b), each Receiving Party may disclose the Disclosing Party’s
Confidential Information (a) to the Receiving Party’s employees, consultants, Affiliates, agents, or contractors who are bound
by obligations relating to confidentiality at least as restrictive of those contained herein and who have a need to know such information
in connection with the Receiving Party’s performance of its obligations or practice of its rights under this Agreement, (b) to
Regulatory Authorities or other Governmental Authorities in connection with Drug Approval Applications or Regulatory Approvals in accordance
with this Agreement, or (c) to Regulatory Authorities or other Governmental Authorities to obtain Patents in accordance with this Agreement.

 

b) Certain
Additional Disclosures. Notwithstanding the provisions of Section 10.2, either Party may disclose mBC Clinical Trial Data and OV
Confidential Information to Third Parties as may be necessary in connection with such Party’s evaluation of a potential or actual
investment or acquisition of such Party; provided that any Third Party receiving such disclosure shall be subject to obligations of confidentiality
and non-use with respect to such mBC Clinical Trial Data and such OV Confidential Information consistent with industry standards.

 

10.5 Terms
of Agreement. The terms of this Agreement shall be deemed to be the Confidential Information of both Parties, and neither Party may
disclose such Confidential Information except as otherwise set forth in this Article 10. In addition, either Party may disclose the terms
of this Agreement on a need-to-know basis to such Party’s legal, accounting and financial advisors; provided that in each case
the Person to whom the terms of this Agreement is to be disclosed agrees in writing to be subject to obligations of confidentiality and
non-use with respect to such Confidential Information consistent with industry standards.

 

10.6
Mandatory Disclosure.

 

a) Notification
and Consultation. In the event that the Receiving Party is required by Applicable Law (including regulations applicable to the public
sale of securities) or by court order or judicial or administrative process or by the requirements of a securities exchange on which
the securities of such Party (or its Affiliate) are listed, to disclose any part of the Disclosing Party’s Confidential Information
(including the terms of this Agreement), the Receiving Party shall (a) promptly notify the Disclosing Party of each such requirement
and identify the documents so required thereby, so that the Disclosing Party may seek or request the Receiving Party to seek an appropriate
protective order, confidential treatment or other remedy or waive compliance by the Receiving Party with the provisions of this Agreement
and (b) consult with the Disclosing Party oil the advisability of taking legally available steps to resist or narrow the scope of such
requirement and cooperate in all reasonable respects with the Disclosing Party’s efforts to obtain confidential treatment or a
protective order with respect to any such disclosure.

 

    26

     

    

 

b) Limited
Disclosure. If, in the absence of such a protective order, confidential treatment request, other remedy or waiver by the Disclosing
Party, the Receiving Party is nonetheless required to disclose any part of the Disclosing Party’s Confidential Information or any
material terms or conditions of this Agreement, the Receiving Party may disclose such Confidential Information (including the terms of
this Agreement), except that the Receiving Party shall furnish only that portion of the Confidential Information (including the terms
of this Agreement) that is legally required; provided that if this Agreement is required to be publicly filed, the Parties shall reasonably
agree on a redacted version to be publicly filed.

 

10.7 Injunctive
Relief. Each Party shall be entitled to seek injunctive relief to enforce the terms of this Article 10.

 

11.
TERM AND TERMINATION

 

11.1 Term.
This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force
and expire upon the later of (i) the expiration of the Option Period as extended by the R-Pharm Option Term; or (ii) if OV has exercised
its Exclusive Option and the Parties have not executed a Re-Acquisition Agreement, the expiration of the Royalty Term unless earlier
terminated pursuant to Section 11 (the “Term”).

 

11.2 Termination
by OV. Upon ninety (90) days written notice to R-Pharm, OV may elect to terminate this Agreement for any reason in its sole discretion.

 

11.3 Termination
for Failure to Exercise the Exclusive Option. If OV fails to provide the Option Request Notice before the expiration of the Option
Period, then the Exclusive Option shall expire and this Agreement will terminate upon the expiration of the Option Period.

 

11.4 Termination
for Material Breach. If either Party (the “Non-Breaching Party”) believes that the other Party (the “Breaching
Party”) has materially breached this Agreement, then the Non- Breaching Party may deliver notice of such material breach
to the Breaching Party (a “Default Notice”). If the Breaching Party does not dispute that it has committed a
material breach of this Agreement, then if the Breaching Party fails to cure such breach, or fails to take steps as would be
considered reasonable to effectively cure such breach, within ninety (90) days (or thirty (30) days payment-related breaches) after
receipt of the Default Notice (provided that if such cure cannot reasonably be achieved within such ninety- (90-) (or thirty- (30-),
as applicable) day period, then such ninety- (90-) (or thirty- (30-), as applicable) day period shall be automatically extended for
an additional ninety (90) days), the Non-Breaching Party may terminate this Agreement upon written notice to the Breaching Party. If
the Breaching Party disputes that it has materially breached this Agreement, the dispute shall be resolved pursuant to Section
14.14. If, as a result of the application of such dispute resolution procedures, the Breaching Party is finally determined to be in
material breach of this Agreement (an “Adverse Ruling”), then if the Breaching Party fails to cure such material
breach within ninety (90) days (or thirty (30) days payment-related breaches) after such Adverse Ruling (or such longer period as
established by the courts in such final determination), then the Non-Breaching Party may terminate this Agreement upon written
notice to the Breaching Party.

 

11.5 Termination
for Insolvency. In the event that either Party (a) files for protection under bankruptcy or insolvency laws or files a request for
bankruptcy under any bankruptcy or insolvency laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment
of a receiver or trustee over substantially all of its property that is not discharged within ninety (90) days after such filing, (d)
proposes or is a party to any dissolution or liquidation, (e) files a petition under any bankruptcy or insolvency act or has any such
petition filed against that is not discharged within ninety (90) days of the filing thereof, or (f) admits in writing its inability generally
to meet its obligations as they fall due in the general course (each of the foregoing (a) through (f), an “Insolvency Event”),
then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party.

 

    27

     

    

 

11.6
Effects of Termination. In the event of any termination of this Agreement, then:

 

a) all
rights and licenses granted by each Party to the other Party hereunder shall immediately terminate;

 

b) each
Party and its Affiliates shall promptly return to the other Party or destroy any Confidential Information of the other Party furnished
to the receiving Party by the other Party, except that the receiving Party shall have the right to retain one copy for record keeping
purposes; and

 

c) in
the event that this Agreement is terminated by R-Pharm pursuant to Section 11.4 or 11.5 or by OV pursuant to Section 11.2, at the written
request of R-Pharm, which must be delivered within ninety (90) days after the termination of this Agreement:

 

(i) OV
shall and hereby does assign to R-Pharm, to the extent it is legally permitted to do so, any material Regulatory Documentation and any
other Regulatory Approvals for the Product, in each case, owned by OV (or any of its Affiliates) as of the effective date of termination
and that are solely and exclusively related to the Product, and to the extent it is not legally permitted to do so, OV shall and hereby
does grant to R-Pharm an exclusive “right of reference” (as defined in US FDA 21 CFR 314.3(b)) or similar “right of
reference” (as defined in applicable regulations in the relevant jurisdiction) with respect to such Regulatory Documentation and
other Regulatory Approvals. OV shall and hereby does grant to R-Pharm a non-exclusive “right of reference” (as defined in
US FDA 21 CFR 314.3(b)) or similar “right of reference” (as defined in applicable regulations in the relevant jurisdiction)
with respect to such Regulatory Documentation and other Regulatory Approvals that are necessary for R-Pharm’s development and commercialization
of the Product but that are not solely and exclusively related to the Product;

 

(ii) OV
shall and hereby does grant to R-Pharm a non-exclusive, world-wide, fully paid-up, royalty-free license, with the right to grant and
authorize sublicenses, under the Patents and Know-How Controlled by OV as of the effective date of termination that (i) were actually
used by OV in the Development of the Product hereunder, (ii) are solely and exclusively related to Product, and (iii) are necessary for
the continued Development of such Product (in the form that such Product was being Developed by OV as of the effective date of termination)
for use in the Field (collectively, the “Terminated Product Technology”), to research, develop, make, have made, use,
offer to sell, sell, import, export or otherwise exploit Product (in the form that such Product was being Developed by OV as of the effective
date of termination) in the Field in the Territory; and

 

(iii) If
OV was conducting (i) an ongoing clinical trial of the Product or (ii) the mBC Clinical Trial as of the effective date of termination,
then R-Pharm may notify OV in writing (prior to the effective date of termination of this Agreement) that it will continue such clinical
trial, in which case, the Parties shall negotiate in good faith and mutually agree on an agreement setting forth the terms and conditions,
under which R-Pharm will continue such clinical trial.

 

11.7 Remedies.
Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit
remedies that may otherwise be available in law or equity.

 

11.8 Survival.
Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the
benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations
that are expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, Sections 7.7,
7.8, 7.9, 7.10, 7.11, 11.6, and 11.7 and this Section 11.8, and Articles l (to the extent used in any surviving provisions), and 8, 10,
13 and 14 of this Agreement shall survive the termination or expiration of this Agreement for any reason.

 

    28

     

    

 

12.
REPRESENTATIONS, WARRANTIES, AND COVENANTS

 

12.1 Mutual
Representations and Warranties. Each Party represents and warrants to the other as of the Effective Date that:

 

a) it
is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation;

 

b) it
has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all corporate actions required
by law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions
contemplated by this Agreement;

 

c) this
Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms;

 

d) all
consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party
in connection with this Agreement have been obtained;

 

e) the
execution and delivery of this Agreement and all other instruments and documents required to be executed pursuant to this Agreement,
and the consummation of the transactions contemplated hereby, do not and shall not (i) conflict with or result in a breach of any provision
of its organizational documents; (ii) result in a breach of any other agreement to which it is a party; or (iii) violate any law; and

 

f) except
as otherwise provided herein, neither Party nor any of its respective Affiliates has, and neither will during the Term, enter into agreements
or grant any right, title or interest to any Person that is inconsistent with the rights and licenses granted to the other Party under
this Agreement.

 

12.2 Additional
Representations, Warranties and Covenants of R-Pharm. R-Pharm further warrants and represents to OV as of the Effective Date as follows:
R-Pharm owns, Controls, and/or has the right to provide the copies of the Existing Regulatory Documentation and transfer the Compound
to OV hereunder and it not aware of any pending, imminent, or threatened litigation or dispute relating to such Existing Regulatory Documentation
and Compound;

 

13.
INDEMNIFICATION.

 

13.1 Indemnification
Obligations of R-Pharm. R-Pharm shall indemnify and hold OV, its Affiliates and its respective officers, directors, agents and employees
(“OV Indemnitees”) harmless from and against any and all losses, damages, liabilities, penalties, costs, and expenses
(collectively, “Losses”) arising out of or resulting from any claim, demand, action, suit or proceeding of Third Parties
(collectively, “Third Party Claims”) against or incurred by the OV Indemnitees to the extent arising or resulting
from:

 

a)
any breach of any representation or warranty of R-Pharm set forth in this
Agreement;

 

    29

     

    

 

b)
any breach of any covenant, agreement or undertaking made by R-Pharm in this Agreement; or

 

c) the
willful misconduct of R-Pharm or its Affiliates or its or their respective directors, officers, employees and agents, in connection with
R-Pharm’s performance of its obligations or exercise of its rights under this Agreement;

 

d) provided
however that, such indemnity shall not apply (i) to any actual violation by OV or its Affiliates of Applicable Law after the Effective
Date, or (ii) to the extent OV has an indemnification obligation pursuant to Section 13.2.

 

13.2 Indemnification
Obligations of OV. OV shall indemnify and hold R-Pharm, its Affiliates and their respective officers, directors, agents and employees
(“R-Pharm Indemnitees”) harmless from and against any and all Losses arising out of or resulting from any Third Party
Claims against or incurred by the R-Pharm Indemnitees to the extent arising or resulting from:

 

a)
any breach of any representation or warranty ofOV set forth in this Agreement;

 

b)
any breach of any covenant, agreement or undertaking made by OV in this Agreement; or

 

c) the
willful misconduct of OV or its Affiliates or its or their respective directors, officers, employees and agents, in connection with OV’s
performance of its obligations or exercise of its rights under this Agreement;

 

d) provided
however that, such indemnity shall not apply (i) to any actual violation by R-Pharm or its Affiliates of Applicable Law after the Effective
Date, (ii) to the extent R-Pharm has an indemnification obligation pursuant to Section 13.1.

 

13.3
Indemnification Procedure.

 

a) For
the avoidance of doubt, all Third Party Claims in respect of a R-Pharm Indemnitee or OV Indemnitee shall be made solely by R-Pharm or
OV, respectively.

 

b) A
Party seeking indemnification hereunder (“Indemnified Party”) shall give the other Party (“Indemnifying Party”)
prompt written notice (“Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified
Party intends to base a request for indemnification under this Article 13, but the failure or delay to so notify the Indemnifying Party
shall not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent
that the Indemnifying Party demonstrates that its ability to defend or resolve the relevant claims is adversely affected thereby. The
Indemnification Claim Notice shall contain a description of the claim and the nature and amount of such Loss (to the extent that the
nature and amount of such Loss is known at such time). Upon the request of the Indemnifying Party, the Indemnified Party shall furnish
promptly to the Indemnifying Party copies of all correspondence, communications and official documents (including court documents) received
or sent in respect of any Third Party Claims and Losses.

 

c) If
the Litigation Conditions are satisfied, then the Indemnifying Party shall have the right to assume and control the defense of the
Third Party Claim, at its own expense with counsel selected by it and reasonably acceptable to the Indemnified Party, by delivering
written notice of its assumption of such defense to the Indemnitee within twenty (20) days of its receipt of notice of such Third
Party Claim from the Indemnified Party (but the Indemnifying Party shall in any event have the right to assume and control the
defense of a Third Party Claim that initially sought injunctive relief (including a declaratory judgment) when the only remaining
dispute in such matter is the determination of non- injunctive relief or when the only remaining relief sought by the Third Party in
such matter is non-injunctive relief, whichever is first); provided, however, that the Indemnified Party shall have the right to
retain its own counsel, with the reasonable fees and expenses to be paid by the Indemnifying Party, if (a) representation of the
Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential conflict of
interests between such Indemnified Party and Indemnifying Party, (b) the Indemnifying Party has failed within a reasonable time to
retain counsel, (c) the Indemnified Party shall have reasonably concluded that there may be legal defenses available to it that are
different from or in addition to those available to the Indemnifying Party, or (d) at any time the Litigation Conditions are not
satisfied with respect to such Third Party Claim.

 

    30

     

    

 

d) Subject
to the provisions of paragraph (g) below, the Indemnified Party shall not make any admission of liability, conclude any agreement in
relation to such liability or make any compromise with any Person, body or authority in relation to such liability without the prior
written consent of the Indemnifying Party.

 

e) Subject
to the provisions of paragraph (c) above and paragraphs (f) and (g) below, the Indemnifying Party shall have the right, upon written
notice given to the Indemnified Party within thirty (30) days after receipt of the Indemnification Claim Notice to assume the defence
and handling of any Third Party Claim, at the Indemnifying Party’s sole expense, in which case the provisions of paragraph (f)
below shall govern. The assumption of the defence of a Third Party Claim by the Indemnifying Party shall not be construed as acknowledgement
that the Indemnifying Party is liable to indemnify any indemnitee in respect of the Third Party Claim, nor shall it constitute a waiver
by the Indemnifying Party of any defences it may assert against any Indemnified Party’s claim for indemnification. In the event
that it is ultimately decided that the Indemnifying Party is not obligated to indemnify or hold an Indemnitee harmless from and against
the Third Party Claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all reasonable and justifiable costs
and expenses (including attorneys’ fees and costs of suit) incurred by the Indemnifying Party in its defence of the Third Party
Claim. If the Indemnifying Party does not give written notice to the Indemnified Party, within thirty (30) days after receipt of the
Indemnification Claim Notice, of the Indemnifying Party’s election to assume the defence and handling of such Third Party Claim,
the provisions of paragraph (g) below shall govern.

 

f)
Upon assumption of the defence of a Third Party Claim by the Indemnifying Party: (i) the Indemnifying Party shall have the right to and
shall assume sole control and responsibility for dealing with the Third Party Claim; (ii) the Indemnifying Party may, at its own cost,
appoint as counsel in connection with conducting the defence and handling of such Third Party Claim any law firm or counsel reasonably
selected by the Indemnifying Party; (iii) the Indemnifying Party shall keep the Indemnified Party informed of the status of such Third
Party Claim; and (iv) the Indemnifying Party shall have the right to settle the Third Party Claim on any terms the Indemnifying Party
chooses; provided, however, that it shall not, without the prior written consent of the Indemnified Party, agree to a settlement of any
Third Party Claim which could lead to liability or create any financial or other obligation on the part of the Indemnified Party for
which the Indemnified Party is not entitled to indemnification hereunder or which admits any wrongdoing or responsibility for the claim
on behalf of the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and shall be entitled to participate
in, but not control, the defence of such Third Party Claim with its own counsel and at its own expense. In particular, the Indemnified
Party shall, at the Indemnifying Party’s expense furnish such records, information and testimony, provide witnesses and attend
such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation
shall include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of,
records and information that are reasonably relevant to such Third Party Claim, and making the Indemnified Party, the indemnitees and
its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any
records or information provided.

 

    31

     

    

 

g) If
the Indemnifying Party does not give written notice to the Indemnified Party as set forth in paragraph (d) or fails to conduct the defence
and handling of any Third Party Claim in good faith after having assumed such, the Indemnified Party may, at the Indemnifying Party’s
expense, select counsel reasonably acceptable to the Indemnifying Party in connection with conducting the defence and handling of such
Third Party Claim and defend or handle such Third Party Claim in such manner as it may deem appropriate. In such event, the Indemnified
Party shall keep the Indemnifying Party timely apprised of the status of such Third Party Claim and shall not settle’ such Third
Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld. If the Indemnified
Party defends or handles such Third Party Claim, the Indemnifying Party shall cooperate with the Indemnified Party, at the Indemnified
Party’s request but at no expense to the Indemnified Party, and shall be entitled to participate in the defence and handling of
such Third Party Claim with its own counsel and at its own expense.

 

14.
MISCELLANEOUS

 

14.1 Further
Action. Each Party agrees, without the necessity of any further consideration, to execute, acknowledge, and deliver any and all such
further instruments, and do all further similar acts, as may be necessary or appropriate to carry out the purposes and intent of this
Agreement.

 

14.2 Press
Releases. No Party shall issue any other press release, trade announcement or make any other public announcement or statement with
regard to the transactions contemplated by this Agreement without the other Parties’ prior written consent, which shall not be
unreasonably withheld. Where consent is forthcoming, the Parties agree to consult with each other regarding the content of any such press
release or other announcement. The aforementioned restriction shall not apply to announcements required by any Regulatory Authority or
Governmental Entity under Applicable Law, provided that in such event the Parties shall coordinate the wording and OV shall take into
consideration any requests of R-Pharm. Each Party hereto acknowledges that OV and R-Pharm shall have the right to disclose a brief summary
of the transaction, including the amounts payable by OV under this License Agreement, in its official financial reports.

 

    32

     

    

 

14.3 Notices
and Other Communications. All notices, consents, waivers, and other communications under this Option Agreement must be in writing
and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation of receipt); (b) sent by fax (with
written confirmation of receipt), provided that a copy is immediately sent by an internationally recognized overnight delivery service
(receipt requested); or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt
requested), in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as
a Party may designate by written notice):

 

If
to OV:

 

Oncology
Venture ApS

Venlighedsvej 1

DK-2970
Hoersholm, Denmark

Attention: Chief Executive Officer

Email:
pbj@oncologyventure.com

 

With
a copy to:

 

DechertLLP
1900 K St., N.W.

Washington,
D.C. 20006

Attention:David
E. Schulman

Telephone:(202) 261-3440

 

Ifto
R-Pharm:

 

R-Pharm
US Operating, LLC

3120 Princeton Pike, Suite 201

Lawrence, N.J. 08648 U.S.A.

Attn:
Chief Executive Officer

 

With a copy to:

 

Morgan,
Lewis & Bockius LLP

502 Carnegie Center

Princeton,
NJ 08540

Attention: David Glazer, Esq.

 

Each
Party may change its address for purposes of this License Agreement by written notice to the other Party.

 

14.4 Amendments.
No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of
each Party.

 

14.5 Assignment.
No Party may assign its rights and obligations under this Agreement without the other Party’s prior written consent, which
consent shall not be unreasonably withheld, except that either Party may assign its rights and obligations under this Agreement without
the consent of the other Party to (i) one or more of its Affiliates (provided that such Party shall remain responsible for such Affiliate’s
performance of this Agreement); or (ii) in connection with the transfer or sale of all or substantially all of its assets related to
the subject matter of this Agreement, or in the event of its merger or consolidation or change in control or similar transaction. The
assignor shall remain liable notwithstanding any assignment hereunder.

 

14.6 Third
Party Rights. The provisions of this Option Agreement are for the sole benefit of the Parties and their successors and permitted
assigns, and they shall not be construed as conferring any rights to any Third Party.

 

14.7 Entire
Agreement. This Agreement (together with the Exhibits hereto) sets forth and constitutes the entire agreement and understanding between
the Parties relating to subject matter hereof and in relation to such subject matter supersedes all earlier understandings and agreements,
whether written or oral, between the Parties (including that certain Mutual Non-Disclosure and Confidentiality Agreement by and between
R-Pharm US LLC and OV dated October 11, 2017).

 

    33

     

    

 

14.8 No
Additional Representations or Warranties. Each Party acknowledges that it has not entered into this Agreement in reliance upon any
representation or warranty other than as set out in this Agreement. No representation, warranty, condition or any other term is to be
implied into this Agreement whether by virtue of any usage or course of dealing or otherwise except as expressly set out in it. This
clause shall not exclude the liability of a Party for fraud or fraudulent misrepresentation.

 

14.9 Relationship.
Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between
R-Pharm and OV, or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of
the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an independent contractor,
and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other.

 

14.10 Waiver
of Rights. No failure or delay by a Party to exercise any right or remedy provided under this Agreement or by law or to insist upon
compliance with any term or condition of this Agreement will constitute a waiver of that (or any other) right or remedy or excuse a similar
subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in
writing and signed by the Party giving such waiver. No single or partial exercise of such right or remedy will preclude or restrict the
further exercise of that (or any other) right or remedy.

 

14.11 Severability.
Every provision of this Agreement is intended to be severable. If any provision of this Agreement shall be invalid or unenforceable,
such invalidity or unenforceability shall not affect the other provisions of this Agreement, which shall remain in full force and effect.
The Parties hereto agree to consult each other and to agree upon a new stipulation which is permissible under Applicable Law and which
comes as close as possible to the original purpose and intent of the invalid, void or unenforceable provision.

 

14.12 Counterparts.
This Agreement may be executed in any number of counterparts, each of which is an original but all of which together will constitute
one and the same instrument.

 

14.13 Governing
Law and Venue. This Agreement and the performance, enforcement, breach or termination hereof shall be interpreted, governed by and
construed in accordance with the laws of the State of New York, United States, without giving effect to the conflicts of Laws provision
thereof, and with the exclusion of the International Sale of Goods Vienna Convention on the International Sale of Goods. Except for decisions
that are subject to the decision-making authority of a given Party (or mutual agreement of the Parties, as applicable) or the JDC, as
expressly set forth in this Agreement, in the event of any controversy, claim or counterclaim arising out of or relating to this Agreement,
the Parties shall first attempt to resolve such controversy or claim through good faith negotiations for a period of not less than thirty
(30) days following notification of such controversy or claim to the other Party. If such controversy or claim cannot be resolved by
means of such negotiations during such period, then such controversy or claim (excepting preliminary injunctions) shall be submitted
by the parties for binding arbitration under rules of the International Chamber of Commerce (ICC) to be held in New York City, New York.
The Parties shall bear their own costs of arbitration, unless otherwise awarded by arbitrator(s).

 

14.14 Dispute
Resolution. The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to
either Party’s rights or obligations hereunder. It is the objective of the Parties to establish under this Section 14.14 procedures
to facilitate the resolution of disputes arising under this Agreement (other than any disputes relating to matters with respect to which
under this Agreement a Party has sole decision-making authority or discretion, in which case, such matter shall be determined by such
Party and shall not be part of the dispute resolution procedure set forth in this Section 14.14) in an expedient manner by mutual cooperation
and without resort to litigation. In the event that the Parties are unable to resolve such dispute through diligent review and deliberation
by the Parties within thirty (30) days from the date either Party had designated such matter as a dispute in written notice to the other
Party, then, at any time after such thirty (30) day period, either Party may proceed to enforce any and all of its rights with respect
to such dispute. For clarity, such thirty (30) day period shall not extend any other time periods provided in this Agreement, including
those set forth in Section 11.4.

 

    34

     

    

 

14.15 English
Language. This Agreement is written and executed in the English language. Any translation into any other language shall not be an
official version of this Agreement and in the event of any conflict in interpretation between the English version and such translation,
the English version shall prevail.

 

14.16 Cumulative
Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any
other remedy referred to in this Agreement or otherwise available under law.

 

14.17 Expenses.
Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and
other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery
of this Agreement.

 

14.18 Special,
Indirect and Other Losses. EXCEPT (A) FORA PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 10 AND SECTION 2.8, OR (B) TO THE
EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A THIRD PARTY CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION
UNDER ARTICLE 13, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR
OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED
BY THE OTHER PARTY.

 

14.19 No
Exclusion. Neither Party excludes any liability for death or personal injury caused by its negligence or that of its employees, agents
or sub-contractors.

 

14.20 Compliance
with Law. Each Party shall perform its obligations under this Agreement in accordance with all Applicable Law. No Party shall, or
shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good
faith, may violate, any Applicable Law.

 

14.21 Force
Majeure. If and to the extent that any Party is prevented or delayed from performing any of its obligations under this Agreement
by any unavoidable and unforeseeable event which is beyond the reasonable control of the Party affected, including but not limited to
the following events: earthquake, storm, flood, fire or other acts of nature, epidemic, war (whether or not declared), riot, public disturbance,
strike or lockouts, government actions, terrorist attack or the like (a “Force Majeure”), and promptly so notifies
in writing the other Party, specifying the matters constituting Force Majeure together with such evidence in verification thereof as
it can reasonably give and specifying the period for which it is estimated that the prevention or delay will continue, then the Party
so affected shall be relieved of liability to the other for failure to perform or for delay in performing such obligations (as the case
may be), but shall nevertheless use its Commercially Reasonable Efforts to resume full performance thereof.

 

14.22
Construction.

 

a) The
definitions of the terms herein will apply equally to the singular and plural forms of the terms defined and where a word or phrase is
defined herein, each of its other grammatical forms will have a corresponding meaning. Whenever the context may require, any pronoun
will include the corresponding masculine, feminine, and neuter forms. The word “shall” will be construed to have the same
meaning and effect as the word “will.” The word “any” means “any and all” unless otherwise clearly
indicated by context. The words “including,” “includes,” “include,” “for example,” and
“e.g.” and words of similar import will be deemed to be followed by the words “without limitation.” The word
“or” is disjunctive but not necessarily exclusive. The words “hereof,” “herein” and “herewith”
and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement.

 

b) The
language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall
be applied against either Party hereto.

 

c) Each
Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated
in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption
will apply against the Party which drafted such terms and provisions.

 

[SIGNATURES
FOLLOW ON NEXT PAGE]

 

    35

     

    

 

The
Parties have executed this Agreement as of the Effective Date to evidence their agreement to the terms and provisions set forth herein.

 

	 	Oncology Venture ApS
	 	 
	 	By:	 
	 	Name: 	Peter Buhl Jensen, M.D. 
	 	Title:	Chief Executive Officer
	 	 
	 	R-Pharm US Operating, LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

[Signature
Page to Development, Option and License Agreement]

 

     

     

    

 

EXHIBIT
A: CLINICAL DEVELOPMENT PLAN

 

		●	To
                                            be agreed by the Parties and attached within ninety (90) days after the Effective Date

 

     

     

    

 

EXHIBIT
B: THE COMPOUND

 

IXEMPRA®
(ixabepilone) a cancer medicine. IXEMPRA is used alone or with another cancer medicine called capecitabine. IXEMPRA is used to treat
breast cancer, when certain other medicines have not worked or no longer work.

 

DOSAGE
FORMS AND STRENGTHS

 

IXEMPRA
for injection, 15 mg supplied with DILUENT for IXEMPRA, 8 ml

 

IXEMPRA
for injection, 45 mg supplied with DILUENT for IXEMPRA, 23.5 ml

 

     

     

    

 

EXHIBIT
C: FORM OF PHARMACOVIGILANCE AGREEMENT

 

PHARMACOVIGILANCE
AGREEMENT

 

This
Pharmacovigilance Agreement (hereinafter the “Agreement”) as a part of Distribution Agreement NQ from_/_/                
has been entered by and between:

 

R-Pharm
US, LLC, a legal entity having its registered address at 3120 Princeton Pike, Lawrence, NJ (hereinafter “R-Pharm US”), and                 
., a legal entity having its registered address at                  
(hereinafter Partner), each hereinafter referred to as a “Party” and collectively as the “Parties”, for the
purposes of division of the Parties’ ·rights and obligations regarding monitoring of the Product effectiveness and safety
aimed at identification, assessment and prevention of undesirable effects of the Product use in accordance with the laws applicable to
relations between the Parties.

 

Definitions

 

Adverse
Event/Adverse Drug Experience/ADE: any untoward medical occurrence in a patient or clinical investigation subject administered a
Product and which does not necessarily have to have a causal relationship with the Product.

 

Product:
medicinal product or medical device where a Marketing Authorization Holder is R- Pharm US in the USA and Partner in the                 market.

 

Territory(s)
shall mean                       

 

Effective
Date means the date of this Agreement as designated on the first page of this Agreement.

 

Year
has the meaning from January 1st until December 31st.

 

Agreement
shall mean this Agreement.

 

Product
Technical Complaints and Adverse Drug Experiences

 

1. Hereby
R-Pharm US authorizes Partner to act as a holder and owner of marketing authorization for the Product in terms of collecting, processing,
registration and analysis of information on side effects, ADE and in terms of submission to the authorized federal executive body of
the Territory for control and supervision in healthcare of a Product pharmacovigilance report as stipulated by the laws of the Territory
in force.

 

     

     

    

 

2.
Product technical complaints (hereinafter - “PTC”) related to the quality of Product that are received by Partner shall be
notified to R-Pharm US (or its designee agent) as soon as received but in not more than forty-eight (48) hours. Partner will include
in the notification to R-Pharm US any information received by the complainant such as but not limited to
the Product name, lot number

 

		-	Details
                                            of the patient (sex or age);

 

		-	Details
                                            of the event including outcome;

 

		-	Details
                                            of the reporter (name, title and contact information).

 

The
first communication from Partner to R-Pharm US should be communicated in writing by email (and confirmed by fax) to the contact point
of the Pharmacovigilance contact person of R- Pharm US.

 

4. Partner
is responsible for medical assessment of all cases of Adverse Experiences/events, relevant for Product within the Territory(s).

 

Partner
shall provide R-Pharm US with CIOMS forms for Adverse Experiences/Events relevant to Product originated in the Territory within fourteen
(14) days from the date of initial receipt (day one (1) begins when Partner receives the report about ADE).

 

R-Pharm
US (or its designee agent) shall provide Partner with CIOMS forms for all relevant Suspected Unexpected Serious Adverse Reactions (hereinafter
- “SUSARS”) originated outside of the Territory within fourteen (14) from the date of initial receipt.

 

R-PHARM
US PHARMACOVIGILANCE CONTACT

 

Pro
Pharma Group

Regulatory
/ Medical / Pharmacovigilance/ Safety information exchange

Name:
Tim Smith, Director of Pharmacovigilance

e-mail
DrugSafety@propharmaroup.com

e-mail
Tim.Smith@propharmagroup.com

phone
US 1-844-586-8953

 

R-Pharm
US will contact Partner for further information on an as needed basis.

 

Partner pharmacovigilance contact person:

 

 

5. Partner
shall serve as an expert in the Territory reporting regulations and shall be responsible for submission of safety information reports
to local regulatory authorities (single reports and periodic reports) based on local regulations.

 

     

     

    

 

6. R-Pharm
US (or designee agent) shall provide Partner with periodic safety update reports that were prepared for US regulatory reporting.
Partner shall determine whether each report needs to be submitted to local regulatory authorities based on its regulations, Partner
may modify the format of the report (without modification of content) based on local regulatory requirements; if modification of
content is necessary, R-Pharm US must review and approve the report prior to submission (expiration date), complainant name (in case
of legal entity), number of units involved, and a complete description of the complaint. Partner will include any documents related
to the PTC that could permit R-Pharm US investigate the PTC including but not limited to images or photos, and samples if available.
The PTC information should be communicated in writing by email (and confirmed by fax) to the Quality persons indicated in this
Annex:

 

QUALITY
CONTACT PERSONS:

R-Pharm
US PTC contact person

 

Name:
Jignesh Shah

Title:
VP, Global Supply Chain, Manufacturing and Quality

E-Mail:
jignesh.shah@rpharm-us.com

Phone:
+1 (609) 512-7211

Fax:
+1 (609) 512-7198

 

PTC
contact person Name: Verena Grimm

Title:
Manager Contract QA Biopharmaceuticals

E-Mail:
Verena.Grimm(ivr-pharm.com

Phone:
+49-7303-12-9122

Fax:
+49-7303-12-387

 

<Partner
contact information>

 

3.
Partner is obliged to communicate to R-Pharm US (or designee agent), within the maximum time period of forty-eight (48) hours, any communication
received from a client, hospital or health authority in relation with the potential adverse drug events and/or any other safety issue
relevant for the Product that could potentially affect the safety of the Product.

 

The
first communication from Partner to R-Pharm US shall contain the following elements:

 

		-	Product
                                            name;

 

		-	Lot
                                            number (if applicable);

 

     

     

    

 

7. In
consideration of the expenses incurred by Partner in performance of this Agreement, R- Pharm US shall pay to Partner the fees as set
out in Distribution Agreement.

 

The
Parties agree and acknowledge that the Fees set out in Distribution Agreement shall be valid throughout the first two (2) Years of the
term of this Agreement, it being understood that the Year of the Effective Date counts as the first Year. For all subsequent Years during
the term of this Agreement, the Parties agree to meet not later than thirty (30) days prior to the end of each Year to review and agree
new fees for the following Year. Subject to the parties agreeing new fees, the Fees will be replaced with the newly agreed amounts and
Distribution Agreement will be deemed to be amended accordingly.

 

Other
Exchanged Information (as described below)

 

Certain
information or reports, while not meeting the definition of an Adverse Drug Event (ADE) shall also be exchanged. This information includes:

 

		●	A
                                            case involving pregnancy/lactation exposure to the Product(s) either maternal or paternal

 

		●	Lack
                                            of effect, misuse, product confusion, abuse, overdose, inadvertent or accidental exposure
                                            without an associated ADE, occupational exposure without an associated ADE

 

		●	An
                                            unexpected therapeutic or clinical benefit from use of the Product(s)

 

		●	Any
                                            actions due to safety issues including Product recall (Note: notification of such between
                                            the Parties must be immediate)

 

		●	Actual
                                            or Potential medication errors, suspected transmission by a medicinal Product of an infectious
                                            agent, “off-label” use (including “off-label” pediatric use)

 

		●	events
                                            possibly or probably related to biomedical research, animal research that may potentially
                                            cause significant risk for human subjects including mutagenicity, teratogenicity, or carcinogenicity

 

		●	Any
                                            Product quality complaint for pharmaceuticals and biologicals related to ADE has to be reported.

 

Partner
shall send all Other Exchanged Information described above to R-Pharm US, regardless of an associated ADE unless otherwise stated, utilizing
the terms of ADE reporting set forth in this Agreement.

 

Other
Exchanged Information described above should be reported by Partner to R-Pharm US in accordance with same timelines and contact details
as Adverse Experience/Event reports.

 

Product
recall due to safety issues shall also be handled as an ADE and the notification between the Parties will be immediate. Product recall
due to safety issues shall also be handled as an ADE and the notification between the Parties will be immediate.

 

Monthly
Reconciliation

 

On
a monthly basis, Partner shall provide R-Pharm US with a listing of all reports sent to R- Pharm US in the course of the previous
month. This listing shall be sent to R-Pharm US contact above and will be used by R- Pharm US to confirm that all reports sent by
Partner to R-Pharm US were received by R-Pharm US in the course of the previous month. All ADE reports, initial and follow-up
reports, shall be included on the listing. Should there be discrepancies on the list Partner shall be notified. In the event no
reports were sent by Partner to R-Pharm US in a particular month, a notification will be sent to R-Pharm US indicating zero (0)
reports were sent that month.Exhibit 10.6

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

Execution Version      

 

EXCLUSIVE LICENSE AGREEMENT

 

between

 

ONCOLOGY VENTURE, APS

 

and EISAI
INC.

 

Dated as of July 6, 2017

 

     

    

    

 

TABLE OF CONTENTS

 

	ARTICLE 1 Definitions and Rules of Construction	1
	Section 1.1	Definitions	1
	Section 1.2	Terms Defined Elsewhere in this Agreement	13
	Section 1.3	Rules of Construction	13
	ARTICLE 2 Grant of Rights; Diligence	14
	Section 2.1	Grant of Eisai Intellectual Property and Retention of Rights	14
	Section 2.2	Grant of OV Technology and Retention of Rights	14
	Section 2.3	Sublicenses	15
	Section 2.4	CNS Field Option	15
	Section 2.5	Rights to Inventions	15
	ARTICLE 3 Product Development	16
	Section 3.1	Governance	16
	Section 3.2	Development	17
	Section 3.3	Transfer	17
	Section 3.4	Assistance	17
	Section 3.5	Pharmacovigilance	17
	Section 3.6	Manufacturing; Inventory	18
	Section 3.7	No Other Rights	18
	Section 3.8	Bankruptcy	18
	Section 3.9	No Representation	18
	ARTICLE 4 Commercialization Activities	19
	Section 4.1	Commercialization Responsibilities	19
	ARTICLE 5 Non-Compete 	19
	Section 5.1	Non-Compete	19
	Section 5.2	Change of Control Exception	19
	ARTICLE 6 Product Acquisition	20
	Section 6.1	Third Party Acquirer	20
	Section 6.2	Eisai Option to Re-Acquire	20
	ARTICLE 7 Payments		20
	Section 7.1	Upfront Payment	20
	Section 7.2	Royalties	20
	Section 7.3	Milestones; Survival	22
	Section 7.4	Additional Payment Terms	22
	Section 7.5	Currency Conversion	23
	Section 7.6	Extension Payment	23
	Section 7.7	Taxes	23

 

    -i-

     

    

 

	ARTICLE 8 Regulatory Matters	23
	Section 8.1	Compliance with Laws	23
	Section 8.2	Regulatory Approval	23
	ARTICLE 9 Intellectual Property	23
	Section 9.1	Ownership of Intellectual Property	23
	Section 9.2	Patent Filings, Prosecution and Maintenance of Eisai Intellectual Property and any Joint Intellectual Property	24
	Section 9.3	Extensions of Patent Term for Products	25
	Section 9.4	Enforcement of Eisai Intellectual Property and Joint Intellectual Property	25
	Section 9.5	Enforcement of OV Technology	26
	Section 9.6	Defense of Infringement Claims of Eisai Intellectual Property and Joint Intellectual Property	26
	ARTICLE 10 Indemnification	27
	Section 10.1	Indemnification by Eisai.	27
	Section 10.2	Indemnification by OV	27
	Section 10.3	Waiver	28
	Section 10.4	Insurance	28
	Section 10.5	Limitation of Consequential Damages	28
	ARTICLE 11 Representations and Warranties	28
	Section 11.1	General Corporate Matters	28
	Section 11.2	Intellectual Property Matters	29
	Section 11.3	Eisai Covenants.	30
	Section 11.4	OV Covenants	30
	ARTICLE 12 Confidentiality and Publicity	30
	Section 12.1	Confidentiality	30
	Section 12.2	Publicity	31
	ARTICLE 13 Record-keeping and Audits	32
	Section 13.1	Records Retention	32
	Section 13.2	Audit Request	32

 

    -ii-

     

    

 

	ARTICLE 14 Term and Termination	33
	Section 14.1	Term	33
	Section 14.2	Rights of Termination	33
	Section 14.3	Surviving Rights and Obligations	34
	Section 14.4	Effect of Expiration or Termination; Remaining Inventory	34
	ARTICLE 15 Miscellaneous	36
	Section 15.1	Entire Agreement; Amendments	36
	Section 15.2	Governing Law	36
	Section 15.3	Dispute Resolution	36
	Section 15.4	Partial Illegality	37
	Section 15.5	Waiver of Compliance	37
	Section 15.6	Notices	37
	Section 15.7	Limitation on Liability	38
	Section 15.8	Counterparts	38
	Section 15.9	Further Assurances	38
	Section 15.10	Injunctive Relief	38
	Section 15.11	Jointly Prepared	38
	Section 15.12	Assignment	38
	Section 15.13	Relationship of Parties	38
	Section 15.14	Force Majeure	39
	Section 15.15	Severability	39
	Section 15.16	Third-Party Beneficiaries	39
	Section 15.17	Expenses	39

 

    -iii-

     

    

 

LIST OF EXHIBITS

 

		A	Clinical Development Plan

		B	Compound-Specific Biomarker

		C	Press Release

 

LIST OF SCHEDULES

 

		1	Major Countries

		2	Patents

		3	Compound

		3.3	Data and Information

		3.6	Inventory

		9.2(b)	Certain Product-Specific Patents

 

 

    -iv-

     

    

 

EXCLUSIVE LICENSE AGREEMENT

 

This Exclusive
License Agreement (this “Agreement”) is entered into as of July 6, 2017 (the “Effective Date”),
between Oncology Venture, ApS, a company organized and existing under the laws of Denmark, whose principal place of business is located
at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”)

 

and

 

Eisai Inc., a Delaware corporation having a principal place
of business at 100 Tice Blvd., Woodcliff Lake, NJ 07677 (“Eisai”).

 

RECITALS

 

A. Eisai
is engaged in research and clinical development of oncology compounds, which is currently developing the Compound (as defined below).

 

B. Pursuant
to the MTA (defined below), OV developed and validated the Product-Specific Biomarker (as defined below) for the Compound utilizing certain
materials and data contributed by Eisai.

 

C. OV
and its Affiliates desire to obtain an exclusive license under the Eisai Intellectual Property (defined below) to exclusively develop
the Compound in the Field utilizing the Product-Specific Biomarker pursuant to this Agreement. OV and Eisai have previously executed a
Term Sheet (dated September 26, 2016) (the “Term Sheet”) regarding the terms of such proposed license.

 

D. Eisai
is willing to grant to OV an exclusive license under the Eisai Intellectual Property to develop the Compound in the Field subject to the
conditions set forth in, and pursuant to, this Agreement.

 

AGREEMENT

 

In consideration
of the mutual covenants set forth in this Agreement, OV and Eisai hereby agree as follows.

 

ARTICLE 1

Definitions and Rules of Construction

 

The definitions
and rules of constructions set forth below shall apply throughout this Agreement.

 

Section 1.1 Definitions.

 

“Adverse
Event” has the meaning set forth in the Applicable Law for such term (or comparable term), and will generally mean any
untoward medical occurrence in a subject in any Clinical Trial who has received a Product, medical device or placebo, and that does
not necessarily have a causal relationship with such Product, medical device or placebo, including any unfavorable and unintended
sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the applicable Product,
whether or not related to such Product.

 

    -1-

     

    

 

“Affiliate”
means, with respect to a Person, any Person that is controlled by, controls, or is under common control with such first Person, as
the case may be. For purposes of this definition, the term “control” means (a) direct or indirect ownership of fifty percent
(50%) or more of the voting interest in the entity in question, or fifty percent (50%) or more interest in the income of the entity in
question; provided, however, that if local Law requires a minimum percentage of local ownership of less than fifty percent
(50%), control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of the maximum ownership percentage
that may, under such local Law, be owned by foreign interests, or (b) possession, directly or indirectly, of the power to direct or cause
the direction of management or policies of the entity in question (whether through ownership of securities or other ownership interests,
by contract or otherwise). The Parties acknowledge and agree that Medical Prognosis Institute, ApS (“MPI”) and 2X Oncology,
Inc. (“2X”) is an Affiliate of OV.

 

“Annual
Net Sales” means, on a Product-by-Product basis, total Net Sales by the Selling Parties in the Territory of such Product in
a particular Calendar Year, it being understood and agree that “Annual Net Sales” does not include any sales of diagnostic
products.

 

“Applicable
Laws” means all applicable common law, statutes, ordinances, rules, regulations, guidances and orders of any Governmental Authority,
including Regulatory Laws.

 

“Business
Day” means a day on which banking institutions in both Tokyo, Japan and Copenhagen, Denmark are open for business, excluding
any Saturday or Sunday.

 

“Calendar
Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 or December
31, during the Term, or the applicable part thereof during the first or last calendar quarter of the Term.

 

“Calendar
Year” means any calendar year ending on December 31, or the applicable part thereof during the first or last year of the Term.

 

“Change
of Control” means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party which results in
the stockholders or equity holders of such Party or any Parent Corporation not owning at least fifty percent (50%) of the combined voting
power of the surviving entity immediately after such merger or consolidation, or (b) except in the case of a bona fide equity or debt
financings, whether private or public, in which a Party issues new shares of its capital stock or securities convertible into shares of
such Party, a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial
owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party or Parent Corporation or
(c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business to which the subject matter
of this Agreement relates.

 

“Clinical
Development Plan” means the development plan governing the Phase 2 Clinical Trial to be conducted by OV with respect to
the Compound, the initial draft of which is attached to this Agreement as Exhibit A, as may be amended from time to time by
the JDC pursuant to Section 3.1.

 

    -2-

     

    

 

“Clinical
Trials” means a human clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that
a pharmaceutical product is reasonably safe for continued testing; (b) investigate the safety and efficacy of the pharmaceutical product
for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the pharmaceutical product
in the dosage range to be prescribed; or (c) support Regulatory Approval of such pharmaceutical product or label expansion of such pharmaceutical
product.

 

“CNS Field”
shall mean the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive)
treatment of peripheral of effects of agents causing CNS disease or symptoms.

 

“Combination
Product” means a Product that contains one or more additional active ingredients (whether co-formulated or co-packaged) that
are neither the Compound nor generic or other non-proprietary compositions of matter equivalents.

 

“Commercialization”
means any and all activities of marketing, promoting, distributing, offering for sale or selling the Product in the Field in the Territory,
including, for example, marketing, branding, pricing, distribution, sales, obtaining health insurance reimbursement coverage, market research,
business analytics, pharmacovigilance and medical affairs activities, pre-commercial launch market development activities conducted in
anticipation of Regulatory Approval to sell or market the Product, seeking pricing and reimbursement approvals for the Product (if applicable),
preparing advertising and promotional materials, sales force training, and all interactions and correspondence with a Regulatory Authority
regarding Clinical Trials commenced following Regulatory Approval. When used as a verb, “Commercialize” means to engage in
Commercialization.

 

“Commercially
Reasonable Efforts” means with respect to the performing Party, a level of efforts and resources, not less than reasonable efforts
and resources, that is consistent with the efforts and resources that commonly used in the innovative biopharmaceutical industry by companies
of comparable size and standing to such Party with respect to a product or compound owned by it or to which it has rights of the type
it has hereunder, or similar market potential at a similar stage in the development or product life thereof, taking into account scientific
and commercial factors, including issues of safety and efficacy, product profile, the pricing and launching strategy for the respective
product, difficulty in developing or manufacturing the Product, competitiveness of alternative Third Party products in the marketplace,
the Patent or other proprietary position of the Product (including the ability to obtain or enforce, or have obtained or enforced, such
Patent or other proprietary positions), the regulatory requirements involved and the potential profitability, cost, market share, price
or reimbursement to the performing Party of the Product marketed or to be marketed.

 

“Competitive
Product” means, other than the Product, any pharmaceutical product having a primary mechanism of action (or in the case of
a combination product, any component of such combination product having as its primary mechanism of action) through the inhibition
of poly ADP ribose polymerase, whether currently marketed or in development, that is labeled, advertised, marketed, promoted or
intended for use in the Field.

 

    -3-

     

    

 

“Compound”
means the compound commonly referred to as E7449, a small molecule inhibitor of poly ADP ribose polymerase, as more specifically described
on Schedule 3, and including therapeutically-active variants.

 

“Control” or “Controlled”
means, with respect to any intellectual property right, information, documents or materials of a Party (or, as described below, a
Future Acquirer), that such Party or its Affiliates, or a Future Acquirer, (a) owns or has a license to such intellectual property
right, information, documents or materials (other than pursuant to this Agreement); and (b) has the ability to grant access, a
license or a sublicense to such intellectual property right, information, documents or materials to the other Party as provided in
this Agreement without violating an agreement with or other rights of any Third Party, provided that any intellectual
property Controlled by a Future Acquirer of a Party shall not be treated as “Controlled” by such Party for purposes of
this Agreement, except to the extent that, and only to the extent that, such intellectual property (i) is actually used by such
Party or its Affiliates, or the Future Acquirer, to Develop, Manufacture or Commercialize the Product after the Future Acquirer
qualifies as such; or (ii) comes under the Control of such Future Acquirer due to reference or access by such Future Acquirer to, or
use by such Future Acquirer of, intellectual property of such Party. Notwithstanding the foregoing, with respect to any intellectual
property acquired after the Effective Date for which a Party will be required to make payments to any Third Party in connection with
the access, licenses and sublicenses granted to the other Party under this Agreement, such intellectual property shall not be
treated as “Controlled” by the licensing Party except to the extent that, and only to the extent that and for so long
as, the other Party agrees and does promptly pay to the licensing Party all such payments arising out of the grant of the license to
the other Party (as mutually agreed between the Parties in good faith).

 

“Cover”,
“Covering” or “Covered” means, with respect to a claim of a Patent and a Product, that the manufacture,
use, offer for sale, sale or importation of the Product would infringe a Valid Claim of such Patent in the country in which such activity
occurred, but for the licenses granted in this Agreement (or ownership thereof).

 

“Damages”
means all claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses,
costs of litigation and reasonable attorney’s fees), or judgments, whether for money or equitable relief, of any kind and is not
limited to matters asserted by Third Parties against a Party, but includes claims, threatened claims, damages, losses, suits, proceedings,
liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney’s fees) or judgments incurred
or sustained by a Party in the absence of Third Party claims; provided that no Party shall be liable to hold harmless or indemnify the
applicable indemnified party, as applicable, for any claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs
or judgments for punitive or exemplary damages, except to the extent the Party seeking indemnification is actually liable to a Third Party
for such punitive or exemplary damages in connection with a claim by such Third Party.

 

    -4-

     

    

 

“Data”
shall mean all data and information generated, collected or filed, in relation to research and development activities relating to
the Product in the Field in the Territory, including toxicology data, pharmacological data, non-clinical reports, clinical reports, single
patient clinical report forms, data points and the databases, and stability data, chemical data, quality control data (excluding the closed
portion of any drug master file), adverse event and pharmacovigilance data, marketing data, pharmaco-economic data, branding and naming
research reports, and all CMC data (including CMC (chemistry, manufacturing and control) development reports).

 

“Development”
means all activities related to research, preclinical testing, clinical development efforts, test method development and stability testing,
assay development, toxicology, formulation, process development, formulation development, delivery system development, quality assurance
and quality control development, statistical analysis, clinical pharmacology, clinical studies (including Clinical Trials) and clinical
study regulatory activities, seeking Regulatory Approval and otherwise handling regulatory affairs, statistical analysis and report writing
with respect to the Product. Development shall not include Manufacturing or Commercialization. When used as a verb, “Develop”
means to engage in Development.

 

“Eisai Intellectual Property” means Eisai
Patents and Eisai Know-How.

 

“Eisai
Know-How” means Know-How owned or Controlled by Eisai or its Affiliates as of the Effective Date or during the Term of this
Agreement that is necessary or useful to Develop, Manufacture, or Commercialize the Product in the Field in the Territory.

 

“Eisai Patents” means the Product-Specific
Patents and the Platform Patents.

 

“EMA” means the European Medicines Agency,
and any successor entity thereto.

 

“FDA”
means the United States Food and Drug Administration (or any successor agency having the administrative authority to grant Regulatory
Approval in the United States).

 

“Field”
shall mean as of the Effective Date, any and all preventative, therapeutic and/or diagnostic uses related to cancer in humans; it
being understood and agreed that, effective upon receipt by OV of rights to the CNS Field pursuant to any definitive agreement with Eisai
as contemplated by Section 2.4, references to “Field” in this Agreement shall be deemed to include the CNS Field.

 

“Field
Action” means any action by a Party that meets the criteria of “recall,” “correction,” or “removal”
or similar field or customer action as defined by applicable Regulatory Law, including where any event, incident or circumstance has occurred
that may result in the need for a recall from the market, market suspension or market withdrawal of the Product by a Party in the Territory.

 

“First
Commercial Sale” means, with respect to a Product and any country in the Territory, the first sale of such Product under
this Agreement by a Selling Party for use in the Field to a Third Party in such country, after such Product has been granted
Regulatory Approval for distribution, marketing and sale (in each case to the extent required by Applicable Laws) in the Field by
the competent Regulatory Authorities in such country. For avoidance of doubt, First Commercial Sales exclude transfers or
dispositions of a Product for charitable, promotional (including samples), pre-clinical, clinical or regulatory purposes.

 

    -5-

     

    

 

“Force
Majeure” means any war, revolution, civil commotion, act of terrorism, blockade, epidemic, embargo, labor strike or lock-out,
scarcity of raw materials, flood, fire, earthquake, tsunami, nuclear disaster, unforeseen change in Applicable Law or similar event that
is beyond the reasonable control of the Party affected.

 

“Future Acquirer”
means the Third Party to any Change of Control transaction and any of such Third Party’s Affiliates.

 

“Generic
Product” means, other than the Product, any pharmaceutical product (i) that contains the Compound as an active ingredient(s)
(including an active moiety) as such approved Product; (ii) is approved for use in such country pursuant to (a) Article 10.1 of Directive
2001/83/EC of the European Parliament and Council of 6 November 2001, or any enabling legislation thereof, or any amended or successor
abbreviated route of approval, or (b) any Laws or abbreviated routes of approval in any other countries worldwide that are comparable
to those described above; and (iii) is sold in the same country as such Product by any Third Party that is not a sublicensee of OV or
its Affiliates and did not purchase such product in a chain of distribution that included any of OV or any of its Affiliates or its sublicensees.
A pharmaceutical product that is AB-rated or comparably rated in any jurisdiction outside the United States to the applicable Product
shall be a Competitive Product with respect to such Product in such country.

 

“Good
Clinical Practices” or “GCP” means the then-current ethical and scientific quality standards for designing,
conducting, recording, and reporting trials that involve the participation of human subjects as are required by applicable Regulatory
Authorities or Law in the relevant jurisdiction. In the United States, GCP shall be based on Good Clinical Practices established through
FDA guidances (including Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6)), and, outside the
United States, GCP shall be based on Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6), as each
may be amended and/or updated from time to time.

 

“Good
Laboratory Practices” or “GLP” means the then-current good laboratory practice standards promulgated or endorsed
by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the United States,
as they may be amended and/or updated from time to time).

 

“Good
Manufacturing Practices” or “GMP” means all applicable then-current standards relating to manufacturing practices
for fine chemicals, intermediates, bulk products and/or finished pharmaceutical products, including (a) all applicable requirements detailed
in the FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211 and “The Rules Governing Medicinal
Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products”, as each may be amended and/or
updated from time to time, and (b) all Applicable Laws promulgated by any Governmental Authority having jurisdiction over the manufacture
of any Product, as applicable.

 

    -6-

     

    

 

“Governmental
Authority” means in any country the government entity having authority over the manufacturing, marketing, selling, pricing,
reimbursement, testing, investigating or regulating of the Product, and all states or other political subdivisions thereof and supranational
bodies applicable thereto, including the European Union, and all agencies, commissions, officials, courts or other instrumentalities of
the foregoing.

 

“IFRS”
means the International Financial Reporting Standards developed by the International Accounting Standards Board (IASB).

 

“IND”
means an Investigational New Drug application, Clinical Study Application, Clinical Trial Exemption, or similar application or submission
for approval to conduct Clinical Trials filed with or submitted to a Regulatory Authority in the applicable jurisdiction in conformance
with the requirements of such Regulatory Authority.

 

“Indication”
means any human disease or condition, or sign or symptom of a human disease or condition in a particular target patient population.

 

“Insolvency
Event” means that the Party has (a) commenced a voluntary proceeding under any insolvency law, or (b) had an involuntary
proceeding commenced against it under any insolvency law which has continued undismissed or unstayed for 60 consecutive days, or (c)
had a receiver, trustee or similar official appointed for it or for any substantial part of its property, or (d) made a general
assignment for the benefit of creditors, or (e) had an order for relief entered with respect to it by a court of competent
jurisdiction under any insolvency law. For purposes hereof, the term “insolvency law” means any applicable bankruptcy,
insolvency or other similar law now or hereafter in effect.

 

“Inventions”
means any process, method, composition of matter, article of manufacture, discovery, improvement or finding that is discovered, generated
or invented (whether patentable or not) in the course of activities performed under this Agreement.

 

“Joint
Intellectual Property” means the Joint Know-How and the Joint Patents, and all intellectual property rights therein. The Parties
acknowledge and agree that any “Joint IP”, as such term was defined in the MTA, which was identified, synthesized, invented,
generated, discovered, acquired, conceived or otherwise Developed under the MTA, shall be deemed “Joint Intellectual Property”
hereunder.

 

“Joint
Know-How” means any Know-How that is conceived or developed or, in the case of Patentable Know-How, including any Inventions,
jointly by one or more employees of Eisai or its Affiliates (or a Third Party acting on any of their behalf) and one or more employees
of OV or its Affiliates (or a Third Party acting on any of their behalf) in the course of such Person’s performance of activities
in connection with this Agreement.

 

“Joint Patent” means any Patent that Covers
Joint Know-How.

 

“Know-How”
means (a) any research information (including trade secrets, inventions (whether patentable or not), methods, knowledge, skill, experience,
data, results (including pharmacological, toxicological and clinical test data and results, chemical structures, sequences, processes,
formulae, techniques, research data, reports, standard operating procedures and batch records), analytical and quality
control data, analytical methods (including applicable reference standards), full batch documentation, packaging records, release,
stability, storage and shelf-life data, and manufacturing process information, results or descriptions, software and algorithm and
(b)  tangible manifestations thereof. As used in this Agreement, “clinical test
data” shall include all information related to clinical or non-clinical testing, including patient report forms,
investigators’ reports, biostatistical, pharmaco-economic and other related analyses, regulatory filings and communications,
and the like.

 

    -7-

     

    

 

“Knowledge”
means knowledge after reasonable due inquiry with respect to the applicable facts and information of the employees of each of the Parties
and their Affiliates.

 

“Major Country” means the countries listed
hereto on Schedule 1.

 

“Manufacture”
or “Manufacturing” means all operations necessary or appropriate to make, test, release, package, store, label,
supply and ship a Product, in accordance with applicable packaging, controls industry standards, GMPs, Applicable Laws, and the Product’s
specifications.

 

“Marketing
Authorization Application” or “MAA” shall mean an application for Regulatory Approval in the European Union
to market a product in any country, whether filed with the EMA under the centralized EMA filing procedure or a Regulatory Authority in
any country in the European Union.

 

“MHLW”
means the Ministry of Health, Labor and Welfare of Japan, or the Pharmaceuticals and Medical Devices Agency of Japan, or any successor
to either of them, as the case may be.

 

“Minimum
Clinical Development Plan Criteria” shall mean those specific activities designated as “Minimum Clinical Development
Plan Criteria” in the Clinical Development Plan.

 

“MTA”
means that certain Material Transfer Agreement, dated as of March 15, 2017, by and between the Parties.

 

“NDA”
means a “New Drug Application,” as defined in the United States Federal Food, Drug, and Cosmetic Act, as amended, and applicable
regulations promulgated thereunder by the FDA and all amendments and supplements thereto filed with the FDA, or the equivalent application
filed with any Regulatory Authority, including all documents, data, and other information concerning Product, which are necessary for
gaining Regulatory Approval to market and sell Product in the relevant jurisdiction.

 

“Net
Sales” means, on a country-by-country and Product-by-Product basis in the Field in the Territory, with respect to any
period for each country, the gross amounts invoiced by OV, its Affiliates or its or their sublicensees (each, a “Selling
Party”), as applicable, to unrelated Third Parties for sales of a Product in the Field in such country, less the following
deductions to the extent included in the gross invoiced sales price for such Product or otherwise directly paid, incurred, allowed,
accrued or specifically allocated by the Selling Parties with respect to the sale of such Product in such country: (a) discounts,
including trade, quantity or cash discounts, credits, adjustments or allowances, including those granted on account of price
adjustments, billing errors, rejected goods, or damaged goods, which discounts are applied on a basis consistent with the selling
Person’s practices with respect to the selling Person’s other pharmaceutical products; (b) rebates and chargebacks
allowed, given or accrued (including cash, governmental and managed care rebates, hospital or other buying group chargebacks, cash
and non-cash coupons, retroactive price reductions, and governmental taxes in the nature of a rebate based on usage levels or sales
of such Product); (c) sales, excise, turnover, inventory, value- added, import, export, excise (including annual fees due under
Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48) and other comparable laws)
and other taxes levied on, absorbed, determined or imposed with respect to the sale of such Product (excluding income or net profit
taxes or franchise taxes of any kind); (d) freight and insurance charges, customs charges, postage, shipping, handling, REMS
compliance costs and other transportation costs incurred in shipping such Product; (e) amounts paid or credited to customers for
inventory management services; and (f) the portion of any management fees paid during the relevant time period to group purchasing
organizations, wholesalers and managed care organizations to the extent determined by sales or utilization of such Product. Net
Sales will be determined in accordance with IFRS. Without limiting the generality of the foregoing, transfers or dispositions of a
Product for charitable, promotional (including samples), pre-clinical, clinical, or regulatory purposes will be excluded from Net
Sales, as will sales or transfers of a Product among the Selling Parties.

 

    -8-

     

    

 

Subject to the above deductions, Net
Sales shall be deemed to occur on, and only on, the first sale by a Selling Party to a non-sublicensee Third Party. If non-monetary consideration
is received by a Selling Party for the Product in the relevant country, Net Sales will be calculated based on the average price charged
for such Product, as applicable, during the preceding period, or in the absence of such sales, the fair market value of the Product, as
applicable, as determined by the Parties in good faith.

 

If a Product is sold as part of a Combination
Product, Net Sales will be the product of (i) Net Sales of the Combination Product calculated as above (i.e., calculated as for a non-Combination
Product) and (ii) the fraction (A/(A+B)), where:

 

“A” is the gross invoice
price in such country of the Product comprising the Compound as the sole therapeutically active ingredient; and

 

“B” is the gross invoice
price in such country of the other therapeutically active ingredients contained in the Combination Product.

 

If “A” or “B”
cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, but
the gross invoice price in the above equation shall be determined by mutual agreement reached in good faith by the Parties prior to the
end of the accounting period in question based on an equitable method of determining the same that takes into account, in the applicable
country, variation in dosage units and the relative fair market value of each therapeutically active ingredient in the Combination Product.

 

“Order”
means any award, injunction, judgment, decree, order, ruling, verdict or other decision issued, promulgated or entered by or with
any Governmental Authority of competent jurisdiction.

 

“Out-of-Pocket
Costs” means, with respect to certain activities hereunder, direct expenses paid or payable by either Party or its Affiliates
to Third Parties (other than employees of such Party or its Affiliates) that are specifically identifiable and incurred to conduct such
activities for the Product hereunder and have been recorded in accordance with either U.S. generally accepted accounting principles or
International Financial Reporting Standards, as designated and used by the applicable Party in preparing its financial statements from
time to time.

 

“OV Platform
Technology” means all Patents and Know-How Controlled by OV and/or its Affiliates (a) as of the Effective Date, and (b) during
the Term that do not Cover Inventions and are not Know-How arising in the course of the conduct of Development activities under this Agreement.
The Parties understand and agree that any Patents, Know-How and/or Inventions related to OV’s proprietary biomarker generation platform
Drug Response Predictor (DRPTM) (excluding the Product-Specific Biomarker), shall always be considered “OV Platform Technology”
hereunder.

 

“Parent
Corporation” means any Person which owns, directly or indirectly, at least fifty percent (50%) of the outstanding voting securities
of any Party.

 

“Party” means Eisai and/or OV, as the context
requires.

 

“Patent”
means any and all (a) patent applications filed under Applicable Laws in any jurisdiction, including all provisional applications,
substitutions, continuations, continuations-in- part, divisions, renewals, and all patents granted thereon; (b) all patents, reissues,
reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including supplementary protection
certificates or the equivalent thereof; and (c) any other form of government-issued right substantially similar to any of the foregoing.

 

“Person”
means any individual or entity (including partnerships, corporations, limited liability companies, trusts and Governmental Authorities).

 

“Phase
1 Clinical Trial” means (a) both a Phase 1a Clinical Trial and a Phase 1b Clinical Trial, or (b) a single trial that may contain
elements of both a Phase 1a Clinical Trial and a Phase 1b Clinical Trial.

 

“Phase
1a Clinical Trial” means a human clinical trial of a compound, the principal purpose of which is a preliminary determination
of safety, pharmacokinetics, and pharmacodynamic parameters in healthy individuals or patients, as described in 21 C.F.R. 312.21(a), or
a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

 

    -9-

     

    

 

“Phase
1b Clinical Trial” means a human clinical trial of a compound, the principal purpose of which is a further determination
of safety and pharmacokinetics (including exploration of trends of a biomarker-based or clinical endpoint-based efficacy
relationship to dose which are not designed to be statistically significant) of the compound whether or not in combination with
concomitant treatment after an initial Phase 1a Clinical Trial, prior to commencement of Phase 2 Clinical Trials or Phase 3 Clinical
Trials, and which provides (itself or together with other available data) sufficient evidence of safety to be included in filings
for a Phase 2 Clinical Trial or a Phase 3 Clinical Trial with Regulatory Authorities, or a similar clinical study prescribed by the
Regulatory Authorities in a foreign country.

 

“Phase
2 Clinical Trial” means a human clinical trial of a product in any country that would satisfy the requirements of U.S. 21 C.F.R.
Part 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate evidence of clinical
safety and effectiveness for a particular Indication or Indications in a target patient population, or a similar clinical study prescribed
by the relevant Regulatory Authorities in a country other than the United States.

 

“Phase
3 Clinical Trial” means a human clinical trial of a product in any country that would satisfy the requirements of U.S. 21 C.F.R.
Part 312.21(c) and is intended to (a) establish that the product is safe and efficacious for its intended use, (b) define contraindications,
warnings, precautions and adverse reactions that are associated with the product in the dosage range to be prescribed, and (c) support
Regulatory Approval for such product, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other
than the United States.

 

“Pivotal
Clinical Trial” means a human clinical trial of a product on a sufficient number of subjects that, prior to commencement
of the trial, satisfies both of the following ((a) and (b)):

 

(a) such
trial is designed to establish that such product has an acceptable safety and efficacy profile for its intended use, and to determine
warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is
intended to support Regulatory Approval of such product, or a similar clinical study prescribed by the U.S. or EMA; and

 

(b) such
trial is a registration trial sufficient for filing an application for a Regulatory Approval for such product in the U.S. or the
EMA, as evidenced by (i) an agreement with or statement from the FDA or the EMA on a Special Protocol Assessment or equivalent, or
(ii) other guidance or minutes issued by the FDA or EMA, for such registration trial.

 

“Platform
Patents” means those Patents listed on Schedule 2 attached hereto under the heading “Platform Patents”
as well as any Patent, other than the Product-Specific Patents, owned or Controlled by Eisai or its Affiliates as of the Effective Date
and during the Term that: (a)(i) claims or Covers any Eisai Know-How, and/or (ii) is otherwise necessary or useful to Develop, Manufacture
or Commercialize the Product in the Field in the Territory, and (b) does not specifically describe or reference a Product or exploitation
of a Product in the Field. For clarity, a Patent owned or Controlled by Eisai or its Affiliates that arises after the Effective Date cannot
be both a Platform Patent and a Product-Specific Patent.

 

“Product”
means all preparations, compositions and formulations of the Compound, together with all current and future formulations, versions,
compositions and presentations of product, together with any improvements or modifications, that use the Compound as its active pharmaceutical
ingredient alone or in combination with other therapeutically or prophylactically active pharmaceutical ingredients as part of a Combination
Product.

 

    -10-

     

    

 

“Product-Specific
Biomarker” means the specific DRPTM biomarker Developed exclusively for the Compound by or on behalf of OV pursuant to
the MTA, as more specifically described on Exhibit B.

 

“Product-Specific
Patents” means those Patents listed on Schedule 2 attached hereto under the heading “Product-Specific
Patents” as well as any Patent, other than the Platform Patents, owned or Controlled by Eisai or its Affiliates as of the
Effective Date and during the Term that: (a)(i) claims or Covers any Eisai Know-How and/or (ii) is otherwise necessary or useful to
Develop, Manufacture or Commercialize the Product in the Field in the Territory, and
(b) specifically describes or references a Product or exploitation of a Product in the
Field. For clarity, a Patent owned or Controlled by Eisai or its Affiliates that arises after the Effective Date cannot be both a
Platform Patent and a Product-Specific Patent.

 

“Product
Complaint” means any written, electronic or oral communication that alleges deficiencies related to the identity, quality, durability,
reliability, safety, delivery, effectiveness or performance of the Product after it is released by OV for distribution.

 

“Proprietary
Information” means a Party’s trade secrets, know-how, business plans, manufacturing processes, clinical strategies, product
specifications, scientific data, market analyses, formulae, designs, training manuals and other non-public information (whether business,
financial, commercial, scientific, clinical, regulatory or otherwise) that the Party treats as proprietary and uses Commercially Reasonable
Efforts to protect.

 

“Prosecute”
or “Prosecution” means, with respect to Patents, the preparation of, filing for, prosecuting, responding to oppositions,
nullity actions, re-examinations, revocation actions and similar proceedings (including conducting or participating in interference, oppositions,
reissue proceedings, reexaminations, post-grant proceedings and any other similar proceeding relating thereto) filed by Third Parties
against, and maintaining, Patents.

 

“Regulatory
Approval” means the approval and authorization of a Regulatory Authority in a country or regulatory jurisdiction necessary to
develop, manufacture, distribute, sell or market a pharmaceutical product in that country or regulatory jurisdiction. Regulatory Approval
shall include pricing and reimbursement approval in any country or regulatory jurisdiction in the Territory.

 

“Regulatory
Authority” means, with respect to any country or jurisdiction, any Governmental Authority involved in granting Regulatory Approval
or in administering Regulatory Laws in that country or jurisdiction.

 

“Regulatory
Documentation” shall mean all applications, registrations, licenses, authorizations, approvals (including all Regulatory
Approvals), and correspondence (registration and licenses, pricing and reimbursement correspondence, regulatory drug lists,
advertising and promotion documents) submitted to or received from Regulatory Authorities (including minutes and official contact
reports relating to any communications with any Regulatory Authority) and all supporting documents in connection therewith, and all
non-clinical, preclinical trials and Clinical Trials, tests and biostudies, relating to the use of the Product in the Field, or as
required for regulatory purposes (including all Regulatory Approvals) and all Data contained in any of the foregoing, including all
INDs, NDAs and Regulatory Approvals, regulatory drug lists, advertising and promotion documents, manufacturing data and records,
drug master files, inspection reports, Data from Clinical Trials, adverse event files and complaint files, in each case related to
the Product in the Field, or as required for regulatory purposes.

 

    -11-

     

    

 

“Regulatory
Laws” means all Applicable Laws governing the import, export, testing, investigation, manufacture, marketing or sale of a product,
or establishing recordkeeping or reporting obligations for Product Complaints or Adverse Events, or relating to Field Actions or similar
regulatory matters.

 

“Right
of Reference or Use” means a “Right of Reference or Use” as that term is defined in 21 C.F.R. §314.3(b), and
any non-United States equivalents.

 

“Royalty
Term” means, on a Product-by-Product and country-by-country basis, the period of time commencing on the First Commercial Sale
of any Product in such country and expiring on the later of (a) expiration of the last Valid Claim of any and all Eisai Patents, OV Patents
and Joint Patents Covering such Product in such country and (b) the fifteenth (15th) anniversary of the date of First Commercial
Sale of such Product in such country; provided that, with respect to a Product being Commercialized in the US and the Major Countries,
the Royalty Term shall continue in both the US and the Major Countries until expiration of the last Valid Claim of any and all Eisai Patents,
OV Patents and Joint Patents Covering such Product in the US and each of the countries in the Major Countries.

 

“Successful
Completion” means that, with respect to the Phase 2 Clinical Trial to be conducted by OV and/or its Affiliates or sublicensees
hereunder pursuant to the Clinical Development Plan, there is at least a twenty percent (20%) objective response rate in treated patients
in the Field as contemplated by the initial Clinical Development Plan as of the Effective Date or such amended Clinical Development Plan
that has been mutually agreed to by the Parties.

 

“Term Sheet” has the meaning set forth
in the recitals.

 

“Territory” means worldwide.

 

“Third Party” means any Person other than
the Parties and their Affiliates.

 

“US” or “United States”
means the United States of America.

 

“Valid
Claim” means, with respect to a particular country, (a) a claim of a pending Patent claiming priority from any Patent that
has been pending for no more than five (5) years following the earliest priority filing date for such Patent and that has not been
abandoned, finally rejected or expired without the possibility of appeal or refiling or (b) a claim of an issued and unexpired
Patent and that has not been held permanently revoked, held unenforceable or invalid by a decision of a court or other Governmental
Authority of competent jurisdiction, which decision is unappealed or unappealable within the time allowed for appeal and has not
been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or
otherwise, in the case of (a) and (b) above, which claims the composition of matter or method of use of a Product in the Field. For
clarity, a claim of a Patent that ceased to be a Valid Claim before it issued because it had been pending too long, but subsequently
issued and is otherwise described by clause (a) of the foregoing sentence shall again be considered to be a Valid Claim once it
issues. A Product is “Covered” by a Valid Claim if its registration, manufacture, use, sale, offer for sale, marketing,
Commercialization, distribution, importation or exportation by OV in a given country in the Territory would, but for the rights
granted by Eisai to OV under this Agreement, infringe such Valid Claim.

 

    -12-

     

    

 

Section 1.2Terms Defined Elsewhere
in this Agreement.

 

Capitalized terms defined in other provisions
of this Agreement shall have the meanings specified therein. Those terms include the following:

 

	Term	 	Section
	Additional Third Party License	 	Section 7.2(d)
	Agreement	 	Preamble
	Auditee	 	Section 13.2(e)
	Audit Rights Holder	 	Section 13.2(e)
	Audit Team	 	Section 13.2(a)
	Business Program	 	Section 5.2
	Challenge	 	Section 14.2(e)
	Claim	 	Section 10.1(a)
	Confidential Information	 	Section 12.1(a)
	Development Milestone Events	 	Section 7.3(b)
	Dispute	 	Section 15.3
	Effective Date	 	Preamble
	Eisai	 	Preamble
	Eisai Indemnified Parties	 	Section 10.2(a)
	ICC	 	Section 15.3
	Infringement Claim	 	Section 9.6
	JDC	 	Section 3.1(a)
	OV	 	Preamble
	OV Indemnified Parties	 	Section 10.1(a)
	OV Know-How	 	Section 9.1(b)
	OV Patents	 	Section 9.1(b)
	OV Technology	 	Section 9.1(b)
	Program Acquirer	 	Section 6.1
	Program Acquirer Agreement	 	Section 6.1
	Recovery	 	Section 9.4(a)
	Rules	 	Section 15.3
	Sales Milestone Events	 	Section 7.3(a)
	Term	 	Section 14.1

  

Section 1.3Rules of Construction.

 

(a) Elements
of this Agreement. When a reference is made in this Agreement to a Recital, an Article, a Section, a Schedule, an Attachment or
an Exhibit, such reference is to a Recital, Article or Section of, or a Schedule, Attachment or Exhibit to, this Agreement, unless
otherwise indicated.

 

    -13-

     

    

 

(b) Meaning
of “Include” and Variations Thereof. Whenever the words “include,” “includes” or “including”
are used in this Agreement, they shall be understood to be followed by the words “without limitation.”

 

(c) Use
of Pronouns. Pronouns, including “he,” “she” and “it,” when used in reference to any person, shall
be deemed applicable to entities or individuals, male or female, as appropriate in any given case.

 

(d) Headings.
Article, Section and other headings contained in this Agreement are for reference purposes only and are not intended to describe, interpret,
define or limit the scope, extent or intent of any provision of this Agreement.

 

(e) Variations
on Terms. Standard variations on defined terms (such as the plural form of a term defined in the singular form, and the past tense
of a term defined in the present tense) shall be deemed to have meanings that correlate to the meanings of the defined terms.

 

(f) Currency
References. All references to “dollars” or “$” shall be deemed to be references to the
lawful currency of the United States.

 

ARTICLE 2

Grant of Rights; Diligence

 

Section 2.1Grant of Eisai Intellectual
Property and Retention of Rights.

 

(a) During
the Term, subject to the terms and conditions of this Agreement, Eisai, on behalf of itself and its Affiliates, hereby grants to OV and
OV’s Affiliates an exclusive (even as to Eisai), royalty-bearing right and license under the Eisai Intellectual Property to Develop,
make, have made, store, use, sell, have sold, import, export and otherwise Commercialize Products in the Field in the Territory. For clarity,
in the foregoing sentence, “exclusive” means that neither Eisai nor its Affiliates shall, for its or their own account, and
shall not grant to any Third Party the right and license under the Eisai Intellectual Property to, Develop, make, have made, store, use,
sell, have sold, import, export and otherwise Commercialize Products in the Field in the Territory.

 

(b) Eisai,
on behalf of itself and its Affiliates, hereby grants OV and OV’s Affiliates a Right of Reference or Use to all Data and Regulatory
Documentation (including all Regulatory Approvals) related to the Product owned or Controlled by Eisai or its Affiliates as of the Effective
Date and during the Term for all uses in connection with the Product for Development, Manufacturing and Commercialization in the Field
in the Territory.

 

Section 2.2Grant of OV Technology
and Retention of Rights.

 

(a) During
the Term, subject to the terms and conditions of this Agreement, OV, on behalf of itself and its Affiliates, hereby grants to Eisai
and Eisai’s Affiliates an exclusive (even as to OV), right and license under the OV Technology to Develop, make, have made,
store, use, sell, have sold, import, export and otherwise Commercialize Products, in each case, solely for use outside the
Field in the Territory. For clarity, in the foregoing sentence, “exclusive” means that neither OV nor its Affiliates
shall, for its or their own account, and shall not grant to any Third Party the right and license under the OV Technology to,
Develop, make, have made, store, use, sell, have sold, import, export and otherwise Commercialize Products for outside the Field
(including the CNS Field) in the Territory.

 

(b) OV,
on behalf of itself and its Affiliates, hereby grants Eisai and Eisai’s Affiliates a Right of Reference or Use to all Data and Regulatory
Documentation (including all Regulatory Approvals) related to the Product owned or Controlled by OV or its Affiliates during the Term
for all uses in connection with the Product for Development, Manufacturing and Commercialization, in each case, solely for use outside
the Field (including the CNS Field) in the Territory.

 

    -14-

     

    

 

Section 2.3Sublicenses.

 

(a) OV
shall have the right to grant sublicenses with respect to OV’s rights and obligations under this Agreement to (i) any
Affiliates of OV and (ii) Third Parties pursuant to Article 6; provided that, with respect to sublicenses granted to Third
Parties, subject to Article 6, (x) OV provides Eisai with written notice of such sublicense promptly after the grant of such
sublicense, which notice shall not be required for rights granted to distributors, wholesalers or marketing agents, (y) such
sublicense shall be in writing and shall be consistent with the applicable terms and conditions of this Agreement, and (z) OV shall
remain responsible for performance of this Agreement.

 

(b) Should
this Agreement terminate for any reason, Eisai shall have the right but not the obligation to grant such sublicensee under Section 2.3(a)
a direct license to the Eisai Intellectual Property in the Territory and the Field.

 

(c) Eisai
shall have the right to grant sublicenses with respect to the license and rights granted pursuant to Section 2.2 to Eisai under this
Agreement to (i) any Affiliates of Eisai and (ii) Third Parties, in each of (i) and (ii), solely in connection with carrying out the
activities set forth in Section 2.2; provided that, with respect to sublicenses granted to Third Parties hereunder (x) Eisai
provides OV with written notice of such sublicense promptly after the grant of such sublicense, which notice shall not be required
for rights granted to distributors, wholesalers or marketing agents, (y) such sublicense shall be in writing and shall be consistent
with the applicable terms and conditions of this Agreement, and (z) Eisai shall remain responsible for its obligations under this
Agreement.

 

(d) Should
this Agreement terminate for any reason, OV shall have the right but not the obligation to grant such sublicensee under Section 2.3(c)
a direct license to the OV Technology in the Territory and outside the Field.

 

Section
2.4 CNS Field Option. In the event that Eisai determines to out-license or otherwise, directly or indirectly, grant or sell
rights to the Compound in the CNS Field to a Third Party (including by way of sale of shares, merger, demerger or consolidation),
the Parties understand and agree that Eisai shall promptly notify OV of such decision in writing. OV shall have a six (6) month
period following receipt of such notice (the “Evaluation Period”) to determine whether to enter into negotiations with
Eisai to acquire exclusive rights to Develop, Manufacture and Commercialize the Compound in the CNS Field. During the Evaluation
Period, Eisai shall not negotiate or enter into discussions with any Third Party regarding a license or other arrangement regarding
rights to the CNS Field and shall provide information reasonably requested by OV to enable OV’s determination whether to
expand the Field to include the CNS Field. If, during the Exclusivity Period, OV elects to enter into exclusive negotiations with
Eisai for the CNS Field, OV shall deliver written notice to Eisai of such determination (the “Exercise Notice”).
Following receipt by Eisai of the Exercise Notice, the Parties will negotiate in good faith on an exclusive basis, for up to ninety
(90) days (unless otherwise agreed by the Parties) the terms of expanding the Field to include the CNS Field (the “Exclusivity
Period”). In the event that the Parties are unable to enter into a mutually acceptable definitive agreement prior to the
expiration of the Exclusivity Period, then Eisai shall have the right to negotiate with Third Parties to out-license or otherwise
grant rights to the Compound in the CNS Field.

 

Section 2.5
Rights to Inventions. OV, its Affiliates and permitted sublicensees shall have the right to make Inventions involving the Eisai Intellectual
Property, and to utilize such Inventions to develop, make, have made, store, use, sell, have sold, import, export and otherwise commercialize
Products in the Field in the Territory. Eisai, its Affiliates and permitted sublicensees shall have the right to make Inventions involving
the OV Technology, and to utilize such Inventions to develop, make, have made, store, use, sell, have sold, import, export and otherwise
commercialize Products, in each case, solely for use of the Product outside the Field (including CNS Field) in the Territory; provided,
that any such Inventions shall be deemed included in the Eisai Intellectual Property licensed to OV hereunder.

 

    -15-

     

    

 

ARTICLE 3

Product Development.

 

Section 3.1Governance.

 

(a) Within
thirty (30) days after the Effective Date, Eisai and OV will establish a joint development committee (the “JDC”)
to implement and oversee Development activities in the Field in the Territory pursuant to the Clinical Development Plan, and will
serve as a forum for exchanging data, information and Development strategy regarding the Product. The JDC will consist of six (6)
voting representatives, which initial representatives shall be as follows: (i) for OV, Peter Buhl-Jensen (who shall serve as
Chairman), Steen Knudsen and Mogens Winkel Madsen; and (ii) for Eisai, three (3) members to be designated within ten (10) Business
Days after the Effective Date. OV shall additionally have the right to appoint a non-voting member to sit on the JDC, which initial
non-voting member shall be Bruce Pratt. Each Party will designate a JDC member who will be the primary contact on the JDC for that
Party. Each Party may replace any or all of its representatives on the JDC at any time upon written notice to the other in
accordance with Section 15.6 of this Agreement. Notwithstanding anything to the contrary contained herein, the Parties understand
and agree that the JDC shall be disbanded upon the earlier to occur of (x) Regulatory Approval of the Product by (1) the FDA, (2)
the EMA, (3) any Regulatory Authority in the United Kingdom, Germany or France or (4) any Regulatory Authority in Japan and (y) the
execution of the Program Acquirer Agreement; it being understood that, for clarity, all further Development activities shall either
be, subject to ARTICLE 6, conducted by OV or the Program Acquirer and/or their Affiliates or sublicensees.

 

(b) The
JDC shall meet at least once per Calendar Quarter (or more frequently as the Parties deem necessary) in person or by video or telephone
conference. Meetings of the JDC that are held in person shall alternate between the offices of Eisai and OV with the initial in- person
meeting to be held at the offices of OV, or at such other place as the Parties may agree. Each Party will bear its own costs for travel,
accommodation and the like in relation to attending such meetings. The specific timing and location of the JDC meetings will be determined
by the Chairman (provided, that such meetings shall only be held on dates as such Parties mutually agree). An agenda shall be agreed upon
by the JDC members and be distributed to the Parties by OV no less than ten (10) Business Days before any meeting. OV shall be responsible
for creating the meeting minutes. Each Party shall use reasonable efforts to cause its representatives to attend the meetings of the JDC,
provided that OV’s representative must be present at each meeting. Each JDC representative shall have one (1) vote on the JDC.

 

(c) The
JDC will be responsible for (i) implementing, overseeing and amending the Clinical Development Plan and regulatory strategy for the Product
in the Field in the Territory, including determining whether to amend the Clinical Development Plan to include a second Phase 2 Clinical
Trial for a second Indication, (ii) attempting to resolve disputes arising under this Agreement with respect to Development activities,
(iii) subject to Article VI, discussing offers by Program Acquirers and (iv) performing such other Development functions set forth in
this Agreement.

 

(d) Except
as otherwise set forth in this Agreement, all decisions of the JDC shall be made by a simple majority vote (consisting of more than fifty
percent (50%) of the votes cast), with each representative having one (1) vote. If the JDC cannot, after good faith efforts, agree on
a matter for which the JDC has decision-making authority within fifteen (15) Business Days after it has met and attempted to reach such
decision, then such matter must be elevated to the Chief Clinical Officer, Oncology Business Group for Eisai and the Chief Executive Officer
for OV for attempted resolution through good faith efforts (which shall include at least one discussion in person, by video or telephone
conference) during a period of five (5) Business Days (or longer period
upon mutual agreement of such senior officers in writing), and if after such five (5) Business Day period (or such mutually agreed to
longer period) such matter is still unresolved, then, subject to Section 3.1(e), the Chairman shall have the controlling vote and decision
unless such matter involves an amendment of the Clinical Development Plan that would result in the amendment, deletion or non-performance
of items specified as Minimum Clinical Development Plan Criteria in the initial Clinical Development Plan as of the Effective Date or
such amended Clinical Development Plan that has been mutually agreed to by the Parties.

 

    -16-

     

    

 

Section
3.2 Development. Subject to ARTICLE 6, OV and its Affiliates and/or sublicensees shall be solely responsible for the Development
of Products in the Field in the Territory, whether or not pursuant to the Clinical Development Plan, and shall use Commercially
Reasonable Efforts to complete a Phase 2 Clinical Trial in accordance with the Clinical Development Plan. Subject to the terms and
conditions of this Agreement, OV shall bear one hundred percent (100%) of all costs and expenses associated with the Development of
Products. OV shall provide a summary report to Eisai, through its representatives on the JDC, on a quarterly basis regarding its
Development activities that OV and/or its Affiliates undertake in the preceding Calendar Quarter in accordance with this Section
3.

 

Section 3.3
Transfer. Within sixty (60) days after the Effective Date, Eisai shall disclose and provide to OV the data and information set forth
in Schedule 3.3 and which shall include all tangible embodiments of data and information concerning the Eisai Intellectual Property
and Regulatory Documentation (including without limitation (a) all safety data for the Product and (b) by providing reasonable assistance
with respect to the transfer of ownership, control and sponsorship, as applicable, of any INDs relating to the Product), as well as preclinical
and clinical data, manufacturing and CMC data, in its Control as of the Effective Date critical to, necessary or useful for developing,
making, using or selling Products in the Territory.

 

Section 3.4
Assistance. During the Term, Eisai will cooperate with OV to provide reasonable assistance requested by OV to facilitate the
transfer of Development, Manufacture and Commercialization responsibilities to OV as required under this Agreement, including
providing reasonable assistance with respect to regulatory and Manufacturing transition matters related to Product, and continuing
the transfer to OV of the data and information concerning the Eisai Intellectual Property (and related Regulatory Documentation)
licensed to OV under Section 2.1. Such cooperation will include providing OV with reasonable access by teleconference or in- person
to Eisai personnel involved in the research, Development and Manufacture of Product. Eisai shall provide OV with a reasonable level
of assistance and consultation in connection with the transfer described in this Section 3.4 at no cost for a maximum period of
sixty (60) days after the Effective Date, and thereafter Eisai’s obligations described in this Section 3.4 shall be expressly
contingent upon mutual written agreement on the scope of Eisai’s assistance and related compensation to Eisai in connection
therewith.

 

Section 3.5
Pharmacovigilance. OV will deploy and administer any safety monitoring activity implemented for the Product in the Territory, and
be responsible for all pharmacovigilance activities for the Product in the Territory. In addition:

 

(a) Eisai
shall cooperate with OV and share information concerning the pharmaceutical safety of Product. Eisai shall promptly advise OV of any information
that comes to its knowledge that may affect the safety, effectiveness or labelling of such Product and any actions taken in response to
such information.

 

(b) OV
shall be solely responsible for reporting all adverse drug experiences associated with Product in the Territory, and for establishing,
holding and maintaining the global safety database for Product. Eisai shall provide OV with all Product complaints, adverse event information
and safety data from clinical studies that are in its possession and control and that are necessary or desirable for OV to comply with
all Applicable Laws with respect to the Product.

 

Notwithstanding the foregoing,
within sixty (60) days following Eisai’s written notice to OV that it intends to conduct clinical activities with respect to
the Product as permitted under this Agreement, the Parties shall enter into a reasonable and customary written pharmacovigilance
agreement (the “PV Agreement”) governing each Party’s obligations with respect to reporting to the other Party and
appropriate Regulatory Authorities adverse events, complaints, and other safety-related matters with respect to the Product.

 

    -17-

     

    

 

Section 3.6
Manufacturing; Inventory.

 

(a) Manufacturing.
OV shall be solely responsible for sourcing the Manufacturing and supplying of Product in the Territory and shall be entitled to identify
and manage Third Party contract manufacturers, as well as lead all supply chain management and quality control activities.

 

(b) Inventory.
Eisai hereby agrees to sell to OV, at OV’s written request as set forth below, such quantities of drug substance for Product hereunder
held by Eisai on the Effective Date (including raw materials, intermediates, and finished, unfinished, or partially finished goods) in
the Territory, all of which is described on Schedule 3.6 (the “Inventory”). At any time until twelve (12) months
after the Effective Date, OV shall have the right to make one request for a single delivery of all or a portion of the Inventory. Eisai
shall deliver such Inventory to OV within thirty (30) calendar days of OV’s request and OV shall, within thirty (30) calendar days
of receipt of any such Inventory which it requested from Eisai, pay to Eisai an amount equivalent to fifty percent (50%) of the U.S. Dollar
value set forth in Schedule 3.6 for such requested and delivered Inventory, which U.S. Dollar value Eisai confirms is equal to Eisai’s
documented cost of goods for the Manufacture of such Product incurred with respect to the Manufacturing of such drug substance (as reflected
in the carrying value of this inventory in Eisai’s financial statements). Eisai hereby agrees to conduct stability testing to extend
the expiration date of any clinical trial materials (CTM) included in the Inventory, which testing shall be conducted pursuant to a separate
agreement on commercially reasonable terms to be negotiated in good faith by the Parties following the Effective Date upon the written
request of OV to Eisai.

 

Section 3.7
No Other Rights. Eisai and OV each acknowledges and agrees that, except as expressly granted under this Agreement, no right, title,
or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other
Party. All rights with respect to technology, Patents or other Intellectual Property Rights that are not specifically granted herein are
reserved.

 

Section 3.8
Bankruptcy. All rights and licenses granted under or pursuant to this Agreement, including amendments hereto, are, for all purposes
of 11 U.S.C. § 365(n), licenses of rights to intellectual property as defined in the United States Bankruptcy Code, and any comparable
Law of a relevant jurisdiction. Each Party may elect to retain and may fully exercise all of its rights and elections under 11 U.S.C.
§ 365(n). The Parties further agree that, in the event of the commencement a bankruptcy proceeding by or against a Party under the
United States Bankruptcy Code, the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any
intellectual property licensed to such other Party and all embodiments of such intellectual property, which, if not already in such other
Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon written request
therefor, unless the Party subject to bankruptcy proceeding elects to continue to perform all of its obligations under this Agreement
or (b) if not delivered under clause (a), following the rejection of this Agreement by the Party upon written request therefor by OV.

 

Section 3.9
No Representation. Subject to the foregoing obligation to use Commercially Reasonable Efforts, neither Party makes any representation,
warranty or guarantee that the Product will be successful, or that any other particular results will be achieved with respect to the Product
hereunder.

 

    -18-

     

    

 

ARTICLE 4

Commercialization Activities.

 

Section 4.1
Commercialization Responsibilities. Subject to Article 6, OV shall use Commercially Reasonable Efforts to obtain Regulatory Approval
for the Product in the Major Countries. Subject to the terms and conditions of this Agreement, OV will be responsible, at its own cost,
for all Commercialization activities for the Product in the Field in the Territory where Regulatory Approval is expected to be or has
been obtained, including all costs and expenses relating thereto. Within sixty (60) days after the end of each Calendar Quarter beginning
with the Calendar Year in which the First Commercial Sale is made in a country following receipt of Regulatory Approval in such country,
OV shall deliver to Eisai a report setting forth for the previous Calendar Quarter OV’s and its Affiliates’ gross sales and
Net Sales in the Territory on a country-by-country basis, and inventory levels. OV shall have sole discretion to establish the pricing
and other terms and conditions of sale of the Product to its customers.

 

ARTICLE 5

Non-Compete.

 

Section 5.1
Non-Compete. Neither Party nor its Affiliates shall, at any time during the Term, either on its own behalf or through any
Affiliate or Third Party, directly or indirectly make, market, promote, sell, offer for sale, import, export or otherwise
Commercialize any (a) Competitive Product in the Field, or (b) any other formulations of the Compound, or in-license or otherwise
acquire any product that is a Competitive Product or other formulation of the Compound, in the Field anywhere in the Territory.

 

Section 5.2
Change of Control Exception. Notwithstanding Section 5.1, if a Change of Control occurs with respect to a Party and, in each case,
the Third Party (or any of such Third Party’s then-existing Affiliates) already has, or the acquired assets contain, as applicable,
a program that existed prior to the Change of Control that would otherwise violate Section 5.1 at the time of such Change of Control (a
“Business Program”), then such Third Party (or such Third Party’s Affiliate) or such Party, as applicable, shall
be permitted to continue such Business Program after the closing of such Change of Control and such continuation shall not constitute
a violation of Section 5.1 provided that (i) neither the Eisai Intellectual Property nor the Joint Intellectual Property shall be used
in the Business Program, and (ii) the research or development activities required under this Agreement shall be segregated from any research
or development activities directed to such Business Program, including the maintenance of separate lab notebooks and records (password-protected
to the extent kept on a computer network) and the use of separate personnel to perform the activities under this Agreement and the activities
covered under such Business Program. The Party undergoing the Change of Control shall adopt reasonable procedures to limit the dissemination
of the other Party’s Confidential Information to only those personnel having a need to know such Confidential Information in order
for such Party or the Third Party, as applicable, to perform its obligations or to exercise its rights under this Agreement, including
adopting reasonable procedures and policies that prohibit and limit the use and disclosure of such Confidential Information in a competitive
manner against the other Party and its Affiliates, and adopting reasonable procedures and policies that prohibit or limit such Confidential
Information from being disclosed to or used by any Person who is also working on or making scientific, intellectual property or commercial
decisions regarding the Product at the time of receipt or use of any such Confidential Information, or within three (3) years following
receipt or use of any such Confidential Information.

 

    -19-

     

    

 

ARTICLE 6

Product Acquisition

 

Section 6.1
Third Party Acquirer. Following Successful Completion of a Phase 2 Clinical Trial for the Product pursuant to the Clinical Development
Plan, OV and Eisai shall cooperate to identify one or more potential Third Party (a “Program Acquirer”) to acquire
(whether through sale, license, merger or otherwise) and assume the rights to Develop, Manufacture and Commercialize the Product in the
Field in the Territory. The Parties understand and agree that entry into any such agreement with a Program Acquirer (the “Program
Acquirer Agreement”) shall be at the sole discretion of OV with the consent of Eisai, not to be unreasonably withheld, conditioned
or delayed; provided that, following the expiration of the Option Exclusivity Period, Eisai shall be deemed to consent to such transaction
where the Program Acquirer, together with its Affiliates, had at least One Hundred Million US Dollars ($100,000,000.00) of sales in the
immediately preceding Calendar Year derived from sales of pharmaceutical products. If a suitable Third Party Acquirer is not secured,
OV reserves the right, either itself or through its Affiliates, to advance the Product through Phase 3 Clinical Trials and Commercialize
the Product.

 

Section 6.2
Eisai Option to Re-Acquire. For the period of time commencing with enrollment of the first five (5) patients in a Phase 2 Clinical
Trial for the Product pursuant to the Clinical Development Plan and ending ninety (90) days following Successful Completion of such Phase
2 Clinical Trial (the “Option Period”), Eisai shall have the option to notify OV in writing (the “Eisai Option
Notice”) that it is interested in re-acquiring the rights to Develop, Manufacture and Commercialize the Product in the Field
in the Territory from OV and its Affiliates (the “Eisai Option”). Following receipt by OV of the Eisai Option Notice,
the Parties will negotiate in good faith on an exclusive basis, for up to ninety (90) days (unless otherwise agreed by the Parties) the
terms of Eisai exercising the Eisai Option at a fair market value, which value shall take into consideration the value of the Development
activities performed by OV, its Affiliates and sublicensees pursuant to the Clinical Development Plan, any Data, Know-How, Inventions
or Patents related to the Product and any applicable drug substance for Product held by OV (including raw materials, intermediates, and
finished, unfinished, or partially finished goods, or otherwise) (the “Option Exclusivity Period”). In the event that
the Parties are unable to enter into a mutually acceptable definitive agreement prior to the expiration of the Option Exclusivity Period,
then OV shall have the right (a) to negotiate with any Third Party to out- license or otherwise grant rights to the Field as contemplated
by Section 6.1 or (b) to continue to advance the Product itself.

 

ARTICLE 7

Payments

 

Section 7.1
Upfront Payment. In consideration of the rights granted to OV under this Agreement, OV shall pay to Eisai a one-time, non-refundable
and non-creditable payment of One Million U.S. Dollars ($1,000,000.00) no later than ten (10) Business Days after the Effective Date.
Eisai hereby confirms that OV has previously paid [***] U.S. Dollars ($[***]) pursuant to the MTA.

 

Section 7.2 Royalties.

 

(a) Product
Royalties. OV shall pay Eisai royalties on Annual Net Sales equal to the following portions of Annual Net Sales multiplied by the
applicable royalty rate for such portion during the applicable Royalty Term for each such Product in accordance with Section 7.2(f):

 

	Annual Net Sales	Royalty Rate
	
    Annual Net Sales above $0, up to and including One Hundred Million U.S.

    Dollars ($100,000,000.00)
	[***]
	
    Annual Net Sales above One Hundred
    Million U.S. Dollars ($100,000,000.00), up to and including Two Hundred Fifty Million

    U.S. Dollars ($250,000,000.00)
	[***]
	
    Annual Net Sales above Two Hundred
    Fifty Million U.S. Dollars ($250,000,000.00), up to and including Five Hundred Million U.S.

    Dollars ($500,000,000.00)
	[***]

	
    Annual Net Sales above Five Hundred

    Million U.S. Dollars ($500,000,000.00)
	[***]

 

    -20-

     

    

 

Each Royalty Rate set forth in the table
above will apply only to that portion of the Annual Net Sales of Product in the Territory during a given Calendar Year that falls within
the indicated range.

 

For example, if Annual Net Sales of Product
in the Territory by OV, its Affiliates and sublicensees was Three Hundred and Fifty Million U.S. Dollars ($350,000,000), then the royalties
payable with respect to such Annual Net Sales, subject to adjustment as set forth in this Section 7.2(a), would be:

 

[***].

 

(b) Royalty
Term; Reduction. OV’s royalty obligations to Eisai under Section 7.2 shall be on a country-by-country basis for the
applicable Royalty Term in such country; provided that the royalty amounts payable with respect to Annual Net Sales shall be reduced
on a country-by-country basis, [***] of the amounts otherwise payable pursuant to Section 7.2(a), during any portion of the Royalty
Term in which there is not at least one (1) Valid Claim of a Patent within the Eisai Intellectual Property or Joint Intellectual
Property that Covers such Product in such country. Only one royalty shall be payable by OV to Eisai for each sale of a Product.

 

(c) Royalty
Reduction for Generic Product Competition. If, on a Product-by- Product, country-by-country and Calendar Quarter-by-Calendar Quarter
basis,

 

A Generic Product(s) has a market share
of greater than twenty-five percent (25%) but less than or equal to fifty percent (50%); or

 

A Generic Product(s) has a market share
of more than fifty percent (50%);

 

then the royalties payable with respect
to Annual Net Sales pursuant to Section 7.2(a) in such country during such Calendar Quarter shall be reduced by [***] if subsection (a)
applies, and [***] if subsection (b) applies, respectively, of the royalties otherwise payable pursuant to Section 7.2(a). Market share
shall be based on the aggregate market in such country of such Product and the Competitive Product(s) (based on sales of units of such
Product and such Competitive Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other
reliable data source as reasonably agreed by the Parties).

 

(d) Royalty
Reduction for Third Party Payments. If OV, in its sole discretion, determines that any Third Party intellectual property rights
are required in order to avoid infringement of such Third Party intellectual property rights in connection with the Development,
Manufacture, or Commercialization of the Product for the Field, then OV may negotiate and obtain a license under, or otherwise pay
amounts with respect to any litigation regarding, such Third Party’s intellectual property rights (each such Third Party
license or payment referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to
Eisai under this Agreement with respect to Annual Net Sales of any Product by OV, its Affiliates or sublicensees in such country
will be reduced by [***] of the amounts payable to Third Parties pursuant to any Additional Third Party Licenses, such reduction to
continue (and be carried forward for use) until all such amounts have been expended.

 

(e) Cumulative
Effect of Royalty Reductions. In no event shall the royalty reductions described in Sections 7.2(b), (c) and (d), alone or together,
reduce the royalties payable by OV for a given Calendar Quarter pursuant to Section 7.2(a) to less than [***] of the amounts payable by
OV for a given Calendar Quarter pursuant to Section 7.2(a). OV may carry over and apply any such royalty reductions which are incurred
or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter, to any subsequent Calendar Quarter(s), and shall begin
applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter.

 

(f) Payment
of Royalties. OV shall: (a) within forty-five (45) days following the end of each Calendar Quarter in which a royalty payment accrues,
provide to Eisai a report for each country in the Territory in which sales of Product occurred in the Calendar Quarter covered by such
statement, specifying for such Calendar Quarter: the number of Products sold; the gross sales and Annual Net Sales in each country’s
currency; the applicable royalty rate under this Agreement; the royalties payable in each country’s currency, including an accounting
of deductions taken in the calculation of Annual Net Sales in accordance with OV’s normal practices used to prepare its audited
financial statements for internal and external reporting purposes; the applicable exchange rate to convert from each country’s currency
to U.S. Dollars under Section 7.5; and the royalty calculation and royalties payable in U.S. Dollars, and (b) make the royalty payments
owed to Eisai hereunder in accordance with such royalty report in arrears, within sixty (60) days from the end of each Calendar Quarter
in which such payment accrues.

 

    -21-

     

    

 

Section 7.3
Milestones; Survival. OV shall pay Eisai the applicable milestones set forth in this Section 7.3. For each of Sections 7.3(a) and
(b) of this Agreement, the Parties understand and agree that in no event will more than one (1) milestone payment be paid with respect
to any specific event triggering a payment under this Agreement.

 

(a) Sales
Milestones. OV shall make a one-time sales milestone payment of Fifty Million U.S. Dollars ($50,000,000.00) to Eisai the first time
Annual Net Sales of Products in a given Calendar Year in the Field in the Territory achieve One Billion U.S. Dollars ($1,000,000,000.00).
For clarity, such milestone shall be due and payable one time only.

 

(b) Development
Milestones. OV shall make the following development milestone payments to Eisai that are set forth below upon the first achievement
by or on behalf of OV, its Affiliates or sublicensees of the Development milestone events (“Development Milestone Events”)
set forth below with respect to the first Product in the Field that achieves such event in the Field. For clarity, each milestone set
forth below shall be due and payable one time only (regardless of the number of Products or Indications to achieve any such Development
Milestone Event).

 

	
     

    Milestone

 Number
	
     

    Development Milestone Event

    (For the first Product that achieves
    such event)
	
    Milestone

 Payments

    (in $ millions)

	1	
    Successful Completion of a Phase 2 Clinical Trial for
the Product
	[***]
	2	Dosing of the first patient in a Phase 3 Clinical Trial for the Product	[***]
	3	Submission of an NDA to the FDA for the Product in the United States	
    
[***]

	4	Submission of an MAA to the EMA for the Product in the European Union	
    [***]

	5	Submission of an NDA to the MHLW for the Product in Japan	
    [***]

	6	Receipt of Regulatory Approval of the Product in the United States from the FDA	
    [***]

	7	Receipt of Regulatory Approval of the Product in the European Union from the EMA	
    [***]

	8	Receipt of Regulatory Approval of the Product in Japan from the MHLW	
    [***]

 

The Parties understand
and agree that submission of an NDA or MAA shall only be deemed to occur if such NDA or MAA has been accepted by the applicable Regulatory
Authority for review (and for example no “complete response letter” or similar communications have been delivered).

 

Additionally, the
Parties understand and agree that the Development Milestone Numbers 3–8 set forth in the table above shall be reduced by [***] if,
at the time of achievement of such Development Milestone by OV and/or its Affiliates or its or their permitted sublicensees, Eisai and/or
its Affiliates or its or their permitted sublicensees have received Regulatory Approval for the Compound in the CNS Field.

 

Section 7.4 Additional Payment Terms.

 

(a) Accounting.
All payments hereunder shall be made in the United States in U.S. Dollars by wire transfer to a bank to be designated in writing by
Eisai. Conversion of sales recorded in local currencies to Dollars shall be performed in a manner consistent with OV’s normal
practices used to prepare its audited financial statements for internal and external reporting purposes.

 

(b) Late Payments.
Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement shall bear
interest at an annual rate equal to the lesser of: (a) one and one half percentage points (1.5%) above the prime rate as published
by Citibank, N.A., New York, New York, or any successor thereto, at 12:01 a.m. on the first day of each Calendar Quarter in which
such payments are overdue or (b) the maximum rate permitted by Applicable Law; in each case calculated on the number of days such
payment is delinquent, compounded monthly.

 

    -22-

     

    

 

Section 7.5
Currency Conversion. All amounts payable and calculations under this Agreement will be in U.S. Dollars. As applicable, Net Sales and
any Milestone Payments will be translated into U.S. Dollars using OV’s then-current standard exchange rate methodology for the translation
of foreign currency sales into U.S. Dollars (in accordance with IFRS). If, due to restrictions or prohibitions imposed by national or
international authority, a given payment cannot be made as provided in this Section 7.5, the Parties will consult with a view to finding
a prompt and acceptable solution. If the Parties are unable to identify a mutually acceptable solution regarding such payment, then OV
may elect, in its sole discretion, to deliver such payment in the relevant jurisdiction and in the local currency of the relevant jurisdiction.

 

Section 7.6
Extension Payment. If OV and/or its Affiliates or sublicensees have not achieved Successful Completion of the first Phase 2 Clinical
Trial of the Product prior to the fourth (4th) anniversary of the Effective Date, then, in OV’s sole discretion, it may notify Eisai
of its intention to continue Development activities of the Compound. In the event that Eisai and OV mutually agree to such continued Development
activities by OV, OV shall pay a one-time payment to Eisai of [***] (the “Extension Payment”) on the fourth (4th)
anniversary of the Effective Date.

 

Section 7.7
Taxes. OV may withhold from payment made to Eisai under this Agreement any income tax required to be withheld by OV under the laws
of the country or jurisdiction where OV has commercially sold Products. If any tax is withheld by OV, OV shall provide Eisai receipts
or other evidence of such withholding and payment to the appropriate tax authorities on a timely basis following that tax payment. Each
Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant
agreement or treaty which is in effect. The Parties shall discuss applicable mechanisms for minimizing such taxes to the extent possible
in compliance with Applicable Law. In addition, the Parties shall cooperate in accordance with Applicable Law to minimize indirect taxes
(such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement.

 

ARTICLE 8

Regulatory Matters

 

Section 8.1
Compliance with Laws. Each Party shall comply in all material respects with all Applicable Laws, including all Regulatory Laws, that
pertain to its activities under this Agreement and, except as otherwise provided herein, each Party shall bear its own cost and expense
of such compliance.

 

Section
8.2 Regulatory Approval. In seeking any Regulatory Approval in the Territory, OV shall have primary responsibility for all
communications, submissions and interactions with Regulatory Authorities, including serving as sponsor of any required
investigational new drug or device applications or exemptions and preparing and submitting the application for Regulatory Approval.
Eisai shall fully cooperate with OV, provide consulting advice on regulatory strategies, communications and submissions, and provide
any additional regulatory documentation and data reasonably requested by OV in connection with seeking Regulatory Approval in the
Territory. OV shall bear all costs and expenses of obtaining such Regulatory Approval. OV shall maintain such approval throughout
the Term (and bear all associated costs and expenses). OV shall own all and be responsible for preparing, filing and maintaining all
regulatory filings and Regulatory Approval that are required for the Development, Manufacture, use, or Commercialization of the
Product in the Field in the Territory, provided that: (i) OV shall provide Eisai with copies of material regulatory submissions to,
and material communications with, any Governmental Authority in the Territory and Eisai shall have the right to review and comment
on such submissions and communications, and (ii) OV shall take such actions and otherwise cooperate with Eisai as may be reasonably
requested by Eisai to enable Eisai to perform activities assigned to Eisai under this Agreement.

 

ARTICLE 9

Intellectual Property

 

Section 9.1 Ownership
of Intellectual Property.

 

(a) Inventorship.
Inventorship of Inventions shall be determined by application of U.S. patent law pertaining to inventorship.

 

(b) OV.
As between the Parties, OV will be the sole owner of any Inventions and intellectual property rights therein that are discovered, developed,
invented or created solely by OV, its Affiliates or Third Parties acting on its or its Affiliates’ behalf while conducting activities
under this Agreement (such Inventions and intellectual property rights, “OV Know-How”) and any Patents that claim such
OV Know-How (“OV Patents” and, together with the OV Know- How, the “OV Technology”), and will retain
all of its rights, title and interest thereto.

 

    -23-

     

    

 

(c) Joint
Intellectual Property. Any Joint Intellectual Property will be owned jointly by OV and Eisai on an equal and undivided basis, including
all rights, title and interest thereto, subject to any assignment, rights or licenses expressly granted by one Party to the other Party
under this Agreement. Except as expressly provided in this Agreement, neither Party will have any obligation to account to the other for
profits with respect to, or to obtain any consent of the other Party to license or exploit, Joint Intellectual Property by reason of joint
ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any such consent or
accounting. At the reasonable written request of a Party, the other Party will in writing confirm that no such accounting is required
to effect the foregoing regarding Joint Intellectual Property. To the extent necessary in any jurisdiction to effect the foregoing, each
Party hereby grants to the other Party a non-exclusive, royalty-free, fully-paid, worldwide license, with the right to grant sublicenses,
to practice such Joint Intellectual Property for any and all purposes, subject to any licenses granted by one Party to the other under
this Agreement. The Parties understand and agree that any Patents, Know-How and/or Inventions related to or generated by OV’s proprietary
biomarker generation platform Drug Response Predictor (DRPTM) shall always be considered “OV Platform Technology” hereunder
and never constitute Joint Intellectual Property; provided, however, that the Product-Specific Biomarker shall be deemed “Joint
Intellectual Property”.

 

(d) OV
Platform Technology. As between the Parties, OV will own and retain all of its rights, title and interest in and to the OV Platform
Technology.

 

(e) Cooperation.
The determination of whether Know-How and inventions claimed in Patents that are conceived, discovered, developed or otherwise made or
reduced to practice by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property
rights) therein, will, for purposes of this Agreement, be made in accordance with Applicable Law in the United States. In the event that
United States law does not apply to the conception, discovery, development, making or reduction to practice of any Know-How or Patents
hereunder, each Party will, and does hereby, assign, and will cause its Affiliates to so assign, to the other Party, without additional
compensation, such right, title and interest in and to any Know-How and Patents as well as any intellectual property rights with respect
thereto, as is necessary to fully effect ownership as would have been determined under U.S. law unless otherwise provided in this Article
9.

 

Section 9.2 Patent Filings,
Prosecution and Maintenance of Eisai Intellectual Property and any Joint Intellectual Property.

 

(a) The
Parties agree to cooperate in the Prosecution of all Patents under this Section 9.2, including obtaining and executing necessary powers
of attorney and assignments by the named inventors, providing relevant technical reports to the filing Party concerning the invention
disclosed in such Patents and Patent applications, obtaining execution of such other documents which are needed in the Prosecution of
such Patents and Patent applications, and shall cooperate with the other Party so far as reasonably necessary with respect to furnishing
all information and data in its possession reasonably necessary to obtain or maintain such Patents and Patent applications.

 

(b) On
a country-by-country basis, the Parties understand and agree that Eisai shall have the right (but not the obligation) to Prosecute any
Eisai Patents in such country, at Eisai’s expense, and shall control any interferences, oppositions, reissue proceedings, reexaminations,
post-grant proceedings and any other similar proceeding relating thereto, in each such country in the Territory. Eisai shall inform and
consult with OV regarding the Prosecution of all such Eisai Patents sufficiently in advance of any deadline for taking any substantive
action in connection therewith to permit meaningful consultation, and shall give due consideration to any of OV’s suggestions, recommendations
or requests with respect to such filing or strategies. Notwithstanding the foregoing, OV shall have the right (but not the obligation),
exercisable at any time upon written notice to Eisai, to Prosecute any Product-Specific Patents, at OV’s expense, and to control
any interferences, oppositions, reissue proceedings, reexaminations, post- grant proceedings and any other similar proceeding relating
thereto, in each such country in the Territory; provided that, OV shall not have the right Prosecute any of the Product-Specific
Patents set forth on Schedule 9.2(b) hereto. OV shall inform and consult with Eisai regarding the Prosecution of all such
Product-Specific Patents sufficiently in advance of any deadline for taking any substantive action in connection therewith to permit meaningful
consultation, and shall give due consideration to any of Eisai’s suggestions, recommendations or requests with respect to such filing
or strategies (including reasonable requests in connection with Eisai’s strategy for the Product outside the Field). Each Party
shall pay for its own costs with respect to any consultation hereunder.

 

    -24-

     

    

 

(c) OV
shall have the first right (but not the obligation) to Prosecute any Patents for any Joint Intellectual Property, in both Parties’
names, and to control any interferences, oppositions, reissue proceedings, reexaminations, post-grant proceedings and any other similar
proceeding relating thereto, in the Territory; provided that the costs of such Prosecution shall be borne equally by the Parties. OV shall
inform and consult with Eisai regarding the Prosecution of all such Joint Intellectual Property sufficiently in advance of any deadline
for taking any substantive action in connection therewith to permit meaningful consultation, and shall give due consideration to any of
Eisai’s suggestions or recommendations(including reasonable requests in connection with Eisai’s strategy for the Product outside
the Field). Each Party shall pay for its own costs with respect to this consultation.

 

(d) If
OV elects in any country not to Prosecute, or elects to abandon any Joint Intellectual Property or declines to control any related interference,
opposition, reissue proceeding, reexamination, post-grant proceeding and similar proceeding, OV shall give Eisai reasonable written notice
to this effect sufficiently in advance (but in any event no later than at least sixty (60) days prior to the date upon which the subject
matter of such Joint Patent shall become unpatentable or such Joint Patent shall lapse or become abandoned) to permit Eisai, in its sole
discretion and expense, to undertake such Prosecution, or to control such interferences, oppositions, reissue proceedings, reexaminations,
post-grant proceedings and similar proceeding, without a loss of rights. If Eisai does so elect, then OV shall provide such cooperation
to Eisai, including the execution and filing of appropriate instruments, as may reasonably be requested to facilitate the transition of
such Joint Patent activities, and shall assign all of its right, title and interest to such Joint Patents, other than its rights thereto
provided by this Agreement, to Eisai electing to pursue such Joint Patent activities. For clarity, Eisai shall have the right, in its
sole discretion, to abandon such Patent at any time after it takes control pursuant to this Section 9.2(d).

 

(e) Each
Party agrees to cooperate with the other with respect to the Prosecution of Joint Intellectual Property and related interferences, oppositions,
reissue proceedings, reexaminations, post-grant proceedings and similar proceeding thereof. If required under Applicable Law in order
for the prosecuting Party to control such interferences, oppositions, reissue proceedings, reexaminations, post-grant proceedings and
similar proceeding relating to the Joint Intellectual Property, the other Party shall join as a party to such interferences, oppositions,
reissue proceedings, reexaminations, post-grant proceedings and similar proceeding.

 

Section 9.3 Extensions
of Patent Term for Products.

 

(a) Eisai shall have
the sole right, but not the obligation, to seek patent term extensions, adjustments, restorations, or supplementary protection
certificates under Applicable Law with respect to any Platform Patents for the Product in the Territory; it being understood and
agreed that, if Eisai seeks a patent term extension, then OV agrees to cooperate with respect to any measures required by Applicable
Law for Eisai to obtain such extension. Eisai, its agents and attorneys will give due consideration to all suggestions and comments
of OV regarding any such activities, including the choice of which Patent to apply term extensions to, but in the event or a
disagreement between the Parties, Eisai shall have the final decision making authority. For clarity, (a) any such extended Patent
will remain included in the definition of Valid Claim for purposes of extending the Term and (b) Eisai shall have the right, in its
sole discretion, to abandon such Patent at any time.

 

(b) OV
shall have the sole right, but not the obligation, to seek patent term extensions, adjustments, restorations, or supplementary protection
certificates under Applicable Law with respect to any Product-Specific Patents for the Product in the Territory; it being understood and
agreed that, if OV seeks a patent term extension, then Eisai agrees to cooperate with respect to any measures required by Applicable Law
for OV to obtain such extension. OV, its agents and attorneys will give due consideration to all suggestions and comments of Eisai regarding
any such activities, including the choice of which Patent to apply term extensions to, but in the event or a disagreement between the
Parties, OV shall have the final decision making authority. For clarity, (a) any such extended Patent will remain included in the definition
of Valid Claim for purposes of extending the Term and (b) OV shall have the right, in its sole discretion, to abandon such Patent at any
time.

 

Section 9.4 Enforcement
of Eisai Intellectual Property and Joint Intellectual Property.

 

(a) If
either Party learns of any infringement or violation by a Third Party of any Eisai Intellectual Property or Joint Intellectual Property
in the Territory, whether or not within the Field, it shall notify the other Party as soon as practicable. Thereafter, (a) OV shall have
the sole right (but not the obligation), subject to Section 9.4(b), at its own cost to take the appropriate steps to enforce or defend
any Product-Specific Patents in the Field and/or Joint Intellectual Property, as applicable, against Third Parties and (b) Eisai shall
have the sole right (but not the obligation) at its own cost to take the appropriate steps to enforce or defend any Platform Patents in
the Field against Third Parties. Any settlements, damages or other monetary awards relating to such infringement or violation by a Third
Party of any Eisai Intellectual Property and/or Joint Intellectual Property (a “Recovery”) recovered by either Party
will be forwarded to OV (if not then previously paid to OV) and any such Recovery pursuant to a suit, action or proceeding brought pursuant
to this Section 9.4(a) will be allocated first to the costs and expenses of the enforcing or defending Party, and second, all remaining
Recoveries shall be deemed to be Net Sales.

 

    -25-

     

    

 

(b) Solely with
respect to any Product-Specific Patent which claims the composition of matter of a Product which is then being Commercialized by
Eisai outside the Field, in the event that OV does not exercise its rights to enforce or defend such Patent under Section 9.4(a) (i)
within ninety (90) days following the first notice provided above with respect to such infringement or violation or (ii) provided
such date occurs after the first such notice of such infringement or violation is provided, ten (10) Business Days before the time
limit, if any, set forth under Applicable Law for filing of such actions, whichever comes first, then Eisai may undertake such
enforcement or defense at its sole cost and expense; provided, that Eisai shall fully consider and use reasonable efforts to
accommodate OV’s global intellectual property litigation positions in all such decisions with respect to any such enforcement
or defense action that may impact such global positions.

 

(c) If either Party
brings any suit, action or proceeding under this Section 9.4, the other Party agrees to be joined as party plaintiff if necessary to
prosecute the suit, action or proceeding and to give the prosecuting Party reasonable authority to file and prosecute the suit,
action or proceeding; provided, however, that neither will not be required to transfer any right, title or interest in or to any
property to the other in order to confer standing on the prosecuting Party hereunder. the non-prosecuting Party will provide
reasonable assistance to the prosecuting Party including by providing access to relevant documents and other evidence and making its
employees available, subject to the prosecuting Party’s reimbursement of any reasonable Out-of- Pocket Costs incurred by the
non-prosecuting Party in providing such assistance.

 

Section 9.5
Enforcement of OV Technology. If either Party learns of any infringement or violation by a Third Party of any OV Technology in the
Territory, it shall notify the other Party as soon as practicable. Thereafter, OV shall have the sole right to (a) enforce all OV Technology
against Third Parties and (b) any settlements, damages or other monetary awards recovered pursuant to a suit, action or proceeding brought
pursuant to this Section 9.5.

 

Section 9.6
Defense of Infringement Claims of Eisai Intellectual Property and Joint Intellectual Property. If any Third Party asserts a claim,
demand, action, suit or proceeding against a Party (or any of its Affiliates), alleging that any Product, the use or practice of the Eisai
Intellectual Property or the Joint Intellectual Property infringes, misappropriates or violates the intellectual property rights of any
Person (any such claim, demand, action, suit or proceeding being referred to as an “Infringement Claim”), the Party first
having notice of the Infringement Claim shall promptly notify the other Party thereof in writing specifying the facts, to the extent known,
in reasonable detail. With respect to any Infringement Claim in the Field in the Territory, the Parties shall negotiate in good faith
a resolution with respect thereto. If settlement is deemed an appropriate resolution and the Parties cannot settle such Infringement Claim
with the Third Party within thirty (30) days after receipt of the notice pursuant to the notice pursuant to this Section 9.6, then subject
to indemnification requirements of ARTICLE 10, the following shall apply:

 

(a) In
the case of any such Infringement Claim against either Party individually or against both OV and Eisai, in each case, with respect to
the Product in the Field in the Territory, then OV shall assume control of the defense of such Infringement Claim. Eisai, upon request
of OV and if required by Applicable Law, agrees to join in any such litigation at OV’s expense, and in any event to reasonably cooperate
with OV at OV’s expense. Eisai will have the right to consult with OV concerning such Infringement Claim and to participate in and
be represented by independent counsel in any litigation in which Eisai is a party, at its own expense. OV shall have the exclusive right
to settle any Infringement Claim against OV alone or both Parties without the consent of Eisai, unless such settlement shall have a material
adverse impact on Eisai (in which case the consent of Eisai shall be required). OV shall fully consider and use reasonable efforts to
accommodate Eisai’s global intellectual property litigation positions in all such decisions with respect to any such defense or
settlement that may impact such global positions. If (a) OV elects (in a written communication submitted to Eisai within a reasonable
amount of time after notice of the alleged patent infringement) not to defend or control the defense of, or otherwise fails to initiate
and maintain the defense of, any such claim, suit or proceeding, within such time periods so that Eisai is not prejudiced by any delays,
Eisai shall have the right (but not the obligation) to control the defense of such Infringement Claim, and OV upon request of Eisai and
if required by Applicable Law, agrees to join in any such litigation at Eisai’s expense.

 

    -26-

     

    

 

(b) If
either Party individually shall control of the defense of any such Infringement Claim described in this Section 9.6, the other Party shall
cooperate, and shall cause its and its Affiliates’ employees to cooperate, with the controlling Party in all reasonable respects
in connection therewith, including giving testimony and producing documents lawfully requested, and using its reasonable efforts to make
available to the controlling Party, at the controlling Party’s cost, such employees who may be helpful with respect to such suit,
investigation, claim or other proceeding.

 

(c) Neither
Party, nor its Affiliates, nor its or their employees, agents or independent contractors, shall be liable to the other Party or any of
its Affiliates in respect of any good faith act, omission, default, or neglect of such Party, any of its Affiliates, or its or their employees,
agents or independent contractors in connection with the Prosecution of Eisai Intellectual Property, OV Technology or Joint Intellectual
Property.

 

ARTICLE 10

Indemnification

 

ARTICLE 10 shall survive the expiration or termination of
this Agreement.

 

Section 10.1 Indemnification
by Eisai.

 

(a) Scope.
Eisai shall indemnify and hold harmless OV and its Affiliates and their respective, directors, officers, employees and agents (collectively,
the “OV Indemnified Parties”) from and against any and all Damages, arising out of or resulting from any claim, demand,
action, suit or proceeding by a Third Party (collectively, a “Third Party Claim”) based upon or arising from: (i) any
breach by Eisai of any of its representations, warranties or obligations under this Agreement; (ii) any actual violation by Eisai or any
of its Affiliates or licensees or sublicensees (other than OV) of Applicable Laws or any Development of the Product outside of the Field
in the Territory or Commercialization of the Product in or outside the Field in the Territory by Eisai or any of its Affiliates or licensees
or sublicensees (other than OV) on, prior to or after the Effective Date; or (iii) any willful act or omission of Eisai or its Affiliates
or subcontractors or any of their respective employees or agents relating to the activities in connection with this Agreement.

 

(b) Defense. OV
shall give Eisai prompt written notice of any Third Party Claim with respect to which Eisai’s indemnification obligations
apply, but any delay or failure of such notice shall not excuse Eisai’s indemnification obligations except to the extent that
Eisai’s legal position is actually and materially prejudiced thereby. Eisai shall have the right to assume and control the defense
and settlement of any Third Party Claim; provided, however, that following conditions must be satisfied: (i) Eisai must provide to
OV written acknowledgement to OV of Eisai’s obligation to indemnify OV hereunder against Damages that may result from the
Third Party Claim, and (ii) OV shall not have given Eisai written notice that it has determined, in the exercise of its reasonable
discretion based on the advice of counsel, that a conflict of interest makes separate representation by OV’s own counsel
advisable, (iii) the Third Party Claim does not include damages other than monetary damages for which indemnity hereunder is
available, (iv) the Third Party Claim does not relate to or arise in connection with any criminal proceeding, action, indictment,
criminal allegation or investigation, and (v) if requested by OV, Eisai has reasonably demonstrated Eisai’s financial ability
to pay for the defense of such Third Party Claim and to satisfy the full amount of any Damages that may result from such Third Party
Claim. OV shall have the right to participate in the defense of the Third Party Claim at its own expense, but in any event shall
cooperate with Eisai in the investigation and defense of the Third Party Claim.

 

(c) Settlement.
If Eisai is entitled to, and does, assume and control the defense and settlement of any Third Party Claim with respect to which its indemnification
obligations apply, then Eisai shall not settle such Claim without OV’s prior written consent (which consent shall not be unreasonably
withheld, conditioned or delayed), unless (i) the sole relief provided in such settlement is monetary in nature and shall be paid in full
by Eisai and (ii) such settlement does not include any finding or admission of a violation by OV, its Affiliates or sublicensees of any
Applicable Laws or Third Party’s rights.

 

Section 10.2 Indemnification
by OV.

 

(a) Scope.
OV shall indemnify and hold harmless Eisai and its Affiliates and their respective directors, officers, employees and agents (collectively,
the “Eisai Indemnified Parties”) from and against any and all Damages in connection with any Third Party Claim based
upon or arising from: (i) any breach by OV or any of its Affiliates of any of OV’s representations, warranties or obligations under this
Agreement; (ii) any actual violation by OV or any of its Affiliates of Applicable Laws; (iii) any willful act or omission of OV or its
Affiliates or any of their respective employees or agents relating to the activities in connection with this Agreement; or (iv) any exploitation
by OV and its Affiliates of the Product.

 

    -27-

     

    

 

(b) Defense. Eisai
shall give OV prompt written notice of any Third Party Claim with respect to which OV’s indemnification obligations apply, but any
delay or failure of such notice shall not excuse OV’s indemnification obligations except to the extent that OV’s legal position is
actually and materially prejudiced thereby. OV shall have the right to assume and control the defense and settlement of any such
Third Party Claim; provided, however, that following conditions must be satisfied: (i) OV must provide to Eisai written
acknowledgement to Eisai of OV’s obligation to indemnify Eisai hereunder against Damages that may result from the Third Party
Claim, and (ii) Eisai shall not have given OV written notice that it has determined, in the exercise of its reasonable discretion
based on the advice of counsel, that a conflict of interest makes separate representation by Eisai’s own counsel advisable,
(iii) the Third Party Claim does not include damages other than monetary damages for which indemnity hereunder is available, (iv)
the Third Party Claim does not relate to or arise in connection with any criminal proceeding, action, indictment, criminal
allegation or investigation, and (v) if requested by Eisai, OV has reasonably demonstrated OV’s financial ability to pay for
the defense of such Third Party Claim and to satisfy the full amount of any Damages that may result from such Third Party Claim.
Eisai shall have the right to participate in the defense of the Third Party Claim at its own expense, but in any event shall
cooperate with OV in the investigation and defense of the Third Party Claim.

 

(c) Settlement. If
OV is entitled to, and does, assume and control the defense and settlement of any Third Party Claim with respect to which its
indemnification obligations apply, then OV shall not settle such Claim without Eisai’s prior written consent (which consent shall
not be unreasonably withheld, conditioned or delayed), unless (i) the sole relief provided in such settlement is monetary in nature
and shall be paid in full by OV and (ii) such settlement does not include any finding or admission of a violation by Eisai, its
Affiliates or sublicensees of any Applicable Laws or Third Party’s rights.

 

Section 10.3
Waiver. Any waiver by an indemnified Party of its rights under this ARTICLE 10 must be set forth expressly and in writing in order
to be effective.

 

Section 10.4
Insurance. Each Party shall maintain insurance with creditworthy insurance companies or self insure in accordance with Applicable
Laws against such risks and in such amounts as are usually maintained or insured against by such Party.

 

Section 10.5
Limitation of Consequential Damages. Except for (a) Third Party Claims that are subject to indemnification under this ARTICLE 10,
(b) claims arising out of a Party’s willful misconduct, or (c) a Party’s breach of ARTICLE 5 or ARTICLE 12 or any other confidentiality
obligations under this Agreement, neither Party nor any of its Affiliates will be liable to the other Party or its Affiliates in connection
with this Agreement for any incidental, consequential, special, punitive or other indirect damages or lost or imputed profits or royalties,
lost data or cost of procurement of substitute goods or services, whether liability is asserted in contract, tort (including negligence
and strict product liability), indemnity or contribution, and irrespective of whether that Party or any representative of that Party has
been advised of, or otherwise might have anticipated the possibility of, any such loss or damage.

 

ARTICLE 11

Representations and Warranties

 

ARTICLE 11 shall survive the expiration or termination of
this Agreement.

 

Section 11.1
General Corporate Matters. Each Party hereby represents and warrants to the other Party that:

 

(a) Organization
and Power. It is a corporation or limited liability company duly organized, validly existing and in good standing under the laws of
its jurisdiction of incorporation or organization. It has all requisite power and authority to conduct its business and engage in the
transactions provided for in this Agreement.

 

(b) Authorization
and Validity of Agreements. The execution, delivery and performance by it of this Agreement, and the consummation by it of the transactions
contemplated hereby, have been duly authorized and approved by all necessary corporate or equivalent action on its part. This Agreement
has been duly executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance
with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or other laws relating to or affecting creditors’
rights generally and by general equity principles.

 

    -28-

     

    

 

(c) Absence of
Conflicts. The execution, delivery and performance by it of this Agreement, and the consummation by it of the transactions
contemplated hereby, do not and will not: (i) violate any Applicable Laws; (ii) conflict with, or result in the breach of any
provision of, its certificate or articles of incorporation, bylaws or equivalent organizational documents; (iii) result in the
creation of any lien or encumbrance of any nature upon any property being transferred or licensed by it pursuant to this Agreement;
or (iv) violate, conflict with, result in the breach or termination of, or constitute a default under (or event which, with notice,
lapse of time or both, would constitute a default under), any permit, contract or agreement to which it is a party or by which any
of its properties or businesses are bound.

 

(d) Consents.
No authorization, consent or approval of, or notice to or filing with, any Governmental Authority is required for the execution, delivery
and performance by it of this Agreement (excluding approvals of Regulatory Authorities as contemplated herein).

 

(e) Affiliates.
Where this Agreement refers to an action or obligation to be undertaken by a Party’s Affiliates, such Party will cause such Affiliates
to undertake such obligations or other actions, and such Party will be responsible and liable for any acts or omissions by its Affiliates.

 

Section 11.2 Intellectual Property
Matters. Eisai hereby represents and warrants to OV that, as of the Effective Date:

 

(a) Ownership.
Eisai has sole and exclusive ownership of the Eisai Intellectual Property. Eisai has not granted to any Person other than OV a license,
covenant not to sue or similar right with respect to any component of the Eisai Intellectual Property in the Field or the CNS Field in
the Territory. The Eisai Intellectual Property in the Field and the CNS Field in the Territory are free of any lien, covenant, easement,
lien, lease, sublease, option, encumbrance, security interest, mortgage, pledge or claim of any nature, including limitations on transfer
or any subordination arrangement in favor of a Third Party.

 

(b) Patents.
Schedule 2 sets forth a complete and correct list of all Eisai Patents owned or otherwise Controlled by Eisai and its Affiliates,
and, except as set forth on Schedule 2, Eisai, together with its Affiliates, is the sole and exclusive owner of, and has
the sole right, title and interest in and to, the Eisai Patents listed on Schedule 2 (as updated from time to time) and
the related Know-How. To its Knowledge, the Eisai Patents are valid and enforceable and none of the Eisai Patents are currently involved
in any court, administrative, interference, reissue, re- examination, cancellation or opposition proceedings, and neither Eisai nor any
of its Affiliates has received any written notice from any Third Party of such actual or threatened proceedings or challenge.

 

(c) No
Additional IP. To Eisai’s Knowledge, there is no intellectual property right, in particular no Eisai Patents, owned by or licensed
to Eisai or its Affiliates other than the Eisai Intellectual Property, that are necessary for OV or its Affiliates and sublicensees to
Develop and Commercialize the Product as set forth herein.

 

(d) Third
Party Obligations. Eisai and its Affiliate are not subject to any payment obligations to Third Parties as a result of the execution
or performance of this Agreement.

 

(e) Data and
Information. Eisai has furnished or made available to OV all material information that is in Eisai’s or its
Affiliates’ possession concerning the Eisai Intellectual Property and Product relevant to the safety, efficacy, or CMC data
thereof, and all Regulatory Documentation, Data and other correspondence with Regulatory Authorities relating to the Product, and to
Eisai’s Knowledge, such information is accurate, complete and true in all material respects.

 

(f) Non-Infringement.
As of the Effective Date and to Eisai’s Knowledge, the use, manufacture, marketing, sale, promotion, importation, distribution and
commercialization of the Product in the Field or the CNS Field in the Territory does not infringe, violate or misappropriate the intellectual
property rights of any Person.

 

(g) IP
Claims. As of the Effective Date, no Person has made, nor has Eisai received, any written, nor to the Knowledge of Eisai has any Person
threatened, any written or oral, claim of ownership, inventorship or Patent infringement, or any other claim of intellectual property
misappropriation or violation, from any Third Party (including by current or former officers, directors, employees, consultants, or personnel
of Eisai or any predecessor) with respect to the Eisai Intellectual Property, or initiated a lawsuit against Eisai, in any case (i) challenging
the ownership, validity or enforceability of any of the Eisai Intellectual Property in the Field or the CNS Field in the Territory, (ii)
alleging that the license, use or practice of them infringes, violates or misappropriates: (A) the intellectual property rights of any
Person; or (B) the rights of any Third Party, or (iii) seeking to enjoin or restrain such use or practice. Eisai has no Knowledge that
any Person intends to assert such a claim or initiate such a lawsuit, or that any Person has a valid basis to do so.

 

    -29-

     

    

 

(h) Claims.
There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Eisai’s Knowledge, threatened against Eisai, nor is Eisai a party to any judgment or settlement, which
would be reasonably expected to adversely affect or restrict the ability of Eisai to consummate the transactions contemplated under this
Agreement and to perform its obligations under this Agreement, or which would affect the Eisai Intellectual Property, or Eisai’s
Control thereof, or the Product.

 

(i) Infringement
by Others. As of the Effective Date and to the Knowledge of Eisai, Eisai has no reason to believe that any Person has infringed, violated
or misappropriated any of the Eisai Intellectual Property in the Field or the CNS Field in the Territory.

 

Section 11.3 Eisai Covenants.

 

(a) Except as set forth
in Section 15.12, neither Eisai nor its Affiliates will (a) assign, transfer, convey, encumber (including any liens or charges, but
excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third
Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject to
subsection (b), below) or dispose of, any assets specifically related to the Compound in the Field, including with respect to
Products and related diagnostic products developed therefor, or pre-clinical or Clinical Trial results or other data specifically
related to the Compound in the Field, or any intellectual property specifically related to any of the foregoing (the
“Licensed Assets”), except to the extent such assignment, transfer, conveyance, encumbrance or disposition would
not conflict with or adversely affect in any respect any of the rights granted to OV hereunder, (b) license or grant to any Third
Party, or agree to license or grant to any Third Party, any rights to any Licensed Assets if such license or grant would conflict
with or adversely affect in any respect any of the rights granted to OV hereunder, or (c) disclose any Confidential Information
relating to the Licensed Assets to any Third Party if such disclosure would impair or conflict in any respect with any of the rights
granted to OV hereunder.

 

(b) Neither
Eisai nor any of its Affiliates will effect any corporate restructuring or enter into any new agreement, transfer ownership of the Eisai
Intellectual Property, or Eisai’s interest in the Joint Intellectual Property, or obligate itself to any Third Party, or amend an
existing agreement with a Third Party, in each case, in a manner that restricts, limits, or encumbers the rights granted to OV under this
Agreement.

 

(c) Eisai
will update Schedule 2 from time to time to include any Patents that are necessary or useful to Develop, Manufacture or
Commercialize the Product in the Field in the Territory (including, for the avoidance of doubt, any Patents Covering Eisai’s interest
in any Joint Intellectual Property); provided that, regardless of Eisai’s failure to update such Schedule 2, such
Patents shall be deemed to be included in the definition of Eisai Patents.

 

(d) During
the Term, in no event shall Eisai or its Affiliates enable or assist any Third Party in obtaining a right or license in the CNS Field,
or otherwise grant a right of use, license, option, acquisition or other rights to a Third Party in the CNS Field, unless and until Eisai
has complied in good faith with the obligations set forth in Section 2.4.

 

Section 11.4
OV Covenants. OV shall perform all of its obligations under this Agreement, and shall comply in all material respects with all Applicable
Laws in the exercise of its rights under this Agreement, including development, marketing, distribution and sale of the Products. OV’s
specifications for the text (including any trademarks, logos or other graphics) for all marketing material used in connection with Product,
and any such marketing material for the Product provided by OV or its designee, shall be true and accurate in all respects, comply in
all material respects with all Applicable Laws and not infringe or otherwise violate the intellectual property of any person.

 

ARTICLE 12

Confidentiality and Publicity

 

Section 12.1
Confidentiality. In the course of their activities pursuant to this Agreement, the Parties anticipate that they may disclose Confidential
Information to one another and that either Party may, from time to time, be a disclosing Party or a recipient of Confidential Information.
The Parties wish to protect such Confidential Information in accordance with this Section 12.1. The provisions of this Section 12.1 shall
apply to disclosures furnished to or received by a Party and its agents and representatives (which may include agents and representatives
of its Affiliates). Each Party shall advise its agents and representatives of the requirements of this Section 12.1 and shall be responsible
to ensure their compliance with such provisions.

 

    -30-

     

    

 

(a) Definition of
Confidential Information. For purposes hereof, “Confidential Information” with respect to a disclosing Party
means all Proprietary Information, in any form or media, concerning the disclosing Party or its Affiliates that the disclosing Party
or its Affiliates furnish to the recipient, whether furnished before or after the date hereof, and all notes, analyses,
compilations, studies and other materials, whether prepared by the recipient or others, that contain or reflect such Proprietary
Information; provided, however, that Confidential Information does not include information that (i) is or hereafter becomes
generally available to the public other than as a result of a disclosure by the recipient, (ii) was already known to the recipient
prior to receipt from the disclosing Party as evidenced by prior written documents in its possession not subject to an existing
confidentiality obligation to the disclosing Party, (iii) is disclosed to the recipient on a non-confidential basis by a person who
is not in default of any confidentiality obligation to the disclosing Party, (iv) is independently developed by or on behalf of the
recipient without reliance on the Confidential Information received hereunder, or (v) is required to be submitted to a governmental
agency for the purpose of obtaining product approval, provided that the recipient will make a good faith attempt to obtain
confidential treatment of the information by such agency. The contents of this Agreement shall be deemed to be Confidential
Information of each Party. For clarity, Confidential Information shall not include clinical data contained in clinical reports that
are not permitted under Applicable Laws to be redacted.

 

(b) Treatment
of Confidential Information. The recipient of Confidential Information shall (i) use such Confidential Information solely and exclusively
in connection with the discharge of its obligations under this Agreement and (ii) not disclose such Confidential Information without the
prior written consent of the disclosing Party to any Person other than those of its and/or its Affiliates’ agents and representatives
who need to know such Confidential Information in order to accomplish the objectives for which it was disclosed. Notwithstanding the foregoing,
if the recipient of Confidential Information becomes legally compelled to disclose any Confidential Information in order to comply with
Applicable Laws or with an order issued by a court or regulatory body with competent jurisdiction, the recipient shall (x) provide prompt
written notice to the disclosing Party so that the disclosing Party may seek a protective order or other appropriate remedy or waive its
rights under this Section 12.1; and (y) disclose only the portion of Confidential Information that is legally required to furnish; provided
that, in connection with such disclosure, the recipient shall use Commercially Reasonable Efforts to obtain assurance that confidential
treatment will be given with respect to such Confidential Information. If any Party is required to file this Agreement with any Governmental
Authority, such Party shall redact the terms of this Agreement to the extent possible in order to keep particularly sensitive provisions
confidential.

 

(c) Return
and Destruction. Upon the termination or expiration of this Agreement, upon the request of the disclosing Party, the recipient of
Confidential Information shall promptly redeliver to the disclosing Party all Confidential Information provided to the recipient in tangible
form or destroy the same and certify in writing that such destruction has occurred; provided, however, that nothing in this Agreement
shall require the alteration, modification, deletion or destruction of computer backup tapes made in the ordinary course of business.
All notes or other work product prepared by the recipient based upon or incorporating Confidential Information of the disclosing Party
shall be destroyed, and such destruction shall be certified in writing to the disclosing Party by OV. Notwithstanding the foregoing, legal
counsel to the recipient shall be permitted to retain in its files one copy of all Confidential Information to evidence the scope of and
to enforce the Party’s obligation of confidentiality under this Section 12.1.

 

(d) Term
of Obligation. The obligations under this Section 12.1 shall remain in effect from the date hereof through the seventh (7th)
anniversary of the expiration or termination of this Agreement.

 

(e) Prior
Agreements. The provisions of this Section 12.1 shall supersede and replace any prior agreements between the Parties relating to Confidential
Information covered hereby, including, for the avoidance of doubt, that certain Confidentiality Agreement entered into by and between
Eisai and OV prior to the Effective Date.

 

Section 12.2
Publicity. Upon or following the Effective Date, the Parties may issue the press release attached hereto as Exhibit C. Neither
Party shall issue any other press release or otherwise publicize this Agreement without the prior written consent of the other
Party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that consent shall not be
required in connection with disclosures (a) required by Applicable Law, (b) relating to previously disclosed information, and (c)
expressly authorized by Section 12.1. In the event of a required press release or other public announcement, the Party making such
announcement shall provide the other Party with a copy of the proposed text prior to such announcement.

 

    -31-

     

    

 

ARTICLE 13

Record-keeping and Audits

 

ARTICLE 13 shall survive the expiration or termination of
this Agreement.

 

Section 13.1
Records Retention. OV and its Affiliates shall maintain reasonably detailed records of Net Sales, and any other information reasonably
necessary for the calculation of payments to be made to Eisai pursuant to this Agreement. OV shall be fully responsible for its Affiliates
retention obligations herein. Each Party shall maintain reasonably detailed records of any information necessary to comply with Applicable
Laws or this Agreement. OV and its Affiliates shall maintain its sales records for at least three (3) years following the date of sale.

 

Section 13.2 Audit Request.

 

(a) Audit
Team. Each Party may, upon request and at its expense (except as provided for herein), cause an internationally recognized independent
accounting firm selected by it (except one to whom the Auditee has a reasonable objection) (the “Audit Team”) to audit
during ordinary business hours the books and records of the other Party and the correctness of any payment made or required to be made
to or by such Party, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing
its work pursuant to this Agreement, the Audit Team shall enter into an appropriate confidentiality agreement with the Auditee obligating
the Audit Team to be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less
restrictive than the obligations set forth in Article 13.

 

(b) Limitations.
In respect of each audit of the Auditee’s books and records: (i) the Auditee may be audited only once per year, (ii) no
records for any given year for an Auditee may be audited more than once; provided that the Auditee’s records shall
still be made available if such records impact another financial year which is being audited, and (iii) the Audit Rights Holder
shall only be entitled to audit books and records of an Auditee from the three (3) calendar years prior to the Calendar Year in
which the audit request is made.

 

(c) Audit
Notice. In order to initiate an audit for a particular Calendar Year, the Audit Rights Holder must provide written notice to the Auditee.
The Audit Rights Holder exercising its audit rights shall provide the Auditee with notice of one or more proposed dates of the audit not
less than sixty (60) days prior to the first proposed date. The Auditee will reasonably accommodate the scheduling of such audit. The
Auditee shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate
with such audit.

 

(d) Payments. If
the audit shows any under-reporting or underpayment, or overcharging by any Party, that under-reporting, underpayment or
overcharging shall be reported to the Audit Rights Holder and the underpaying or overcharging Party shall remit such underpayment or
reimburse such overcompensation (together with interest at a rate per annum equal to the lesser of the three (3) month LIBOR (but no
less than zero percent (0%)) plus five percent (5%), as reported by The Wall Street Journal) to the underpaid or overcharged Party
within forty-five (45) days after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or
underpayment or an overcharge by any Party for that period in excess of five percent (5%) of the amounts properly determined, the
underpaying or overcharging Party, as the case may be, shall reimburse the applicable underpaid or overcharged Audit Rights Holder
conducting the audit, for its respective audit fees and reasonable Out-of- Pocket Costs in connection with said audit, which
reimbursement shall be made within forty-five (45) days after receiving appropriate invoices and other support for such
audit-related costs.

 

(e) Definitions.
For the purposes of the audit rights described herein, an individual Party subject to an audit in any given year will be referred to as
the “Auditee” and the other Party who has certain and respective rights to audit the books and records of the Auditee
will be referred to as the “Audit Rights Holder.”

 

(f) Any
information received by a Party pursuant to this Section 13.2 shall be deemed to be Confidential Information for purposes of Section 12.1.
Such information shall be used solely for the purpose for which the audit was conducted.

 

    -32-

     

    

 

ARTICLE 14

Term and Termination

 

Section 14.1
Term. This Agreement shall become effective as of the Effective Date and shall continue in full force and effect on a Product-by-Product
and country-by-country basis until (a) if there has not been a First Commercial Sale of a Product in the Field in such country before
the fifteenth (15th) anniversary of the Effective Date, the fifteenth (15th) anniversary of the Effective Date, or (b) if there has been
a First Commercial Sale of a Product in the Field in such country before the fifteenth (15th) anniversary of the Effective Date, expiration
of the Royalty Term for such Product in such country or group of countries as specified in the definition of “Royalty Term”
herein (the “Term”). This Agreement may be terminated before expiration of the Term only by mutual agreement of the
Parties in writing or in accordance with Section 14.2.

 

Section 14.2 Rights of Termination.

 

(a) Termination
for Material Breach. In the event that a Party commits a material breach of its overall obligations under this Agreement in a manner
that fundamentally frustrates the purpose of this Agreement (other than payment obligations), taken as a whole, and such material breach
of its overall obligations is not cured within ninety (90) days (or such other time period as mutually agreed by the Parties), or a material
breach of its payment obligations under this Agreement that is not cured within thirty (30) days, after such Party receives written notice
from the non-breaching Party, which notice shall specify the nature of the breach and demand its cure, the non-breaching Party may terminate
this Agreement in its entirety upon written notice to the breaching Party.

 

(i) Notwithstanding
the foregoing, if a material breach is not susceptible to cure within the cure period specified in Section 14.2(a), the non-breaching
Party’s right of termination shall be suspended only if, and for so long as, (i) the breaching Party has provided to the non-breaching
Party a written plan that is reasonably calculated to effect a cure, (ii) such plan is reasonably acceptable to the non-breaching Party
and (iii) the breaching Party commits to and does carry out such plan; provided, however, that, unless otherwise mutually agreed by the
Parties in such plan, in no event shall such suspension of the non-breaching Party’s right to terminate extend beyond sixty (60)
days after the original cure period.

 

(ii) Notwithstanding
the foregoing, if either Party is alleged to be in material breach and disputes such termination through the dispute resolution procedures
set forth in this Agreement, then the other Party’s right to terminate this Agreement shall be tolled for so long as such dispute
resolution procedures are being pursued by the allegedly breaching Party in good faith and, if it is finally and conclusively determined
that the allegedly breaching Party is in material breach, then the breaching Party shall have the right to cure such material breach after
such determination within the cure period provided above in this Section 14.2(a).

 

(b) Termination for Convenience.
Prior to its expiration, OV may terminate this Agreement in its entirety, in its sole discretion, at any time upon at least one hundred
and twenty (120) days prior written notice to Eisai for any reason.

 

(c) OV
Right of Termination for Safety Reasons. Notwithstanding anything to the contrary in this Agreement, OV shall have the right to terminate
this Agreement upon thirty (30) days written notice in the event that:

 

(i) a
competent Regulatory Authority in a Major Country prohibits the further clinical use of the Product in the applicable country or regulatory
jurisdiction within the Territory under 21 C.F.R. § 312.44 on grounds of safety (or equivalent grounds with respect to any country
or regulatory jurisdiction in the Territory outside of the United States); or

 

(ii) a
clinical hold imposed by a competent Regulatory Authority in a Major Country relating to the Product is definitively converted to
“inactive status” by such Regulatory Authority under 21 C.F.R. § 312.45 on grounds of safety (or equivalent grounds
with respect to any country or regulatory jurisdiction in the Territory outside of the United States), despite OV’s use of
Commercially Reasonable Efforts to eliminate such clinical hold.

 

(d) Bankruptcy.
This Agreement may be terminated by written notice by a Party at any time during the Term if the other Party shall file in any court or
agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or other Insolvency Event or for reorganization
or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party shall be served
with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60)
days after the filing thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party
shall make a general assignment for the benefit of its creditors.

 

    -33-

     

    

 

(e) Termination
for Patent Challenge. Each Party shall have the right to terminate this Agreement upon written notice to the other effective upon
receipt, if a Party or any of its wholly-owned Affiliates formally challenges the validity of any Patents that are licensed to it under
this Agreement (subject to the exceptions described in this Section 14.2(e), a “Challenge”) (other than as may be necessary
or reasonably required to assert a defense, cross-claim or a counter-claim in an action or proceeding asserted by a Party or any of its
wholly-owned Affiliates under this Agreement against the other Party or any of its Affiliates or to respond to a court request or order
or administrative law, request or order); it being understood and agreed that a Party’s right to terminate this Agreement under
this Section 14.2(e) shall not apply to any actions undertaken by an Affiliate of such Party that first becomes such an Affiliate as a
result of a Change of Control involving such Party, where such new Affiliate was undertaking any of the activities described in the foregoing
clause prior to such Change of Control if such new Affiliate terminates or otherwise ceases participating in such action, proceeding,
challenge or opposition within thirty (30) days after the effective date of such Change of Control. If a sublicensee of a Party initiates
a Challenge of the intellectual property described in this Section 14.2(e), then such Party shall, upon written notice from the other
Party, terminate such sublicense. Neither Party shall, and each Party shall ensure that its Affiliates and sublicensees do not, use or
disclose any Confidential Information of the other Party or any nonpublic information regarding the Prosecution or enforcement of any
Patents to which a Party or any of its Affiliates or sublicensees are or become privy as a consequence of the rights granted to such Party
pursuant to this Agreement, in initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person
with respect to, any Challenge.

 

(f) Eisai
Right of Termination for Development.

 

(i) If
OV and/or its Affiliates or sublicensees have not achieved Successful Completion of the first Phase 2 Clinical Trial of the Product prior
to the fourth (4th) anniversary of the Effective Date and OV elected not to pay the Extension Payment pursuant to Section 7.6,
Eisai may terminate this Agreement in its entirety, in its sole discretion, at any time following the fourth (4th) anniversary
of the Effective Date, on at least one hundred and twenty (120) days prior written notice.

 

(ii) Where
OV elected to pay the Extension Payment pursuant to Section 7.6, if OV and/or its Affiliates or sublicensees have not achieved Successful
Completion of the first Phase 2 Clinical Trial prior to the seventh (7th) anniversary of the Effective Date, then Eisai may
terminate this Agreement in its entirety, in its sole discretion, at any time following the seventh (7th) anniversary of the
Effective Date, on at least one hundred and twenty (120) days prior written notice.

 

Section 14.3
Surviving Rights and Obligations. Any provisions required for the interpretation or enforcement of this Agreement shall survive the
expiration or termination of this Agreement. Expiration or termination of this Agreement shall not relieve any Party of any obligations
that are expressly indicated to survive expiration or termination. Except as otherwise expressly provided, expiration or termination of
this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such
expiration or termination. If a license to intellectual property rights survives expiration or termination, each Party shall provide to
the other (to the extent it has not previously done so) all Proprietary Information reasonably useful or necessary for such other Party
to exploit such license, including reasonable technical assistance; provided that such Proprietary Information shall remain subject to
Section 12.1 so long as it is possessed by a Party.

 

Section 14.4 Effect of Expiration
or Termination; Remaining Inventory.

 

(a) Upon
expiration or termination of this Agreement, neither Party shall have any further rights or obligations hereunder in the Territory except
pursuant to provisions that expressly survive such expiration or termination (including, for the avoidance of doubt, this Section 14.4).

 

(b) After expiration
(but not after early termination) of this Agreement pursuant to Section 14.1, on a Product-by-Product, country-by-country basis, the
rights and licenses granted (i) by Eisai to OV under this Agreement to Develop, Manufacture and Commercialize the Products in the
Field , including any permitted sublicense, shall immediately cease, and (ii) by OV to Eisai under this Agreement in connection with
Eisai’s Development, Manufacture or Commercialization of the Product outside the Field shall convert to irrevocable,
non-exclusive, royalty-free, fully paid-up, non-terminable rights and licenses, with the right to grant sublicenses (through
multiple tiers).

 

    -34-

     

    

 

(c) Upon early
termination of this Agreement, subject to Section 14.3 and this Section 14.4, OV shall immediately discontinue and cease all use of
any trademark(s) registered by Eisai in the Territory. Following any such termination of this Agreement, subject to Section 14.3 and
this Section 14.4, Eisai shall have the right and option to purchase any trademark(s) registered by OV or its Affiliates for the
Product on a country-by-country basis. The purchase price shall be negotiated by the Parties on a country-by-country basis in good
faith on the basis of a third party willing and able to purchase such trademark(s). If the Parties are unable to come to an
agreement on the purchase price within thirty (30) days (or such other days as mutually agreed upon by the Parties) of Eisai
exercising the right and option to purchase, the Parties will appoint an independent third party valuator to conduct a valuation of
such trademark(s) on the basis of how much a willing and able third party will pay for such trademark(s), and the Parties shall
share the costs of such third party valuation. The valuation of the third party will be the purchase price to be paid by Eisai to
OV.

 

(d) Upon
early termination of this Agreement or expiration of the Agreement, OV shall, on behalf of itself and its Affiliates, grant to Eisai and
its Affiliates (i) a perpetual, fully paid-up, exclusive right and license under OV’s interest to the Joint Intellectual Property
and (ii) a perpetual, fully paid-up, non-exclusive right and license under any OV Technology Developed by OV and/or its Affiliates or
sublicensees under this Agreement, in each case of (i) and (ii) as reasonably required to (A) develop, validate or optimize the Product-Specific
Biomarker for clinical and commercial use as a companion diagnostic for the Product in the Field in the Territory and (B) conduct a targeted-enrollment
of a Phase 2 Clinical Trial for the Product in the Field in accordance with the Clinical Development Plan.

 

(e) Upon expiration
or early termination of this Agreement,

 

(i) OV
shall, and shall cause its Affiliates and take all reasonable steps to cause its licensees and permitted sublicensees to, transfer back
to Eisai those items transferred to OV under Section 3.3.

 

(ii) OV
shall, and shall cause its Affiliates and take all reasonable steps to cause its licensees and permitted sublicensees to, transfer to
Eisai all safety data and CMC data (including for clarity any documentation solely containing such safety data and CMC data) for the Product;
provided that to the extent such a transfer of safety data and CMC data is not permitted under Applicable Laws or such documentation contains
clinical data generated by OV (including Affiliates, licensees and permitted sublicensees) other than safety data and CMC data, OV shall,
and shall cause its Affiliates and take all reasonable steps to cause its licensees and permitted sublicensees to, provide Eisai an automatic
Right of Reference or Use to the safety and CMC data in such documentation for the Product.

 

(iii)
Subject to Eisai’s rights to safety data and CMC data set forth above in Section 14.4(e)(ii), with respect to any ongoing
Clinical Trials at such time, Eisai shall notify OV whether or not Eisai elects to take over such Clinical Trial(s). In the event
that Eisai elects to take over such Clinical Trial(s), subject to Applicable Laws, OV shall transfer, or cause the transfer by an
Affiliate and take all reasonable steps to cause its licensees and permitted sublicensees to transfer, all Regulatory Documentation
for the Product and Eisai shall have the right to any data generated by such trials and Controlled by OV; provided that, to the
extent such a transfer of Regulatory Documentation is not permitted under Applicable Laws, OV and its Affiliates will provide Eisai
an automatic Right of Reference or Use to such Regulatory Documentation for the Product. Whether or not Eisai elects to take over
any of such Clinical Trials as described in this Section 14.4(e)(iii), Eisai shall pay to OV a reverse royalty rate of three percent
(3%) on Annual Net Sales of such Product beginning on and after the date of First Commercial Sale of the Product in the US or Major
Countries (whichever occurs first) until OV and any licensee and sublicensee has been reimbursed for one hundred percent (100%) of
its direct and documented (which documentation Eisai shall have a right to review) out-of- pocket expenses incurred with respect to
and to the extent allocable to the Development of such Product. If Eisai does not elect to have an ongoing Clinical Trial
transferred to Eisai, then the Parties shall work together to conduct an orderly wind-down of such ongoing Clinical Trial(s) in a
manner medically necessary to safely transition subjects out of such ongoing Clinical Trial(s), in any event subject to Applicable
Laws and the advice and guidance of all applicable Regulatory Authorities and clinical trial monitoring boards.

 

(f) Upon termination of
this Agreement, subject to Section 14.3, the Selling Parties shall be permitted to import, market, promote, distribute, use, offer to
sell and sell their remaining inventories of Product for a period of one hundred eighty days (180 days) and, for such purpose, the rights
and licenses granted hereunder to OV shall continue in effect but shall be non-exclusive in the Territory. Furthermore, upon termination
of this Agreement, Eisai shall have to the right to purchase any clinical supply of the Product (including raw materials, intermediates,
and finished, unfinished, or partially finished goods) on terms substantially similar to OV’s purchase of Inventory set forth in
Section 3.6.

 

    -35-

     

    

 

ARTICLE 15

Miscellaneous

 

Section
15.1 Entire Agreement; Amendments. This Agreement, including the Exhibits hereto, constitutes the entire agreement between the Parties
concerning its subject matter and supersedes all previous negotiations, agreements and commitments with respect thereto, as of the Effective
Date. This Agreement shall not be released, discharged, amended or modified in any manner except by a written instrument signed by duly
authorized officers or representatives of each of the Parties. There are no covenants, promises, agreements, warranties, representations,
conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein.

 

Section
15.2 Governing Law. Any claim or controversy relating in any way to this Agreement shall be governed by and interpreted exclusively
in accordance with the laws of the State of New York, without regard to the conflicts of law principles thereof. This Agreement shall
not be governed by the United Nations Convention on Contracts for the International Sale of Goods of April 11, 1980.

 

Section
15.3 Dispute Resolution. The Parties shall attempt in good faith to resolve any dispute or claim between them arising out of or relating
to this Agreement (“Dispute”) promptly by negotiations between executives or other representatives of the Parties with authority
to resolve the Dispute. If a Dispute should arise, such representatives shall confer in person or by telephone at least once and attempt
to resolve the matter. Such conference shall take place within ten (10) days of a written request therefor at a mutually agreed time and
location.

 

If the Dispute
is not settled within thirty (30) days of the conference or time to confer described above, either Party may submit the Dispute for
arbitration. The Dispute shall be finally settled under the Rules of Arbitration (the “Rules”) of the
International Chamber of Commerce (the “ICC”). The place of the arbitration shall be New York. The language of
the arbitration shall be English. There shall be three (3) arbitrators, one of whom shall be appointed by each of the Parties in
accordance with the Rules, and the third of whom shall be appointed by the ICC. The arbitrator appointed by the ICC shall act as the
chairperson of the arbitrating body. The arbitrators shall decide the matters in the Dispute in accordance with the laws of the
State of New York, without reference to the conflict of laws rules thereof or the United Nations Convention on Contracts for the
International Sale of Goods.

 

The arbitration
shall be commenced and shall proceed according to the Rules, except as otherwise provided herein. Any Confidential Information disclosed
in the arbitration shall be subject to the confidentiality provisions of this Agreement. Any time period specified in the Rules shall
be extended or accelerated upon the Parties’ written agreement. At the request of either Party, all time periods specified in the Rules
may, at the discretion of the arbitrators, be accelerated or extended to the extent necessary to comply with the timetables specified
in the Rules or for the reasonable management of the arbitration.

 

The procedures
specified in this Section 15.3 shall be the sole and exclusive procedures for the resolution of Disputes; provided, however, that a Party
may, in addition or as an alternative to seeking interim relief from the ICC, seek injunctive or other provisional judicial relief in
any court of competent jurisdiction if in its reasonable judgment such action is necessary to avoid irreparable harm or to preserve the
status quo.

 

The decision
of the arbitrators shall be final and binding on all Parties to the arbitration. Judgment upon any award rendered by the arbitrators may
be entered by any court having jurisdiction over the Party against whom enforcement is sought. Each of the Parties hereby consents, for
the benefit of the other Party, to the service of process by certified or registered mail or by an express delivery service providing
a return receipt at its address set forth for notices herein.

 

While the
procedures set forth above are being followed, the Parties shall continue to perform their respective obligations under this Agreement.
Each Party shall bear its own costs and fees, including attorneys’ fees and expenses, in connection with the arbitration, except that
the arbitrators shall be empowered to assess costs and fees against any Party who the arbitrators find to have acted in bad faith or to
have maintained a frivolous position in the arbitration.

 

    -36-

     

    

 

Section
15.4 Partial Illegality. If any provision of this Agreement or the application thereof to any Party or circumstances shall be declared
void, illegal or unenforceable, the remainder of this Agreement shall be valid and enforceable to the extent permitted by Applicable Laws.
In such event, the Parties shall use their best efforts to replace the invalid or unenforceable provision by a provision that, to the
extent permitted by the Applicable Laws, achieves the purposes intended under the invalid or unenforceable provision. Any deviation by
any Party from the terms and provisions of this Agreement in order to comply with Applicable Laws shall not be considered a breach of
this Agreement.

 

Section
15.5 Waiver of Compliance. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents
or employees, except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving
Party, which waiver shall be effective only with respect to the specific obligation and instance described therein.

 

Section
15.6 Notices. All notices and other communications in connection with this Agreement shall be in writing and shall be sent to the
respective Parties at the following addresses, or to such other addresses as may be designated by the Parties in writing from time to
time in accordance with this Section 15.6, by registered or certified mail, postage prepaid, or by express courier service, or service
fee prepaid, or by email upon confirmed delivery sent by the recipient in return in accordance with this Section 15.6.

 

		To Eisai:	 Eisai Inc.

Attention: Chief Medical Officer,

Oncology Business Group

155 Tice Blvd.

Woodcliff Lake, NJ 07677

Facsimile: 201-746-3204  

 

With copy to:

 

Eisai Inc.

Attention: General Counsel

100 Tice Blvd. Woodcliff Lake, NJ 07677

Facsimile: 201-746-3204  

 

		To OV:	Oncology Venture, ApS

Venlighedsvej 1

DK-2970 Hoersholm, Denmark

Attention: Chief Executive Officer

Email:
pbj@oncologyventure.com

 

With a copy to:

 

Dechert LLP

1900 K Street, NW

Washington D.C. 20006

Attention: David E. Schulman

Email: david.schulman@dechert.com

 

    -37-

     

    

 

All notices shall be deemed given
and received (a) if delivered by hand, immediately, (b) if sent by mail, ten (10) Business Days after posting, (c) if delivered by express
courier service, three (3)  Business Days in the jurisdiction of
the recipient, (d) if sent by fax, at the time shown in the confirmed electronic receipt, or on the first Business Day thereafter if
the notice is sent on other than a Business Day, or (e) if sent by email, the date indicated as being sent in the recipient’s email
browser.

 

Section
15.7 Limitation on Liability. NOTWITHSTANDING THE FOREGOING, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL,
INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES UNDER THIS AGREEMENT, EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM A PARTY’S
WILLFUL MISCONDUCT OR ARE PAYABLE IN CONNECTION WITH A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 10 FOR LIABILITY OWED TO
THIRD PARTIES.

 

Section
15.8 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which
together shall be deemed to be one and the same instrument.

 

Section
15.9 Further Assurances. From time to time, as and when requested by any Party, the other Party shall execute and deliver, or cause
to be executed and delivered, all such documents and instruments and shall take, or cause to be taken, all such further actions as such
other Party may reasonably deem necessary or desirable to carry out the intentions of the Parties embodied in this Agreement.

 

Section 15.10
Injunctive Relief. The Parties acknowledge and agree that, in addition to any other remedies available in law or equity, either Party
shall be entitled to temporary and permanent injunctive relief in the event of a breach under this Agreement.

 

Section 15.11
Jointly Prepared. This Agreement has been prepared jointly and shall not be strictly construed against either Party. Ambiguities,
if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous
provision.

 

Section 15.12
Assignment.

 

(a)
Generally. Subject to Section 6.1 and this Section 15.12, a Party shall not have the right to assign, by operation of law
or otherwise, any of its rights or obligations under this Agreement without the prior written consent of the other Party. Any assignment
not in accordance with this Section 15.12 shall be void.

 

(b) OV.
Notwithstanding the limitations in Section 15.12(a), OV may assign this Agreement, or any rights or obligations hereunder in whole
or in part, to (a) one or more Affiliates or (b) its successor in interest in connection with the merger, consolidation, or sale of
all or substantially all of its assets or that portion of its business pertaining to the subject matter of this Agreement, provided that
in each case OV shall remain liable for all obligations imposed upon OV under this Agreement as if no such assignment had
occurred.

 

(c)
Eisai. Notwithstanding the limitations in Section 15.12(a), Eisai may assign this Agreement, or any rights or obligations
hereunder in whole or in part, to (a) one or more Affiliates solely as provided in this Section 15.12 or (b) its successor in connection
with the merger, consolidation, or sale of all or substantially all of its assets or that portion of its business pertaining to the subject
matter of this Agreement, provided that in each case Eisai shall remain liable for all obligations imposed upon OV under this Agreement
as if no such assignment had occurred.

 

Section
15.13 Relationship of Parties. Each Party to this Agreement is an independent contractor, and nothing in this Agreement shall be construed
to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed
to create the relationship of partners, principal and agent, or joint-venture partners between the Parties. Employees and agents of one
Party are not employees or agents of the other Party, shall not hold themselves out as such, and shall not have any authority or power
to bind the other Party to any contract or other obligation.

 

    -38-

     

    

 

Section
15.14 Force Majeure. If the performance of any obligation under this Agreement is prevented, restricted or interfered with by reason
of any Force Majeure event, then the Party so affected shall be excused, upon giving prior written notice to the other Party, from such
performance to the extent of such prevention, restriction or interference, provided that the Party so affected shall use reasonable commercial
efforts to avoid or remove such causes of nonperformance and shall continue performance to the extent reasonably possible and, in any
event, at such time as the Force Majeure conditions come to an end. If the Force Majeure conditions prevent performance completely and
such prevention continues for more than one hundred and eighty days (180) days, then the Parties shall attempt to negotiate a mutually
acceptable compromise within the spirit and intent of this Agreement. If they are unable to reach a mutually acceptable compromise within
ninety (90) days and if performance is still completely prevented at the end of that time, then the Party who is not affected by the Force
Majeure conditions shall have the option, by delivery of written notice of termination to the affected Party, to terminate this Agreement
with immediate effect and such termination shall be treated as a termination for material breach by Party affected by the Force Majeure,
except that in such event no cure period shall apply and the terminating Party shall have the right to effect such termination upon written
notice, in its sole discretion, (a) solely with respect to the country or Product affected by such non-performance or (b) the Agreement
in its entirety.

 

Section
15.15 Severability. If any one or more of the terms or provisions of this Agreement is held by a court of competent jurisdiction
or arbitrator to be void, invalid or unenforceable in any situation in any jurisdiction, such holding shall not affect the validity
or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the invalid, void or
unenforceable term or provision in any other situation or in any other jurisdiction and the term or provision shall be considered
severed from this Agreement, unless the invalid or unenforceable term or provision is of such essential importance to this Agreement
that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid or unenforceable
term or provision. If the final judgment of such court or arbitrator declares that any term or provision hereof is invalid, void or
unenforceable, the Parties agree to (a) reduce the scope, duration, area or applicability of the term or provision or to delete
specific words or phrases to the minimum extent necessary to cause such term or provision as so reduced or amended to be
enforceable, and (b) make a good faith effort to replace any invalid or unenforceable term or provision with a valid and enforceable
one such that the objectives contemplated by the Parties when entering this Agreement may be realized.

 

Section 15.16
Third-Party Beneficiaries. Nothing in this Agreement, whether express or implied, is intended to confer any rights or remedies under
or by reason of this Agreement on any Persons other than the Parties hereto and their respective successors, assigns, and Affiliates.

 

Section
15.17 Expenses. Except as expressly provided herein (including with respect to the allocation of Out-of-Pocket Costs), each of OV
and Eisai agrees to pay, without right of reimbursement from the other, all costs and expenses incurred by it and its Affiliates incident
to the preparation, execution and delivery by it of this Agreement and the performance of its obligations hereunder, including the fees
and disbursements of counsel, accountants, financial advisors, experts, consultants and employees employed by such party in connection
with the preparation, execution and delivery by it of this Agreement and with the performance of its obligations contemplated hereby.

 

[REMAINDER OF PAGE INTENTIONALLY
BLANK; SIGNATURE PAGE FOLLOWS]

 

    -39-

     

    

 

The Parties have executed this
Agreement as of the Effective Date to evidence their agreement to the terms and provisions set forth herein.

 

	 	Oncology Venture, ApS
	 	 
	 	By:	         
	 	Name: 	Peter Buhl Jensen
	 	Title:	Chief Executive Officer

 

[Signature Page to Exclusive License Agreement]

 

     

     

    

 

The Parties have executed this
Agreement as of the Effective Date to evidence their agreement to the terms and provisions set forth herein.

 

	 	EISAI INC.
	 	 
	 	By:	         
	 	Name: 	
	 	Title:	

 

[Signature Page to Exclusive License Agreement]

 

     

     

    

 

EXHIBIT A

 

Clinical Development Plan

 

[***]

 

     

     

    

 

EXHIBIT B

 

Product-Specific Biomarker

 

[***]

 

     

     

    

 

EXHIBIT C

 

Press Release

 

	 	 

 

Press release issued by Oncology Venture Sweden
AB 

Hoersholm, Denmark, July XXth 2017

Press release

 

Oncology Venture and Eisai Forge Exclusive
Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

 

2X Oncology to conduct
Phase 2 Study of 2X-121 in metastatic breast cancer patients

 

Hoersholm, Denmark, July XX, 2017 –
Oncology Venture Sweden AB (“OV” or the “Company”) and Cambridge, MA –2X Oncology, Inc. (“2X”)
a spinout of Oncology Venture, today announced that that the Oncology Venture has entered into an exclusive global license agreement
with Eisai Inc. for Eisai’s Phase 2 PARP inhibitor E7449 – now called 2X-121. 2X-121 will be developed by 2X Oncology (“2X”),
a precision medicine company developing targeted therapeutics to address significant unmet needs in women’s cancer.

 

2X-121 is a small molecule targeted inhibitor
of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells. The PARP inhibitor demonstrated clinical
activity in a prior Phase 1 study in a number of cancers, including ovarian and breast. The drug also has potential to treat brain metastases
and primary brain tumors based on its ability to pass through the blood-brain barrier.

 

“We are excited to in-license this promising
PARP-inhibitor from Eisai. The cutting-edge science and compelling clinical data behind 2X-121 in combination with our unique Drug Response
Predictor (DRPTM) biomarker technology provide an exceptional risk-reduced opportunity to develop effective treatments for hard to
treat cancers,” said Peter Buhl Jensen, M.D., CEO of Oncology Venture.

 

Oncology Venture successfully validated its DRPTM
biomarker for 2X-121 using clinical biopsy materials and blinded patient response data provided by Eisai under a prior agreement between
the companies.

 

The drug will be developed in the pipeline of 2X Oncology,
Inc., a Cambridge, MA-based spin-out of Oncology Venture, developing precision medicines for unmet needs in women’s cancers.

 

“We plan to initiate a
focused Phase 2 trial of 2X-121 for the treatment of metastatic breast cancer later this year, using a DRPTM biomarker to identify
patients who are most likely to respond to and benefit from treatment with this promising therapeutic,” said George O. Elston,
CEO of 2X Oncology, Inc. “Positive data from this study will position this program for a pivotal Phase 2 study initiation
in 2018,” Mr. Elston added.

 

Under the terms of the agreement, Oncology Venture will
be responsible for the development and commercialization of 2X-121 in oncology. Oncology Venture will, through 2X Oncology, Inc., execute
a mutually agreed upon clinical development plan, which includes an initial Phase 2 clinical study in patients with metastatic breast
cancer using the DRPTM biomarker. Further terms of the agreement were not disclosed.

 

     

     

    

 

About 2X-121

 

2X-121 has a novel dual-inhibitory action against both PARP 1/2
and Tankyrase 1/2. The molecule is also active in P-glycoprotein expressing cells, suggesting it may overcome PARP inhibitor
resistance. A Phase 2 study (>20 patients) is planned using a DRPTM biomarker in metastatic breast cancer patients to
identify patients likely to respond to and benefit from treatment with 2X-121. Positive data from this study will position the
program for a pivotal Phase 2 study initiation in 2018.

 

In a prior Phase 1 study conducted without a DRPTM,
two patients had a durable partial response (281 and 208 days, respectively). 2X-121 was well tolerated with no myelotoxicity observed.
The planned Phase 2 study using a DRPTM is expected to significantly improve response rates seen in this initial study.

 

About
the Drug Response Predictor (DRPÔ)
Companion Diagnostic

 

Developed by and in-licensed from Medical Prognosis Institute
A/S (MPI.ST), the DRPTM screening platform utilizes messenger RNA (mRNA) gene expression signatures from patient biopsies to identify
patients with a high likelihood of responding to specific cancer-fighting therapies. This DRPTM method builds on the comparison of
sensitive vs. resistant human cancer cell lines, including genomic information from cell lines, combined with clinical tumor biology and
clinical correlates in a systems biology network. Specific DRPTMs are developed for each pipeline product, which will enable Oncology
Venture and its spin-out 2X Oncology to identify and predict which patients are most likely to respond and thereby benefit from a given
pipeline product. This would enable likely responders to receive appropriate treatment while expediting the decision path for predicted
non-responders, saving them critical time and money in their cancer fight.

 

About Oncology Venture Sweden AB

 

Oncology Venture Sweden AB is engaged in the research
and development of anti-cancer drugs through its wholly- owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive
license to use the Drug Response Predictor (DRPTM) platform in order to significantly increase the probability of success in clinical
trials. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all
patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond
to the treatment will be treated. Focusing on this defined patient group reduces risk and costs are reduced while increasing efficiencies
in the development process. The current Oncology Venture product portfolio includes LiPlaCis for breast cancer in collaboration with Cadila
Pharmaceuticals; Irofulven for prostate cancer; and APO010, an immuno-oncology product in development for the treatment of multiple myeloma.

 

In addition to 2X Oncology, of which OV currently owns
92%, Oncology Venture has spun out Danish OV-SPV 2, which will test and potentially develop an in-licensed, oral phase 2 Tyrosine Kinase
inhibitor.

 

About 2X Oncology

 

2X Oncology Inc. is developing targeted therapeutics
that leverage the proprietary Drug Response Predictor (DRPTM) biomarker technology to address significant unmet needs in women’s
cancer. The DRPTM generates a precision mRNA-based companion diagnostic for each compound, enabling the identification of patients
that are most likely to respond and benefit from treatment.

 

The 2X pipeline includes product candidates focused on
breast and ovarian cancers and primary and secondary brain tumors. Our product candidates have been selectively in-licensed using strict
criteria, including established clinical efficacy and safety and a known mechanism of action. We expect to advance these programs through
focused Phase 2 studies using a targeted DRPTM CDx with key data available in 2018. Learn more at 2xoncology.com.

 

     

     

    

 

About Eisai Inc.

 

At Eisai Inc., human health care (hhc) is
our goal. Eisai gives its first thoughts to patients and their families, and helping to increase the benefits health care provides.
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., Eisai Inc. has a passionate commitment to patient care that is
the driving force behind Eisai’s efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology
(dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery,
development, and marketing capabilities. Eisai’s U.S. headquarters, commercial and clinical development organizations are
located in New Jersey; discovery labs are in Massachusetts and Pennsylvania; and the global demand chain organization resides in
Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.

 

Eisai Co., Ltd.

 

Eisai Co., Ltd. is a leading global research and development-based
pharmaceutical company headquartered in Japan. Eisai defines its corporate mission as “giving first thought to patients and their
families and to increasing the benefits health care provides,” which Eisai calls its human health care (hhc) philosophy.
With over 10,000 employees working across its global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai
strives to realize its hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including
oncology and neurology. For more information about Eisai Co., Ltd., please visit www.eisai.com.

 

DRPTM is a trademark of Medical Prognosis Institute
A/S.

 

	Contact	 	 
	For Oncology Venture	 	For 2X Oncology, Inc.
	Ulla Hald Buhl	 	Amy Raskopf
	Chief Operating Officer, Chief IR & Communications	 	Corporate Communications
	+45 2170 1049	 	+1 917-673-5775
		 	Twitter: @2xoncology

 

Peter Buhl Jensen

Chief Executive Officer

+45 21 60 89 22

 

This information is information that Oncology
Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication,
through the agency of the contact person set out above, on July XXth, 2017

 

     

     

    

 

Schedule 1

 

Major Countries

 

United States, Canada, Germany, France, the United Kingdom,
Spain, Italy, China, Japan, Russia, Brazil, and Australia.

 

     

     

    

 

Schedule 2

 

Eisai Patents

 

Platform Patents

 

None.

 

Product-Specific Patents

 

[See next page.]

 

     

     

    

 

	Eisai Ref Nurnbet	_...., ,. ll ca do n Nurn.ber	Cou n’”~ Name	Stat us	Fllll’III? Date	Pate nt Nurnbet	ISsue Date	WGSRef Null\ber
	PARP-01 6-UlA U	2008308664	Aust ralla	Granted	 	2008308664	10/ 30/ 2014	E0459 .7000 3AUOO
	PARP·Ol 6· U1B0	266/ 2008	Ban.cil a d es h	Pend l n.:>	10/2/2008	 	 	E04 59 . 700038000
	PARP·Ol 6· U l BR	PI0820S18·3	Btanl	Pendlr’IQ:	10/2/2008	 	 	E04 59 . 70003Blt00
	PARP-01 6-Ul CA	2700903	Canada	Granted	10/2/2008	2700903	S/ 30/ 2017	E0459 .70003CA OO
	PARP·Ol 6· U lCL	3 20-2010	Chile	Pendln.:>	4/5/2010	 	 	E04 59 . 70003Cl00
	PARP-01 6-Ul CN	200880118681.4	Chl.na (Peo ple ’s Repu.bllc)	Granted	10/2/2008	200880118681	4/ 30/ 2014	E04 59 .7000 3CNOO
	PARP-016-U lEG	PCTS19/2 010	S M      !	Pendlr’IQ:	10/2/2 008	 	 	E04 59 . 70003EGOO
	PARP-01 6-Ul EP	08836018.S	Eurooea n Patent Conven	Granted	10/2/2008	220937S	8/ 27/ 2014	E04 59 .7000 3 EPOO
	PARP-01 6-UlA T	08836018.S	Austr ia	Granted	10/2/2008	220937S	8/ 27/ 2014	E0469 .7000 3ATOO
	PARP-01 6-Ul BE	08836018.S	5er,1, o,.m	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 38£00
	PARP-01 6-Ul BG	08836018.S	&JIGa. ria	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 3 BGOO
	PARP-01 6-Ul CH	8836018.S	Swlu ertand	Granted	10/2/2008	220937S	8/712014	E04 59 .7000 3CHOO
	PARP-01 6-Ul CY	08836018.S	Cvorus	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 3CYOO
	PARP-01 6-Ul CZ	08836018.S	Czec h Re pub lic	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 3C200
	PARP-01 6-Ul DE	08836018.S	Germanv	Granted	10/2/2008	220937S	8/ 2712014	E04 59 .7000 3 DEOO
	PARP-01 6-Ul DK	08836018.S	Den mart	Granted	10/2/2008	220937S	8/ 27/ 2014	E04 59 .7000 30 KOO
	P ARP-01 6-UlE E	08836018.S	Estonia	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 3 EEOO
	PARP-01 6-UlES	08836018.S	Sruln	Granted	10/2/2008	220937S	8/ 27/ 2014	E04 59 .7000 3 ESOO
	PARP-01 6-Ulfl	08836018.S	Flnland	Granted	10/2/2008	220937S	8/ 27/ 2014	E04 59 .7000 3 FIOO
	PARP-01 6-UlF R	08836018.S	France	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 3FROO
	PARP-01 6-Ul GB	08836018.S	Un.iled Klngd om	Granted	10/2/2008	220937S	8/ 27/ 2014	E0459 .7000 3GBOO
	P ARP-01 6-Ul GR	08836018.S	G<eece	Granted	10/2/2008	2209375	8/ 2712014	E04 59 .7000 3GROO
	P ARP-01 6-Ul HK	111 009 18 .6	Hon:e.Kone:	Granted	10/2/2008	HK11 467 92	7/ ’1/ 20 !.S	E0459 .7000 3 HKOO
	P ARP-01 6-Ul HR	08836018.S	Croatia	Granted	10/2/2008	220937S	8/ 27/ 2014	 

 

     

     

    

 

	PARP-01 6-Ul HU	08836018.S	Hun arv	Granted	10/2/2008	220937S	8/ 2712014	 
	PARP-01 6-Ull E	08836018.S	Ireland	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-UUS	08836018.S	Iceland	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-u u r	08836018.S		Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-Ull T	08836018.S	Lit h ua nia	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-Ull U	08836018.S	Luxe rnboure.	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-Ull V	08836018.S	Latvia	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-Ul MC	08836018.S	Monaco	Granted	10/2/2008	220937S	8/ 2712014	 
	PARP-01 6-Ul MT	08836018.S	Malta	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-01 6-Ul NL	08836018.S	The Net he rtands	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-Ul NO	08836018.S	No rwav	Granted	10/2/2008	220937S	8/ 2712014	 
	PARP-016-Ul PL	08836018.S	Poland	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-Ul PT	08836018.S	Portue:al	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-UlRO	08836018.S	Romania	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-UlS E	08836018.S	Sweden	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-UlS L	08836018.S	Sloven.la	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-Ul TR	08836018.S	Turt ev	Granted	10/2/2008	220937S	8/ 27/ 2014	 
	PARP-016-UUL	204776	Israel	Granted	10/2/2008	204776	12/2S/ 20l.S	 
	PARP-016-UUO	W·00 2010 01 0S9	Indonesia	Granted	10/2/2008	  IDP0036467	7/25/ 2014	 
	PARP·Ol 6· U11N	1312/ KO LNP/ 2010	India	Pending	10/2/ 2008	 	 	E04 59 . 70003 1NOO
	PARP-016-U UO	1>14 33/ 2008	Jo r da n	Pe nd ln.:>	10/2/2008	 	 	E04 59 . 7000 3JOOO
	PARP-016-UU P	2010-S 28132	Ja pa n	Granted	10/2/2008	S439380	12/20/ 2013	E04 59 .7000 3JPOO
	PARP-016-Ul KR	10-20 10. 7009S88	Kor e, a Reoubkl of	Granted	10/2/2008	10/l S96S26	2/16/ 2016	E0459 .7000 3 Kll00
	PARP-016-Ull K	1S7S7	S ri Lan.ka	Granted	10/2/2008	1S7S7	10/14/ 2013	E04 59 .7000 31.XOO
	P ARP-016-Ul MX	M)(/a/2010/003564	Mexico	Granted	10/2/2008	308Sl 3	4/ S/2013	E0459 .7000 3 MXOO
	PARP-016-Ul MY	P12010001 496	Malaysia	Granted	10/2/2008	MY·1S5 23 7•A	9/ 30/ 201S	E0459 .7000 3 MYOO
	P ARP-016· Ul N2	5850 12	New Zealand	Granted	10/2/2008	S8S012	10/ 8/ 2012	E04 59 .7000 3 NZOO
	PARP-016-Ul PE	205 .201	Peru	Abando ned	4/5 /20 10	 	 	E0459 .7000 3PEOO
	PARP-016-Ul PH	1·2010. 500633	Phrn--..ines	Granted	10/2/2008	1·2010·S00633	S/ 16/ 2016	E04 59 .7000 3 PHOO

  

     

     

    

 

	PARP·Ol 6· U l PK	11 66/ 2008	Pa k1sta n	Pending	10/2/ 2008	 	 	E04 59 . 70003 P KOO
	P ARP-016-UlR U	2010117397	Russian Fede ration	Granted	10/2/2008	248S122	6/ 20/ 2013	E0459 .7000 3 RUOO
	PARP-016 UlSA	8290618	Saud] Arabia	Abandoned	10/2/2008	 	 	E04 59 .7000 3SAOO
	PARP-016-UlSG	201002181-4	Singapore	Granted	10/2/2008	160117	12/14/ 2012	E0459 .7000 3SGOO
	PARP-0160- l SG	201200734,8..2	Sing apo re	Granted	10/2/2008	18S272	4/ 22/ 2016	E04 59 .7000 3SGOO
	PARP·Ol 6· U l TH	80 1005083	Tha ila nd	Pending	10/2/ 2008	 	 	E04 59 . 70003 THOO
	PARP-016-Ul TW	9 7138 1 66	Ta iwan	Granted	10/2/2008	1426912	2/ 21/2014	E04 59 .7000 3TW’OO
	PARP-016-UllJ A	a 201005 11 7	UkralM	Granted	10/2/2008	99483	8/ 27/ 2012	E0459 .7000 3 UAOO
	PARP-016-f>l US	60/ 977,l lS	un.iled States of America	Con...e.rted	10/3/2007	 	 	E04 59 .7000 3 USOO
	PARP-016-UllJ S	12/24,4 399	Un.iled States of America	Granted	10/2/2008	8 236 802	7/8/2012	E0459 .7000 3 USOO
	PARP-016-Cl US	13/ 527,lSS	un.iled States of America	Unflfed	10/2/2008	8 ,89 4, 989	ll / S/ 2014	E0459 .7000 3 USOO
	PARP-0160-   l US	14/ 538,447	Un ited States of America	Abandoned	10/2/2008	 	 	E04 59 .7000 3 USOO
	PARP-016-Ul VN	1·20 10-0 1 09 2	Vietna m	Granted	10/2/2008	16364	12/ 20/ 2016	E0459 .7000 3 VNOO
	PARP-016-Ul PC PARP-016-UlZA	PCT 2008/07 2010/ 02317	Patent Cool’ll’>ra t io n T re a South Africa	Con...e.rted Granted	10/2/2008

 10/2/2008	2010/02317	9/ 2S/ 20 ll	E04 59 .7000 3 \VOOO E04 59 .7000 3 ZAOO

 

     

     

    

 

Schedule 3

 

Compound

 

Structure: 8-(is1oindolin-2-ylmethyl)-2Hpyridazino[3,4,5-de]quinazolin-3(9H)-one
L-tartrate salt

 

     

     

    

 

Schedule 3.3

 

Data and Information

 

[***]

 

     

     

    

 

Schedule 3.6

 

Inventory

 

[***]

 

     

     

    

 

Schedule 9.2(b)

 

Certain Product-Specific Patents

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]